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Post-translational regulation of BiP by FICD-mediated AMPylation and 
deAMPylation 
Luke Aleksander Perera 
Regulation of the amount and activity of Binding Immunoglobulin Protein (BiP) contributes to 
protein-folding homeostasis. BiP’s abundance is modulated transcriptionally by the canonical 
unfolded protein response (UPR). Conversely, a metazoan-specific, endoplasmic reticulum 
(ER)-resident, Fic domain containing protein (FICD) is able to dynamically adjust BiP’s 
activity through AMPylation and deAMPylation. These two mutually antagonistic reactions, 
catalysed by the single active site of FICD, are reciprocally regulated by an oligomeric state-
dependent switch. Under conditions of low unfolded protein load this bifunctional 
(monomeric) Fic enzyme AMPylates and inactivates excess ATP-bound BiP. However, with 
increasing ER stress dimeric FICD rapidly deAMPylates the inactive BiP-AMP store — 
enabling extra BiP to re-enter the chaperone cycle and thereby increase the organelle’s 
chaperone capacity (in a post-translational strand of the UPR). In this thesis, through structural, 
biochemical and biophysical techniques, I address the fundamental nature of FICD’s post-
translational regulation of BiP. By obtaining high-resolution crystal structures of trapped 
deAMPylation complexes (of FICD•BiP-AMP) I elucidate the basis of FICD substrate 
engagement, reveal the mechanism of Fic domain deAMPylation and clarify the essential role 
of the gatekeeper Glu234 residue (characteristic of the Fic domain inhibitory -helix) in this 
hydrolytic reaction. These structures also explain FICD’s exquisite selectivity for its 
AMPylation substrate — ATP-bound, domain-docked BiP — with FICD’s tetratricopeptide 
repeat domain binding a tripartite assembly of BiP’s nucleotide binding domain, docked linker 
and substrate binding domain, that is unique to the aforementioned Hsp70-state. My studies 
also shed light on the structural basis of the monomerisation-dependent switch between FICD’s 
two mutually antagonistic activities — which centres on a monomerisation-induced increase 
in gatekeeper Glu234 flexibility. Upon monomerisation, increased Glu234 flexibility permits 
AMPylation competent binding of MgATP in FICD’s active site whilst simultaneously 
impairing the ability for Glu234 to properly align an attacking water molecule for efficient 
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Chapter 1: Introduction 
Chapter 1.1: The BiP chaperone cycle 
Protein folding homeostasis in the endoplasmic reticulum (ER) is essential for cell viability 
and proper cellular function. A failure to maintain folding homeostasis in this cellular 
compartment can lead to an accumulation of misfolded proteins, cell death and a number of 
diseases (Balch et al, 2008; Walter & Ron, 2011). ER homeostasis is achieved through the 
ability of a cell to match the ER folding capacity to the burden of unfolded protein. As the 
major ER chaperone, binding-immunoglobulin protein (BiP) dominates the chaperoning 
capacity of the ER (Bakunts et al, 2017). BiP both acts as the sensor and principal responder 
to increased ER stress (Kozutsumi et al, 1988; Chang et al, 1989; Bakunts et al, 2017; Vitale 
et al, 2019; Amin-Wetzel et al, 2019). In response to an excess of unfolded proteins, well-
defined transcriptional and translational programmes, which constitute the unfolded protein 
response (UPR), are initiated (Walter & Ron, 2011). These result in a considerable 
transcriptional upregulation of BiP, so as to increase the amount of ER chaperone to match the 
levels of unfolded client.  
BiP (also known as glucose-regulated protein 78; GRP78) is a member of the ubiquitous and 
highly conserved heat shock protein of 70 kDa (Hsp70) chaperone family. There is a high 
degree of structural conservation across all Hsp70s. These proteins are made up of two 
domains, a nucleotide binding domain (NBD) and a substrate binding domain (SBD), separated 
by an interdomain linker. In turn, the SBD is composed of two distinct subdomains an -helical 
lid subdomain (SBD) and a -sheet rich subdomain (SBD), which contains a groove 
responsible for binding extended/unfolded client peptides. BiP, as an ER chaperone carries out 
a number of essential functions, most notably the facilitation of de novo secretory-pathway 
protein folding, an inhibition of protein aggregation and a regulation of protein degradation 
and secretion (Otero et al, 2010). All of these functions, which are also shared by other Hsp70 
members in varying cellular environments, are solicited through the binding of (partially) 
unfolded clients within BiP’s SBD. In so doing, BiP either elicits an ATP-dependent holdase 
function (Sekhar et al, 2015) or unfoldase activity on the client protein. The latter mediated, at 
least in part, through a J-domain protein (JDP) stimulated mechanism of substrate ultra-affinity 
and an excluded volume-based effect dubbed entropic pulling (De Los Rios & Barducci, 2014; 





The ability of BiP to act as an effective chaperone is predicated on its capacity to undergo large 
conformational changes: from a linker buried and lid open ATP-bound state (BiP:ATP) with 
fast substrate on and off rates; to a linker exposed and lid closed ADP state (BiP:ADP) with 
slow substrate binding kinetics and much longer substrate residency times (Kityk et al, 2015; 
Yang et al, 2015). Both ligands (nucleotide and substrate peptides) and protein co-chaperones 
(JDP and nucleotide exchange factors; NEFs) act as allosteric modulators of the Hsp70 
conformational equilibrium (Zhuravleva et al, 2012). Biochemical insights into this chaperone 
cycle have gradually been complemented by solution structure and crystallographic snapshots 
of Hsp70 proteins in two principal conformations and bound to various cofactors (Figure 
1.1.1).  
 
Figure 1.1.1: The allosteric BiP chaperone cycle. a, A cartoon representation of the chaperone cycle. BiP, like 
all Hsp70 proteins, can exist in two major conformations. In the presence of MgATP, BiP principally assumes a 
domain-docked conformation (BiP:ATP) with low substrate affinity. In the absence of nucleotide or presence of 
MgADP, BiP favours its domain-undocked, linker extended and lid-closed state (BiP:ADP), which possesses high 
substrate affinity. This equilibrium can be modulated by changing nucleotide content, levels of unfolded substrate 
(grey) and by co-chaperone proteins — nucleotide exchange factors (NEFs) and J-domain proteins (JDPs). 
Schematised (sub)domain architecture is annotated: substrate binding domain-/ (SBD/); nucleotide binding 
domain (NBD). b, Structural view of the BiP chaperone cycle. Domains are colour-coded as in a. All structures 
are presented in the same view and are aligned to BiP in the ATP-state (PDB 5E84) via its SBD or, in the case 
of the Hsp70•JDP structure, via its NBD. The Hsp70•JDP structure is in fact derived from the E. coli homologues 
(DnaK•DnaJ; PDB 5NRO) and does not contain an SBD-bound substrate. BiP in the ADP-state is an overlay of 
an SBD-truncated BiP structure (PDB 7A4U) with an intact BiP SBD (PDB 5E85, both structures are coloured 





Hsp70•NEF complex (lid-truncated bovine Hsc70 with yeast (Hsp110) NEF protein Sse1; PDB 3C7N). Co-
chaperones are coloured in pink. 
The amount of active BiP, able to progress through the chaperone cycle, is tightly regulated by 
altering the amount of BiP in the ER and by modulating BiP’s activity. The former is achieved 
through transcriptional regulation mediated by the canonical UPR. This results in a proteostasis 
system which contains inherent latencies associated with transcription, translation and 
chaperone protein turnover. Conversely, BiP activity can be modulated through post-
translational modification (PTM), which offers a more dynamic means of regulating the 
functional ER chaperone capacity (Preissler & Ron, 2019). The best understood regulatory 
PTM is BiP adenylylation, more commonly known as AMPylation.  
 
Chapter 1.2: Post-translational modification of BiP 
BiP was identified as the principal target for incorporation of radioactive signal upon in vivo 
treatment of cells with [3H]-adenosine (Carlsson & Lazarides, 1983). BiP was also 
radioactively labelled upon incubation of cells with [32P]-orthophosphate and upon ex vivo 
(cell lysate) treatment with [32P]-NAD+ (Chambers et al, 2012; Carlsson & Lazarides, 1983). 
On this basis the BiP modification was originally misidentified as ADP-ribosylation (Carlsson 
& Lazarides, 1983). Subsequent mass spectrometry (MS) analysis has definitively identified 
this PTM to represent AMPylation (Ham et al, 2014; Preissler et al, 2015b) — the covalent 
addition of an AMP moiety from an ATP co-substrate onto a hydroxyl group containing protein 
side chain. Both in vivo and in vitro, BiP AMPylation is specifically localised to the covalent 
modification of Thr518, a residue within the loop linking  and  (ℓ7,8) of BiP’s SBD 
(Preissler et al, 2015b; Broncel et al, 2016; Casey et al, 2017). This finding was consistent with 
the previous assignment of ADP-ribosylation to BiP’s SBD (Gaut, 1997; Chambers et al, 
2012). 
BiP AMPylation is an inactivating modification, heavily biasing BiP towards its ATP-state 
(independent of NBD nucleotide content), resulting in high rates of BiP-substrate dissociation 
and reduced ATPase activity (Wieteska et al, 2017; Preissler et al, 2015b). The bulky 
modification of ℓ7,8 is sufficient to trap BiP, crystallographically, in its domain-docked ATP-
state despite being made nucleotide free (apo) during protein purification (Figure 1.2.1). It also 
renders BiP refractory to JDP-mediated ATPase stimulation (Preissler et al, 2017b). The 





propensity for the reorganisation of ℓ7,8 (and by extension the shift from a  to a 
 sheet) required for the transition the SBD from its ATP- to ADP-state (Preissler et al, 
2017b; Zhuravleva & Gierasch, 2015). Conversely, the same lid (SBD)-truncated BiP 
construct, when left unmodified and made apo, crystallises (as anticipated) in its domain-
undocked ADP-state (Figure 1.1.1b; PDB 7A4U) (Preissler et al, 2020).  
 
Figure 1.2.1: AMPylation inactivates BiP by locking it in an ATP like–state. a, A cartoon representation of 
the chaperone cycle extended to schematise the additional role of BiP AMPylation in providing a readily 
accessible buffer of inactive chaperone. b, Alignment (via the NBD) of BiP:ATP (PDB 5E84; coloured as in a 
and Figure 1.1.1b) with SBD-truncated BiP-AMP:Apo (PDB 5O4P; yellow) and DnaK:ATP (PDB 4B9Q; 
grey). Despite being free of nucleotide BiP-AMP clearly adopts a domain-docked, lid-open, ATP-state 
conformation; with very little deviation from other ATP-bound Hsp70 structures in the NBD region. The modified 
Thr518 (shown), within the BiP-AMP structure, had limited obvious electron density corresponding to the AMP-
moiety, as a result only the -phosphate is modelled. The minor deviation in SBD conformation visible between 
BiP:ATP and BiP-AMP:Apo is largely localised to flexible loops (in particular ℓ5,6), attributable to the corrupting 
effects of a ℓ3,4 truncation introduced into the former and AMPylation of ℓ7,8 in the latter.  
Consistent with the inactivating character of BiP AMPylation, this modification is temporally 
dynamic and the levels of BiP-AMP are modulated in vivo in order to meet the protein folding 
demand within the ER. For example, around 40–60% of the entire BiP pool becomes 
AMPylated within 2–3 h of cycloheximide induced inhibition of protein synthesis, both in cells 
(Laitusis et al, 1999; Preissler et al, 2015b) and in the pancreas of treated mice (Chambers et 
al, 2012). Likewise, mice subjected to overnight fasting (which results in a physiological 
depreciation in pancreatic protein synthesis) exhibited a similar induction of BiP AMPylation, 
which could be rapidly reversed (within 1 h) by refeeding, to a basal level of ~15% AMPylated 
BiP (Chambers et al, 2012). Significant, BiP AMPylation has also been observed in cells 





aftermath of significant UPR-mediated transcriptional upregulation of BiP, in a regime 
following the removal of pharmacological stressors. Under such conditions levels of chaperone 
presumably far exceed the chaperoning requirements of unfolded client protein (Bakunts et al, 
2017), triggering the observed post-translational inactivation of excess chaperone. It should be 
noted that in earlier studies, as mentioned above, the authors believed the BiP PTM in question 
was ADP-ribosylation (Carlsson & Lazarides, 1983; Laitusis et al, 1999; Chambers et al, 
2012). Quantification of the degree of BiP modification was achieved by utilising a 
characteristic (PTM induced) shift in BiP protein migration on an isoelectric focusing (IEF) 
gel. It has since been demonstrated that the IEF shift is entirely AMPylation dependent, as 
knockout of the identified AMPylase abrogates this phenomenon (Preissler et al, 2015b). 
Conversely, as exemplified by mouse refeeding experiments, it has been extensively 
demonstrated that (in a range of cell lines) as ER stress is increased the pool of BiP-AMP is 
swiftly deAMPylated, reactivating the reserve chaperone capacity to enable extra BiP to 
productively engage in the chaperone cycle (Laitusis et al, 1999; Chambers et al, 2012; 
Preissler et al, 2015b). Thus, BiP-AMPylation enables the ER to both reduce the effects of 
transient ER stresses (through deAMPylation) and ameliorate the possibility of over-
chaperoning (through AMPylation). As BiP is reported to have a half-life in the order of days 
(Hendershot et al, 1988; Gulow et al, 2002; Lau et al, 2016; Wang et al, 2017), a BiP buffering 
system based on dynamic AMPylation/deAMPylation is able to operate on a time-scale that is 
inaccessible to a homeostatic feedback system mediated solely by transcriptional regulation 
and protein-turnover. Moreover, the former timescale is better matched to the transient short-
term fluctuations in ER unfolded protein load associated with in vivo demands on secreted 
protein synthesis (Chambers et al, 2012). These properties of the BiP-AMPylation and 
deAMPylation system may contribute to the phenotype observed in the Drosophila visual 
system, whereby impairing the ability to AMPylate BiP results in light-induced blindness 
(Rahman et al, 2012; Moehlman et al, 2018) 
Until relatively recently protein AMPylation was considered to be a PTM that was exclusively 
catalysed by bacterial proteins and often by bacterial effector proteins. Fortunately, on account 
of a horizontal gene transfer from bacteria into the last common metazoan ancestor, there exists 
a single AMPylation capable Fic protein exemplar within the mammalian proteome (Khater & 
Mohanty, 2015a). This protein, FICD, is ER localised and is solely responsible for BiP 





Chapter 1.3: AMPylation 
There are only a small number of identified protein families capable of AMPylating (also 
known as adenylylating) hydroxyl groups in order to covalently link an AMP moiety, via a 
phosphodiester bond, to a target protein. This contrasts with the more transient AMPylation 
catalysed by a number of enzyme families, including aminoacyl-tRNA synthetases and non-
ribosomal peptide synthetases. These enzymes facilitate carboxyl group adenylation, resulting 
in the formation of a mixed anhydride linkage, the product of which often represents a short-
lived reaction intermediate.  
There are three major classes of protein hydroxyl group AMPylating enzymes. The first to be 
identified was characterised by E. coli  glutamine synthetase adenylyl transferase (GS-ATase), 
which AMPylates glutamine synthetase (GS) (Kingdon et al, 1967; Hennig et al, 1970; Brown 
et al, 1971). The GS-ATase protein family is itself part of a larger nucleotidyl transferase 
protein superfamily. The second class of AMPylators, the DrrA-like protein family, represents 
a rare group of proteins with a taxonomical distribution limited to strains of Legionella 
pneumophila (Muller et al, 2010; Khater & Mohanty, 2015a). The N-terminal AMPylation 
relevant domain of DrrA (also known as SidM) is ATase-like, sharing considerable structural 
homology and the catalytic GS-ATase GxDxD motif. However, other than the conserved 
catalytic residues the sequence similarity between GS-ATase and DrrA is small and they 
possess divergent substrate specificities (Khater & Mohanty, 2015a) — the former AMPylates 
GS whereas DrrA AMPylates host organism small GTPases (Muller et al, 2010). The third 
canonical AMPylase protein family is characterised by a Fic (filamentation induced by cAMP) 
protein fold. AMPylation activity of a Fic protein was initially observed in a bacterial effector 
protein (VopS) of the human pathogen Vibrio parahaemol (Yarbrough et al, 2009), despite the 
domain being originally identified 20 years previously from an E. coli mutation resulting in the 
eponymous filamentation phenotype (Utsumi et al, 1982). Fic domain proteins are 
evolutionarily unrelated to either GS-ATase or DrrA like proteins. In addition, SelO (a 
selenocysteine containing pseudokinase that is evolutionarily conserved across bacteria and 
eukaryotes) has recently been described to possess AMPylation and uridine monophosphate 
transferase (UMPylation) activity (Sreelatha et al, 2018; Yang et al, 2020). However, the 
degree to which SelO is able to AMPylate endogenous targets, either in vitro or in vivo, remains 





Since the discovery of Fic domain mediated AMPylation by VopS, many other Fic domain 
containing proteins with AMPylation activity have been characterised. Moreover, a number of 
other chemistries catalysed by this domain have also been documented, including 
phosphorylation, phosphocholination and UMPylation (Castro-Roa et al, 2013; Campanacci et 
al, 2013; Feng et al, 2012); illustrating the potential versatility of the Fic domain fold. It is the 
largest of the three AMPylase families, and is found across the bacterial domain of life and 
scattered throughout the archaeal and eukaryotic phylogenetic branches, with a distribution 
indicative of a bacterial origin followed by multiple horizontal gene transfer events (Khater & 
Mohanty, 2015a). Fic domain containing proteins, along with the related Doc domain proteins, 
contain a conserved active site Fic motif: HPFx(D/E)GN(G/K)R1xxR2. Additionally, the 
bacterial effector protein Pseudomonas AvrB, despite lacking the Fic motif, shares 
considerable structural homology with the Fic domain. Together the Fic, Doc and AvrB family 
proteins have been grouped into one Fido superfamily, despite catalysing divergent chemical 
reactions (Kinch et al, 2009; Khater & Mohanty, 2015a, 2015b).  
The mechanism of Fic domain protein catalysed AMPylation, based on a body of biochemical, 
structural and computation work,  is fairly well understood (Luong et al, 2010; Xiao et al, 2010; 
Khater & Mohanty, 2015b). The AMPylation reaction requires Mg2+ coordination of ATP’s - 
and -phosphates and the conserved histidine of the Fic motif is required for general base 
catalysis (Figure 1.3.1). Following nucleophilic attack of the target protein hydroxyl group 
into the ATP -phosphate, an AMPylated protein and pyrophosphate (PPi) are the resulting 
products (Figure 1.3.1). 
Fic proteins are also characterised by the presence of glutamate containing alpha inhibitory 
helix (inh), which is responsible for autoinhibition of canonical Fic AMPylation activity 
(Engel et al, 2012; Goepfert et al, 2013). Depending on whether the inh is a separate protein 
(as a bacterial antitoxin) or is N- or C-terminally contiguous with the Fic domain; Fic domain 
proteins are classified as either class I, II or III, respectively (Engel et al, 2012). The inhibitory 
glutamate of Fic inh has been demonstrated to sterically and electrostatically occlude ATP -
phosphate binding, and to compete with the -phosphate for interaction with a conserved 
arginine (R2) of the Fic motif. The inhibitory glutamate forces a binding orientation of ATP 
(the co-substrate for AMPylation), within the Fic domain active site, such that its -phosphate 
is incompatible with in-line nucleophilic attack of the target hydroxyl group (Engel et al, 2012; 






Figure 1.3.1: Reaction scheme for Fic domain catalysed protein AMPylation. Residues are labelled according 
to human FICD amino acid sequence. Additionally, the target residue is depicted as FICD’s endogenous target —
BiP’s Thr518 (purple). Note, other Fic proteins are capable of modifying different hydroxyl group-containing 
amino acids. R2 of the Fic motif (Arg374) forms a salt bridge to ATP’s -phosphate, enabling the binding of ATP 
such that its -phosphate is correctly positioned for in-line nucleophilic attack of the target hydroxyl group. The 
Fic motif histidine (His363) catalyses a concerted deprotonation of the hydroxyl group which attacks the backside 
of the -phosphate’s phosphoanhydride bond (in a general base catalysed SN2-type reaction). Extra (partial; ) 
negative charge, delocalised through the - and -phosphates, is stabilised by Mg2+ coordination and the Fic 
domain oxyanion hole (not shown). Following product (PPi and BiP-AMP) dissociation proton exchange with the 
solvent can regenerate the original active site protonation state (not shown). Partial covalent bonds in the proposed 
transition state (‡) are depicted with dashed lines, and polar interactions with hashed lines.  
Like the unrelated DrrA family, many Fic proteins act as bacterial effector proteins targeting 
host protein small GTPases. Conversely, the metazoan specific Fic domain containing protein 
(FICD) is responsible for the AMPylation of the ER Hsp70 protein, BiP (Sanyal et al, 2015; 





evolved from the product of a horizontal gene transfer of a class II Fic domain, from a bacterial 
species, into the metazoan last common ancestor (Khater & Mohanty, 2015a). It has been 
demonstrated to be an ER localised, type II membrane protein (Bunney et al, 2014; Sanyal et 
al, 2015). Human FICD (also known as huntingtin yeast interacting protein E; HYPE) and its 
metazoan homologues exhibit a high degree of sequence and structural conservation. For 
instance, although the C. elegans Fic protein (FIC-1) is one of the most distant metazoan 
relatives of human FICD (sharing 38% amino acid identity) it possesses an almost identical 
tertiary and quaternary structure (Bunney et al, 2014; Truttmann et al, 2016). Both homologues 
reveal a compact, all -helical, tripartite composition: a two TPR motif TPR domain (which 
follows the transmembrane domain and 62 predicted unstructured ER luminal residues), 
followed by a C-terminal capping helix which is continuous with an -helical linker to the 
catalytic Fic domain (Figure 1.3.2). Human FICD forms a dimer both in crystallo and in 
solution, via a bipartite dimerisation interface, which possesses a nanomolar dissociation 
constant (Perera et al, 2019). Moreover, the dimer interface is also highly conserved amongst 
FICD homologues, being present (and facilitating dimerisation) in both worms and flies 
(Truttmann et al, 2016; Casey et al, 2017). 
 
Figure 1.3.2: FICD domain structure. a, A human FICD dimer crystal structure (PDB 6I7G; residues 104–445) 
is displayed with ribbon and semi-opaque surface representation. The protein is coloured according to its domain 
organisation, as schematised in b. In addition, the Fic domain flap region which covers the hydrophobic adenosine 
binding pocket is also highlighted (residues 311–323; turquoise). The dimer is also modelled with its unstructured 
N-terminal region (grey) anchoring it to the ER membrane (and within the ER lumen). b, Schematic representation 
of FICD’s domain organisation. The transmembrane domain (blue), the TPR domain (orange), the α‐helical linker 
(green), the Fic domain (purple) and the core Fic domain (deep purple) are indicated. Selected residues are also 
annotated: inhibitory Glu234 (at the end of inh), Leu258 (within the principal dimer interface surface), Gly299 
(within the secondary dimer interface surface) and the Fic motif. Bottom, schematic of the FICD residue range 





FICD’s ability to AMPylate and inactivate BiP is conserved across metazoa, having been 
observed in flies, mammals and worms (Ham et al, 2014; Preissler et al, 2015b; Truttmann et 
al, 2016). Moreover, it appears that endogenous FICD very selectively AMPylates BiP, with 
high throughput screening techniques only identifying BiP as an FICD modified target which 
colocalises with FICD in the ER lumen (Broncel et al, 2016; Truttmann et al, 2016). 
Furthermore, as mentioned above, FICD specifically modifies Thr518 of BiP. In addition, 
FICD selectively AMPylates the ATP-state of BiP; as evidenced by its substrate preference for 
BiP mutants which are more biased towards the domain-docked state and by FICD’s inability 
to AMPylate BiP mutants which cannot domain-dock in response to ATP or the isolated BiP 
SBD (which also cannot assume an ATP-like state conformation) (Preissler et al, 2015b). The 
means by which FICD specifically engages BiP:ATP is unknown.  
In general, Fic proteins are thought to engage their substrates via the formation of an 
intermolecular -sheet — utilising the Fic domain flap to facilitate positioning of the target 
hydroxyl group within the Fic domain active site. This has been observed for the post-
AMPylation cocrystal structure of the Fic protein IbpA (which lacks an inh) bound to its (in 
crystallo) AMPylated substrate Cdc42-AMP (PDB 4ITR) and in structures of Fic proteins in 
which crystal packing effects result in -sheet flap engagement (Xiao et al, 2010; Goepfert et 
al, 2013). As also exemplified by the structure of IbpA•Cdc42-AMP (the only existing co-
complex structure of a Fic protein bound to its cognate target protein), Fic proteins often 
contain very divergent target recognition modules which are separate from the catalytic Fic 
domain (reviewed in Harms et al, 2016). For example, in the case of  IbpA and VopS, specific 
arm subdomains have evolved to recognise their target small GTPases (Xiao et al, 2010; Luong 
et al, 2010). It is therefore tempting to speculate that the TPR domains of FICD may also 
contribute towards its ability to specifically recognise and bind BiP:ATP. Moreover, as client 
binding within the SBD partitions Hsp70s away from their ATP-state (Figure 1.1.1), FICD’s 
substrate preference for ATP-state BiP suggests a simple mechanism for coupling BiP 
AMPylation to low protein folding loads. 
The ability for BiP to be reversibly and dynamically AMPylated is intrinsic to the utility of this 
modification as a means of buffering chaperone capacity within the ER. As protein AMPylation 
results in a stable, phosphodiester linked, covalent modification; removal of this moiety 






Chapter 1.4: DeAMPylation 
Through work that was initiated during my Master of Research degree rotation project in the 
Ron lab, we found that FICD was able to catalyse deAMPylation of BiP both in vitro and in 
vivo and that endogenous FICD was responsible for the deAMPylation of BiP in cells (Preissler 
et al, 2017a). This deAMPylation activity, although functionally opposed to AMPylation, 
represented a chemically distinct reaction and not simple micro-reversibility of the former — 
generating BiP and AMP as deAMPylation products. Moreover, we found that the catalytic Fic 
motif His363 and the inh-located Glu234 (previously only associated with its role in 
autoinhibiting AMPylation) were entirely necessary for this deAMPylation activity (Preissler 
et al, 2017a). In so doing, we demonstrated FICD to be a bifunctional enzyme in which both 
mutually antagonistic activities were catalysed in its single active site; a feature which is only 
present in a small number of other bifunctional enzymes including RNA polymerase which 
catalyse both mRNA transcription and proofreading in a single active site (reviewed in Sydow 
& Cramer, 2009).  
The finding that FICD is a deAMPylator of BiP-AMP has subsequently been reproduced in the 
Drosophila system (Casey et al, 2017) and also in a divergent class III Fic protein from the 
bacterium Enterococcus faecalis (EfFic) (Veyron et al, 2019). A previous bioinformatic 
analysis of prokaryotic Fic proteins indicated that class I and III Fic proteins are likely both of 
monophyletic origin and are both derived from a single branch of class II Fic proteins (Engel 
et al, 2012). Therefore, the observation that both FICD (a class II Fic protein) and a distantly 
related bacterial class III Fic protein possesses deAMPylation activity, that is dependent on a 
conserved glutamate residue which is structurally homologous to FICD’s Glu234, suggests that 
Fic domain bifunctionality may be a widespread and largely overlooked feature across a large 
branch of the Fic protein family. 
To date FICD is the only known eukaryotic protein to be identified with bona fide 
deAMPylation activity. Conversely, there are two known bacterial deAMPylating enzymes, 
the Legionella pneumophila effector protein SidD and the E. coli protein  GS-ATase. The latter 
represents an interesting parallel to FICD, as GS-ATase (the first identified AMPylase) is also 
a bifunctional enzyme. However, unlike FICD, it uses separate homologous domains to 
catalyse AMPylation and deAMPylation. The latter is facilitated by GS-ATase’s Adenylyl 
Removase domain via a phosphorolytic mechanism (Anderson & Stadtman, 1970). Structural 





fold (Xu et al, 2004, 2010). Conversely, SidD, which catalyses deAMPylation of host protein 
GTPases, is structurally homologous to a metal-dependent protein phosphatase despite 
significant sequence divergence (Chen et al, 2013). Both proteins catalyse deAMPylation 
mechanisms which are depended on a binuclear metal centre (Figure 1.4.1), a common feature 
amongst proteins which catalyse phosphodiesterase or phosphomonoesterase reactions. 
Furthermore, SidD also has a strict requirement for Mg2+ ions  (Chen et al, 2013).  
Contrarily, FICD like other Fic proteins only has a single divalent ion binding site and is 
evolutionarily unrelated to either GS-ATase or SidD. It is, therefore, very likely that FICD (and 
other Fic proteins) exhibit a disparate deAMPylation mechanism. Based on AMP being a 
products of Fic-protein deAMPylation, the mode of nucleotide binding in the Fic domain active 
site and the requirement for a conserved glutamate and histidine, speculative inferences have 
been made that the Fic deAMPylation reaction is acido-basic and hydrolytic in nature (Preissler 
et al, 2017a; Perera et al, 2019; Veyron et al, 2019). However, the enzymology of FICD-
mediated deAMPylation remains to be determined. 
 
Figure 1.4.1: Proposed mechanisms of deAMPylation catalysed by GS-ATase and SidD. a, GS-ATase is 
known to catalyse a phosphorolytic deAMPylation reaction within its adenylyl removase domain, producing ADP 
and unmodified GS. The proposed catalytic mechanism is based on similarity with other nucleotidyl transferases 
and conservation of the aspartic acid triad which scaffolds the binuclear metal centre. b, Likewise, the mechanism 
of SidD hydrolysis is inferred from the phosphatase reaction pathway catalysed by related metalloenzyme. Figure 
adapted from (Chen et al, 2013). 
It has already been noted that levels of BiP-AMP appear to be stably and dynamically adjusted 
in order to meet the protein folding demands within the ER (Preissler et al, 2015b). Such a 
system, catalysed by a single bifunctional enzyme, necessitates a means of regulating these two 






Chapter 1.5: Reciprocal regulation of FICD’s bifunctionality 
Like many other class II or class III Fic proteins, in which the autoinhibitory inh forms part of 
the extended Fic domain, FICD exhibits very little AMPylation activity in vitro (either with 
respect to autoAMPylation, which is often the sole readout for many Fic proteins without 
identified substrates, or substate-directed AMPylation). In fact, in a wild type context dimeric 
FICD activity was found to be heavily biased towards its deAMPylation activity (Preissler et 
al, 2017a). This in vitro observation was consistent with previous in vivo findings, in which 
rescuing the ability of FICD–/– Chinese hamster ovary (CHO) cells to accumulate AMPylated 
BiP could only be achieved by transient transfection with FICDE234G, that is to say, FICD 
lacking its AMPylation-inhibiting glutamate (Preissler et al, 2015b).  
Conversely, a much lower-level (stable) expression of wild type FICD in FICD–/– CHO cell, 
which was still expressed at a considerably higher level than endogenous FICD, was able to 
afford some level of BiP AMPylation rescue (Perera et al, 2019). This was suggestive of a 
protein dosage effect on the regulation of FICD activity. This hypothesis was further 
corroborated by the observation that overexpression of a monomeric variant of FICD 
(FICDL258D) was able to induce conspicuous BiP-AMPylation in FICD–/– CHO cells. Unlike in 
wild type cells, this was the case under both basal and protein translation inhibited 
(cycloheximide treated) conditions, although the levels of AMPylated BiP were able to be 
further increased (from their elevated basal level) by cycloheximide treatment. This in turn, 
was consistent with a model in which monomerisation of FICD results in a switching of the 
enzyme from a poor to a proficient AMPylase.  
A large body of in vitro work confirmed this finding. Indeed, by utilising the nature of a 
catalytically dead (His363Ala) and constitutively dimeric (disulphide-linked) FICD 
(S-SFICD
A252C‐H363A‐C421S) to tightly bind and effectively trap BiP-AMP, the effects of 
monomerisation on FICD’s mutually antagonistic activities was deconvoluted. It was found 
(using [‐32P]‐ATP as the AMPylation co-substrate) that monomeric FICDL258D catalysed 
AMPylation of BiP at a rate around 19-fold greater than that of the dimeric wild type enzyme. 
Concomitantly, by analysing the fluorescence polarisation decrease associated with the 
deAMPylation-mediated release of fluorescent AMP(FAM) from covalently labelled BiP-
AMP(FAM), the deAMPylation activity of FICD was also observed to be diminished by 
monomerisation. In this assay, in which substrate concentrations were limiting, 





Importantly, the apparent oligomeric state-dependent regulation of FICD’s enzymatic activity 
was not restricted to the context of monomerising mutations introduced into FICD. When 
diluted into the nanomolar concentration range, which is in the order of the measured 
dimerisation KD, wild type FICD conspicuously acquired the ability to catalyse an appreciable 
accumulation of BiP-AMP. Moreover, the biphasic relationship between wild type FICD 
concentration and BiP-AMP accumulation was entirely dependent on the ability of FICD to 
monomerise at low concentration. This was illustrated by the fact that accumulation of BiP-
AMP upon dilution of wild type FICDA252C occurred only under (reducing) conditions, in which 
its dimer interface was no longer covalently enforced by an intermolecular disulphide bond 
(Perera et al, 2019). 
 
Figure 1.5.1: FICD’s dimer interface and putative dimer-relay network. a, The conserved bipartite dimer 
interface of FICD is illustrated, based on a human FICD crystal structure (PDB 6I7G). One protomer is shown in 
pink and the other in blue. Residues involved in a putative hydrogen bond network from the major/larger 
dimerisation interface to the active site (in the region of Glu234, atop the inh) are labelled and highlighted in 
green, with H-bonds represented by dotted blue lines. Gly299 which resides in the smaller, secondary dimer 
interface is also highlighted. Note, FICDG299S is partially dimeric in solution, which contrasts with the fully 
monomeric FICDL258D. b, BiPT229A-V461F AMPylation measured by covalent incorporation of [-32P]-AMP. Dimer-
relay FICD mutants (Lys256Ser and Glu242Ala), at concentrations at which they are principally dimeric, are 
significantly more prone to AMPylate BiP than wild type (dimeric) FICD. Gel produced by Steffen Preissler.  
These in vivo and in vitro findings (experiments principally conducted by Cláudia Rato da 
Silva and Steffen Preissler, respectively) provide strong support for a model wherein FICD 





strongly favouring substrate AMPylation. However, the mechanistic basis of this enzymatic 
switch is undetermined. A small hint was afforded by structural observations from previous 
FICD dimer structures, in which a hydrogen bond (H-bond) network linking the dimer interface 
to the inh (and the active site) was apparent (Figure 1.5.1a). Moreover, mutations in this 
putative dimer-relay also caused an increase in the ability of FICD to mediate BiP-AMP 
accumulation, without significantly weakening the dimer interface (Figure 1.5.1b). 
In a parallel to FICD, oligomerisation has been observed to affect autoAMPylation of the class 
III Fic protein from Neisseria meningitidis (NmFic), which in turn modulates its ability to 
autoinhibit AMPylation of its substrate (Stanger et al, 2016). Moreover, mutations in the dimer 
interface of Clostridium difficile’s class II Fic protein (CdFic) also increased its 
autoAMPylation activity (Dedic et al, 2016). Conversely, although monomeric FICDL258D 
exhibits a slight increase in autoAMPylation activity relative to wild type FICD, the overall 
efficiency of this reaction is very low (much less than the efficiency of substrate modification) 
with only a tiny proportion of the total FICDL258D being modified (Perera et al, 2019). Some 
degree of FICD autoAMPylation has been identified, by peptide MS/MS, of FICD’s 
Ser79/Thr80 and Thr183 in both a wild type and FICDE234G context (Sanyal et al, 2015). The 
latter, FICDE234G, being AMPylation unrestrained and deAMPylation incapable exhibits much 
more pronounced substrate and autoAMPylation than FICDL258D (Perera et al, 2019). However, 
crystallisation of the structured region of FICDE234G (residues 104–445; as used in the in vitro 
studies in Perera et al, 2019), in the presence of high concentrations of MgATP, revealed no 
extra density corresponding autoAMPylation of Thr183 or across the rest of the protein (which 
was largely well resolved; PDB 4U07) (Bunney et al, 2014). This provides further support for 
their being a very low stoichiometry of FICD auto-modification, even under favourable 
mutational and environmental conditions. Furthermore, as previously observed, 
monomerisation of FICDE234G via the introduction of Leu258Asp reduces autoAMPylation 
activity (Bunney et al, 2014; Perera et al, 2019). All of this data is consistent with a conclusion 
that FICD monomerisation does not result in an inherent increase in autoAMPylation 
proficiency or activity. Thus, the reciprocal regulation of FICD activity, afforded by 
monomerisation, cannot be a consequence of alterations in FICD’s limited ability to 







Chapter 1.6: Aims 
FICD represents an extremely interesting enzyme with an ability to both inactivate and 
reactivate BiP, the major endoplasmic reticulum chaperone, and thereby modulate chaperoning 
capacity within the ER. To date, it is the only bona fide identified metazoan AMPylator and 
the only example of a eukaryotic deAMPylator. Understanding the basis of FICD’s ability to 
modify BiP, and the mechanistic basis of how FICD is itself regulated, will enable a 
fundamental understanding of the metazoan post-translation unfolded protein response. 
Moreover, a detailed understanding of an endogenous bifunctional regulator of BiP activity, 
may eventually pave the way for rational drug design with the aim of enhancing FICD’s ability 
to inactivate BiP. This is particularly topical, in the current environment of a global pandemic, 
with mounting evidence that small molecule inhibitors of Hsp70s, and BiP in particular, may 
provide pan-antiviral therapeutic benefit (Chan et al, 2006; Taguwa et al, 2015, 2019).  
The catalytic mechanism of Fic domain mediated AMPylation, based on the analysis of a large 
number of bacterial Fic proteins, is fairly well understood. Conversely, very little is known 
about the nature of FICD-mediated deAMPylation, although it is likely that this mechanism is 
conserved across a number of other bacterial Fic domain proteins. Moreover, Fic proteins are 
evolutionarily and structurally very distinct from the two previous identified deAMPylase 
enzymes (both of which are of bacterial origin), and to my knowledge there exists no structures 
of a deAMPylase bound to its deAMPylation substrate. 
In a similar vein, there only exists one structure of a Fic protein bound to its endogenous 
substrate. It is thought that the majority of Fic proteins have incorporated a wide variety of 
specific substrate targeting domains — which have presumably (co)evolved to suit each Fic 
protein’s specific clientele. In the case of FICD, indications that it is able to specifically bind 
ATP-state BiP may provide an additional layer of substrate-level regulation of BiP AMPylation 
(with levels of low unfolded protein naturally resulting in more BiP:ATP as less BiP SBD is 
engaged by unfolded peptide). Support for the existence of substrate-level regulation of BiP 
AMPylation is provided in vivo by the observation that cells only expressing a constitutively 
monomeric FICD retain a measure of regulated BiP AMPylation (Perera et al, 2019). Whether 
or not FICD is able to specifically recognise the ATP-state of BiP remains unconfirmed and 
the means of any such recognition is completely undetermined. 
Finally, monomerisation of FICD has been robustly demonstrated to concomitantly increase 





oligomeric state regulating enzyme activity is far from a rare occurrence. For example, a 
number of transmembrane ER proteins such as the UPR sensor Ire1 are regulated in such a 
fashion (Walter & Ron, 2011; Amin-Wetzel et al, 2019). Conversely, I am not aware of another 
example of oligomeric state-dependent reciprocal regulation of enzymatic activity within a 
single bifunctional active site, as exhibited by FICD (and potentially its homologues). Fully 
elucidating the cause of this enzymatic switch requires a fundamental understanding of both 
the means of deAMPylation and AMPylation at play. 
In this thesis, I therefore aim to provide an in-depth exploration into the mechanistic 
functioning and regulation of FICD bifunctionality. Through a structure-led approach I address 
three fundamental themes pertaining to the nature of FICD’s post-translational regulation of 
BiP. Firstly, I elucidate the mechanism by which FICD engages and deAMPylates BiP-AMP. 
Secondly, I explain FICD’s exquisite selectivity for its AMPylation substrate — ATP-bound 
and domain-docked BiP. I then reveal the structural basis of FICD’s monomerisation-
dependent increase in AMPylation activity and concomitant decrease in deAMPylation 
activity. Finally, I touch on a potential in vivo route of transducing changing levels of ER 
unfolded protein load into an adjustment of FICD’s monomer-dimer equilibrium.  
  




Chapter 2: The mechanism of eukaryotic deAMPylation 
Chapter 2.1: Capturing a deAMPylation complex 
In order to elucidate the mechanism of BiP-AMP deAMPylation, a crystal structure of FICD 
engaged with AMPylated BiP was required. In order to facilitate the crystallisation of such a 
complex the FICD mutation His363Ala was leveraged. As noted previously, mutation of 
FICD’s catalytic histidine not only renders the protein devoid of all enzymatic activity 
(Chapter 1.4, Preissler et al, 2017a), but also enables the formation of a stable complex of 
FICDH363A•BiP-AMP (Chapter 1.5, Perera et al, 2019). This substrate-trapping facilitated 
copurification of FICD and BiP-AMP by size exclusion chromatography (SEC) (Figure 
2.1.1a). As the dimer of FICD is a more active deAMPylase than monomeric FICD 
considerable efforts were made to obtain a cocrystal structure of the former with BiP-AMP. A 
complex of recombinantly expressed and, otherwise wildtype, dimeric human FICDH363A and 
in vitro AMPylated Chinese hamster BiP (in various forms and mutant varieties) readily 
copurified and crystallised in a wide range of polyethylene glycol (PEG) conditions. However, 
despite extensive attempts at crystal optimisation (for example, macro and microseeding, 
hanging and sitting drop, different temperature and microbatch-under-oil crystallisation, in situ 
diffraction, crystal dehydration and annealing) these crystals only yielded very weak diffraction 
data. The reason for these crystals being refractory to even mediocre X-ray diffraction remains 
unknown, although one could speculate that they possessed too much internal heterogeneity. 
Fortunately, a combination of introducing the monomerising Leu258Asp mutation into the ER 
luminal and predicted structured portion of FICD (residues 104–445) and truncation of BiP’s 
flexible -helical lid (residues 27–549) produced a heterodimeric FICDL258D-H363A•BiPT229A-
V461F-AMP complex that crystallised and yielded two very similar sub-2 Å datasets (Figure 
2.1.1b; Table 1). Copurification was achieved by the injection of FICD:BiP-AMP in an 
approximate 3:2 molar ratio in the presence of 250 µM MgATP; the subsequent SEC yielded 
a complex elution peak corresponding in elution volume to that expected from a 97 kDa 
heterodimeric complex of FICDL258D-H363A•BiPT229A-V461F-AMP (Figure 2.1.1a).  





Figure 2.1.1: Copurification and crystallisation of FICD•BiP-AMP. a, FPLC gel filtration chromatogram and 
reducing SDS-PAGE analysis of the indicated fractions. FICD’s His363Ala mutation facilitates trapping and SEC-
based copurification, of a deAMPylation complex of monomeric FICDL258D-H363A and lid-truncated BiPT229A-V461F-
AMP. The elution volumes of molecular weight standards run on the same SEC column are indicated above. A 
protein peak containing excess (39 kDa) monomeric FICD (from the 3:2 injection ratio of FICD:BiP-AMP) is 
also labelled. An unidentified high molecular weight (non-aggregated and relatively stable) species principally 
containing FICD (see fraction a, labelled oligomeric FICD) is also evident. This species is not present when 
FICDL258D-H363A is gel filtered in isolation. b, The pooled protein fractions (c-i from a) enabled heterodimer 
crystallisation and sub-2 Å X-ray diffraction. The sitting drops, containing the crystals which gave rise to the state 
1 and state 2 deAMPylation complex crystals, are pictured. State 1 crystals were obtained from sitting drop 
reservoir conditions of 0.1 M MES pH 6.5, 10% PEG 4000 and 0.2 M NaCl; state 2 crystals were obtained from 
conditions of 0.1 M Tris pH 8.0 and 25% PEG 400 (see Materials and Methods). 
It should be noted, the use of residues 28–549 of BiP excludes the signal sequence and 
unstructured acidic N-terminal region and removes the majority of BiP’s lid subdomain (SBD 
helix B [SBD-B and the -helical bundle). The latter potentially facilitated greater crystal 
homogeneity by removing the part of the lid (SBD-B) which is documented in the E. coli 
Hsp70 homologue (DnaK) to, in the Hsp70 ATP-state, only interact transiently with the NBD 
and partially unfold in solution (Zhuravleva et al, 2012; Rist et al, 2006). Furthermore, removal 
of the distal part of the lid also accelerates substrate dissociation rates from the SBD and 




thereby decreases the opportunity for BiP to bind FICD, or itself, as a substrate. Conversely, 
an intact BiP has a high propensity to bind its own interdomain linker and oligomerise, 
especially in the absence of ATP-replenishment (Preissler et al, 2015a, 2020).  
 
 
Table 1: DeAMPylation complex data collection and refinement statistics. Both deAMPylation complexes 
contain aFICDL258D-H363A (residues 104–445) bound to BiPT229A-V461F-AMP (residues 27–549). Values in 
parentheses correspond to the highest-resolution shell, with the following exception: bThe number of molecules 
in the asymmetric unit cell (a.u.) is shown with the number of molecules in the biological unit in parentheses. cThe 









   Data collection   
Synchrotron stations DLS I04-1 DLS I04-1 
Space group P21212 P21212 














 0.085 (1.299) 0.087 (1.793) 
<I/(I)> 10.3 (1.2) 11.9 (1.0) 
CC1/2 0.992 (0.585) 0.999 (0.536) 
Unique reflections 115633 (5639) 86247 (6270) 
Completeness, % 99.8 (99.3) 100.0 (100.0) 
Redundancy 6.6 (6.5) 6.6 (6.9) 





 0.195 / 0.221 0.177 / 0.231 
Atoms (non-H) 7868 7575 
Average B-factor, Å2 29.0 37.4 
RMS Bond length, Å 0.003 0.003 







MolProbity score c 0.81 (100th) 1.04 (100th) 
PDB code 7B7Z 7B80 
 




The ability to maintain BiP as a monomeric species was further facilitated by introduction of 
the characterised BiP mutations Thr229Ala and Val461Phe, which render BiP ATPase  and 
substrate-binding deficient but otherwise allosterically intact (Gaut & Hendershot, 1993; 
Petrova et al, 2008). The lack of ATP hydrolysis, enabled by the former, allows BiP to remain 
bound to MgATP and therefore in its domain-docked state for prolonged periods of time; a 
feature which favours AMPylation by FICD and also disfavours BiP substrate binding and 
oligomerisation (Preissler et al, 2015b, 2015a).  
Furthermore, excluding the signal sequence regions (which are not present in the mature form 
of either protein) Chinese hamster and human BiP are essentially identical. From residues 20–
654 there is only one residue that varies, a mutation of Ala650Ser from the human to hamster 
protein. This amino acid is in the unstructured C-terminus of the protein, two amino acids 
upstream of the terminal KDEL sequence and is not present in the crystallised BiP-AMP 
construct (residues 27–549). The use of human FICD and hamster BiP together, therefore, 
effectively represents a homologous human system. 
State 1 and state 2 crystals yielded very similar deAMPylation complex diffraction datasets 
and overall structures with almost identical intermolecular contacts (Table 1 and Figure 2.1.2). 
As the state 1 crystal diffracted to a higher resolution (1.70 rather than 1.87 Å) all future figures 
in this chapter will be derived from analysis of the state 1 deAMPylation complex structure. I 
will return to the relevance of the state 2 crystal in Chapter 4. 
 
Figure 2.1.2: Comparison between state 1 and state 2 deAMPylation complex structures. The two structures 
are nearly identical in terms of overall conformation and intermolecular contacts. Features (including domains 
and subdomains) of FICD and BiP-AMP are labelled, and the bound AMP moiety (along with its interacting 
residues) are shown as sticks.  





Figure 2.1.3: Protein-protein interaction surfaces within the deAMPylation complex. The deAMPylation complex 
crystal structure is colour-coded to illustrate its (sub)domain organisation. a, Structural superposition (based on 
alignment of the NBD) of the (state 1) deAMPylation complex with the ATP-state of isolated BiP-AMP (PDB 
5O4P, light grey). b, The intermolecular interaction surface of FICD(TPR1) with BiP is highlighted (viewed from 
inside the complex, looking outwards towards the bulk solvent). The BiP surface is tripartite, composed of its 
NBD, interdomain linker and SBD. Selected interdomain contacting residues are shown (including the contacts 
formed between FICD’s TPR2 motif and Fic domain). Polar interactions (hydrogen bonds and/or salt bridges) are 
depicted by pink dashed lines. Residues mutated in this study are shown in green and labelled. c, The second 
protein-protein intermolecular surface is made up of BiP ℓ7,8 and ℓ5,6 and the catalytic Fic domain. The Fic domain 
flap (which forms an intermolecular -sheet with ℓ7,8) is highlighted in brown. 
The BiP-AMP, crystallised in both structures, is clearly present in a domain-docked, ATP-like 
state — as evidenced by the close similarity to the isolated ATP-state BiP-AMP structure (the 
ATP-state Hsp70 prominently featured in Figure 1.2.1b). Across all 521 C pairs the ATP-
state BiP-AMP structure only possesses a 1.02 Å root-mean-square deviation (RMSD) from 
the deAMPylation complex AMPylated BiP molecule (Figure 2.1.3a; state 1 structure is 
shown). The tertiary structure in the NBD region is particularly similar, with only 0.48 Å 
RMSD across the 384 C pairs.  
The deAMPylation complex displays an extensive bipartite protein-protein interface totalling 
approximately 1366 Å2. The marginally larger of the two interfaces is formed by engagement 
of BiP with FICD’s tetratricopeptide repeat domain motif 1 (TPR1). FICD(TPR1) contacts a 
tripartite BiP surface (695 Å2) comprised of BiP’s NBD, linker and SBD (Figure 2.1.3b and 
Figure 2.1.4). The second surface is comprised of the Fic catalytic domain engaging BiP’s 




SBD, markedly in the region of the AMPylated target residue (Thr518 within ℓ7,8). This 
protein-protein interaction region (totalling 671 Å2) prominently features the Fic flap which 
forms an antiparallel, intermolecular -sheet with BiP ℓ7,8 (Figure 2.1.3c and Figure 2.1.5a).  
 
Figure 2.1.4: Schematised view of all FICD•BiP-AMP intermolecular contacts. All polar (hydrogen bonds 
and electrostatic interactions) and hydrophobic protein-protein contacts between FICD and BiP are illustrated. 
The (sub)domain origin of the interacting residue is also annotated. Residues mutated in the study are labelled in 
green.  
Flap-mediated, sequence independent registration of target protein has been previously 
observed in other Fic proteins (Xiao et al, 2010; Goepfert et al, 2013). FICD’s Fic flap does 
not hydrophobically clamp the target residue (BiP’s Thr518-AMP) (Figure 2.1.5a). Instead, 
FICD’s Val316 (at the end of the Fic flap -strand) makes a number of hydrophobic 
interactions with the adenosine ring of the AMP moiety. This is unlike the Fic protein-substrate 
complex of IbpA•Cdc42-AMP (PDB 4ITR, Figure 2.1.5b) and the Fic proteins structures of 
VbhA/VbhT(Fic) (PDB 3SHG) and SoFic (PDB 3EQX), which display crystallographically 
induced Flap•peptide binding, in which a hydrophobic target residue clamp was observed (Xiao 
et al, 2010; Goepfert et al, 2013). The discrepancy between the FICD deAMPylation complex 
presented here and previous Fic•(pseudo)substrate structures suggests that the hydrophobic 
clamp is not a universal feature of Fic protein substrate engagement.  
 





Figure 2.1.5: The Fic flap does not clamp BiP’s Thr518.  Structural superpositions of the state 1 deAMPylation 
complex (FICD•BiP-AMP) with a single protomer of the dimeric FICD:MgADP structure (PDB 4U0U) and the 
IbpA•Cdc42-AMP post-AMPylation structure (PDB 4ITR), as indicated. All structures are aligned by residues 
348–384 of FICD (which encompasses the conserved Fic motif). The lower panels present more focussed views 
of the Fic domain flap-substrate interacting regions. Hydrogen bonds are indicated with pink dashed lines and 
hydrophobic interactions are annotated with green dashed lines. a, below, The side chains of residues Val314 and 
Val316, which are located within the Fic domain flap of FICD (residues 311–323, highlighted in brown) and sit 
either side of BiP(Thr518-AMP), are not within hydrophobic interaction distance of the Thr518 side chain. b, 
below, In contrast, the Fic flap of IbpA (via Leu3668 and Lys3670) clamps the Tyr32 target residue of Cdc42 (as 
annotated). Note, both FICD’s Val316 and, to a lesser extent, IbpA’s Lys3670 form hydrophobic contacts with 
the adenosine ring. The FICD:MgADP structure is shown for reference in both lower panels. 
As expected, the AMP moiety (covalently attached to BiP’s Thr518) was inserted into the Fic 
domain active site, contributing an additional 306 Å2 interaction surface to the deAMPylation 
complex. The adenosine bound in FICD’s Fic domain hydrophobic pocket occupies 
approximately the same position as in previous (poorer resolved) FICD:nucleotide complexes 
(Bunney et al, 2014) (Figure 2.1.3c, Figure 2.1.5a).  
Although monomeric FICD retains the ability to deAMPylate BiP, its deAMPylation activity 
is reduced relative to the wild type dimeric form of the Fic protein (Perera et al, 2019). In an 




effort to understand how applicable the contacts observed between BiP-AMP and FICDL258D 
may be to a heterotetrameric complex (formed by saturation of both active sites of a dimeric 
FICD with BiP-AMP), two monomeric FICD-containing deAMPylation complexes (state 1) 
were superposed with a dimeric FICD structure (PDB 4U0U; 2.58 Å RMSD over 334 C pairs 
across each FICD protomer). In addition, the complete BiP lid was built into the deAMPylation 
complex via alignment of the full-length BiP:ATP structure (Figure 2.1.6). Note, the full-
length BiP:ATP structure (PDB 5E84) is largely similar to the isolated (lid-truncated) BiP-
AMP structure (PDB 5O4P) (Figure 1.2.1) and should provide a good indication of the position 
of the intact ATP-state BiP lid (which includes SBD’s helix B and -helical bundle).  
 
Figure 2.1.6: The heterodimeric crystal structure is compatible with FICD dimerisation. Superposition of 
two heterodimeric crystal structures (purple BiPs and yellow FICDs) with an FICD dimer structure (PDB 4U0U, 
grey). In addition, the full-length BiP lid is modelled (green) based on alignment with the BiP:ATP structure (PDB 
5E84). This alignment suggests that the heterodimer crystal structure is fully compatible with a transformation 
into a full length heterotetramer deAMPylation complex, and with the proposed ER membrane orientation of 
FICD. The unstructured linker joining the ER membrane to the resolved portion of FICD (starting at expression-
tag Ser103 followed by FICD residues 104–445) is cartooned in orange. Semi-transparent (alternate) surfaces are 
shown, coloured according to coulombic electrostatic potential. Note the charge complementarity between the 
BiP(NBD), negative/red visible on the left, and FICD(TPR1), positive/blue visible on the right. The 
neutral/hydrophobic surface of FICD’s adenosine binding pocket, partially covered by its flap, is also visible on 
the right, bound to BiP’s Thr518-AMP residue. For illustrative purposes the N-terminal unstructured region of 
FICD is shown in the context of an ER membrane (grey rectangle). 
The resulting structural alignment demonstrates that that the heterodimeric deAMPylation 
crystal structure is compatible with a deAMPylation complex of dimeric FICD engaging two 
full-length BiP-AMP molecules and with the type II transmembrane orientation of FICD 




(Bunney et al, 2014; Sanyal et al, 2015). Moreover, the alignment with dimeric FICD (Figure 
2.1.6) also reveals intra-TPR domain movement (of the deAMPylation complex FICD) away 
from the catalytic core, especially in the TPR1 motif region. This is likely a corollary of the 
TPR1 motif’s interaction with the tripartite BiP surface in the context of the deAMPylation 
complex. 
 
Chapter 2.2: Heterotetramer solution structure validation 
The process of crystal packing during macromolecular protein crystallography inherently 
results in the formation of non-physiological protein-protein interactions. Very weak affinity 
surface contacts or low probability protein states can also be stabilised by the high protein 
concentrations required for crystallisation or the particular crystal packing environment. There 
are a number of ways to assess the potential physiological significance of protein-protein 
interfaces observed crystallographically. For instance, the majority of non-natural crystal 
contacts are small in surface area and form relatively non-specific protein-protein interfaces. 
This contrasts with the deAMPylation complex crystal structures in which the bipartite protein-
protein interface (totalling 1370 Å2), noted above, is very large and much greater in surface 
area than any other contacts observed in the crystal structure. Moreover, the PISA estimated 
solvation free energy gain (∆iG) upon formation of this interface (excluding the AMP 
contribution) is –7.3 kcal/mol. The probability of achieving a lower ∆iG for the given interface 
area, if residues were selected at random from the protein surface, was estimated to be 0.35 (P-
value). The PISA calculated ∆iG P-value being < 0.5 suggests that the hydrophobicity of the 
observed protein-protein interface is higher than would be expect from a crystallisation artifact 
(Krissinel & Henrick, 2007). Importantly, the observation that the covalently attached AMP 
residue sits within the active site of FICD (which is known to be responsible for additional and 
removal of the AMP moiety to/from BiP) is the strongest indication that the observed protein 
interface is physiological.  
Nevertheless, it is important to further assess the significance of the protein-protein interface 
observed in the deAMPylation complex and in particular the importance of the FICD(TPR)-
BiP interface. As mentioned above, the heterodimeric deAMPylation crystal structure appears 
compatible with dimerisation of FICD and with a full-length BiP lid subdomain (Figure 2.1.6). 
However, it is known that monomeric FICD although capable of deAMPylation is a poorer 
deAMPylase than dimeric FICD (Perera et al, 2019). Therefore, it does not necessarily follow 




that dimeric FICD will interact with BiP-AMP in the same fashion. Moreover, irrespective of 
concentration or crystal packing artifacts, crystals provide a single structural snapshot, 
presumably of a local energy minimum. This may deviate from the average structure of a 
protein (complex) in solution.  
Therefore, in order to assess the validity of the structural insights gained from the heterodimeric 
deAMPylation complex crystal (obtained with monomeric FICDL258D-H336A and a lid-truncated 
BiP-AMP), and its applicability to the complex formed between dimeric FICD (a stronger 
deAMPylase than FICDL258D) and BiP-AMP, a solution-based structural method was employed 
using intact proteins (dimeric FICDH363A and ‘full-length’ BiPT299A-V461F). It should be noted, 
that the full-length BiP commonly used for in vitro experiments, and throughout this study, is 
in fact composed of BiP residues 27–635. As mentioned above this excludes the N-terminal 
signal sequence and short unstructured acidic patch. In addition, truncation to residue 635 
removes the C-terminal 19 amino acids which are unstructured and include the KDEL region. 
These regions are not required for the vitro functionality of BiP (Preissler et al, 2015a, 2015b).  
Low-resolution structures of biomacromolecules can be resolved in solution by small angle X-
ray and neutron scattering (SAXS/SANS). SAXS is sensitive to electron density, while SANS 
is sensitive to atomic nuclei. For mixed complexes with two components, contrast variation 
SANS is able to distinguish between proteins that are differentially isotopically labelled. To 
enable this analysis, matchout (partially) deuterated proteins were expressed by collaborators 
working in the Institut Laue–Langevin Deuteration laboratory (Grenoble, France). E. coli cell 
pellets were shipped to the UK to enable further protein purification. Partially deuterated 
(dProtein) and non-deuterated (hProtein) complexes of dimeric FICDH363A and full-length 
BiPT299A-V461F-AMP were copurified by SEC into buffers with varying D2O content. Contrast 
variation solution scattering data were subsequently collected (Figure 2.2.1). 





Figure 2.2.1: Small angle neutron scattering curves. Buffer subtracted contrast variation SANS data from 
complexes of a, non-deuterated FICDH363A (hFICD) with partially deuterated BiPT229A-V461F-AMP (dBiP-AMP) 
and b, partially deuterated FICDH363A (dFICD) with non-deuterated BiPT229A-V461F-AMP (hBiP-AMP). Scattering 
intensity data, I(q), is plotted against the modulus of the scattering vector, q. SANS data is acquired over a range 
of sample buffer conditions with varying D2O content (indicated). Overlaid dotted black lines are theoretical 
scattering curves based on the modelled heterotetramer shown in (Figure 2.1.6), dashed green lines are the 
theoretical scattering curves from flex-fitting of the input heterotetramer model with a constrained FICD dimer 
interface. Error bars represent SEM with respect to the number of pixels used in the radial data averaging.  
Analysis of the low-q Guinier region provides information pertaining to the forward scattering, 
I(0), and radius of gyration, Rg, in each solution (Figure 2.2.2); where q is the magnitude of 
the scattering vector.  




where  is the incident neutron beam wavelength (in nm) and the scattering angle (in degrees) 
is 2. The low-q region is described as the low scattering angle range where qRg < 1.5 (ideally 
< 1.3) and the Guinier approximation is therefore valid (Guinier & Fournet, 1955). 





Plotting ln(I(q)) against q2 permits the fitting of a derivation of Equation 2: 




𝑞2  (3) 




This permits the extraction of I(0) and Rg values for each scattering curve. The q limits for 
fitting are shown (vertical dashed lines in Figure 2.2.2) and result in qRg < 1.3 (with the 
exception of the fitting of dFICD•hBiP-AMP in 80% D2O buffer where qRg = 1.4). On the 
whole, the Guinier scattering curves presented little evidence of polydispersity (in the form of 
interparticle repulsion or aggregation).  
 
Figure 2.2.2: Guinier plots of the SANS data. a, Guinier plot of partially deuterated FICD and non-deuterated 
AMPylated BiP across a range of %D2O buffer conditions. b, as in a but complexes of non-deuterated FICD and 
partially deuterated AMPylated BiP are analysed. Vertical dotted lines indicate the q-range over which the Guinier 
curve fitting was implemented. Due to apparent interparticle repulsion (which is evident as q → 0) the lower q-
fitting limit was increased for the dFICD•hBiP-AMP sample in 80% D2O (purple dotted line) such that all fits (in 
both a and b) were made in a region where qRg ≤ 1.4. 
The scattering amplitude, I(0), is directly proportional to both the square of the contrast and 
the fractional term in Equation 4, also known as n the number density (Zaccai et al, 2016): 




where V is the volume of the complex (cm3), c is the concentration of the protein complex 
(g/cm–3), NA is Avogadro’s number (6.022 × 10
23 mol–1) and MW is the molecular weight of the 
protein complex (g mol–1, equivalent to Da). ∆ is the contrast of the sample (cm–2), which is 
defined as the difference in scattering length density (SLD) between the protein complex and 
the buffer (protein – buffer). As the SLD of the buffer is dominated by the D2O content (and 
therefore to a good approximation increases linearly with %D2O) and the SLD of the protein 
also varies linearly with %D2O, due to labile hydrogen/deuteron (H/D) exchange, it follows 
that √𝐼(0) 𝑐⁄ ∝ %D2O.  




Figure 2.2.3: Scattering amplitude plot. Linear best-fit curves are 
displayed with dashed lines and 95% confidence interval bands in 
colour-matched solid lines. Error bars are derived from SE of Guinier 
fits (Figure 2.2.2).  
 
 
The determination of I(0) values, combined with measurement of the sample protein  
concentration, therefore facilitated the calculation of each complex’s contrast match point 
(CMP; Figure 2.2.3) — the %D2O value at which there is no contrast (∆ = 0). The resulting 
analysis produced CMP values of 77% D2O (95% CI: 72 to 82% D2O) for hFICD•dBiP-AMP 
and 61% D2O (95% CI: 57 to 66% D2O) for dFICD•hBiP-AMP.  
Theoretical CMPs can also be calculated based on protein (complex) amino acid composition 
and buffer compositional effects. Assuming a 1:1 protein complex and 95% labile H/D-
exchange, comparison of the experimentally observed CMPs with theoretical values calculated 
by MULCh (Whitten et al, 2008), suggest that dFICD was 63.8% deuterated at non-
exchangeable hydrogens and dBiP-AMP was 66.5% deuterated. These values of protein 











MW (kDa) 220 220 ± 10 250 ± 30   
Rm [Rg of complex] (Å) 60.1 
58 ± 19 (43 to 
70) 
63 ± 14 (58 to 
68) 
57.8 59.7 
Rg of FICDs (Å) 34.5 41 (17 to 55) 38 (14 to 52) 36.9 37.2 
Rg of BiPs (Å) 69.0 63 (52 to 73) 74 (69 to 79) 66.3 69.0 
2 (reduced data) 2.4 ± 2   2.4 ± 0.8 1.7 ± 0.4 
 
wa 
Table 2: Low-q SANS parameters and flex-fitting results. Summary of biophysical parameters derived from 
forward scattering (MW; molecular weight) and Stuhrmann analysis of the contrast variation SANS data over the 
low-q (Guinier) region. Copurified complexes of non-deuterated FICDH363A (hFICD) with partially deuterated 
BiPT229A-V461F-AMP (dBiP-AMP) and partially deuterated FICDH363A (dFICD) with non-deuterated BiPT229A-
V461F-AMP (hBiP-AMP) were analysed. The mean MW ± SD is calculated across all curves excluding the 60% 
D2O datasets, which are close to the contrast match points for both partially deuterated complexes. Radii of 
gyration parameters are best fit or interpolated values ± SE (and/or 95% CI) from the Stuhrmann curve fittings 
(Figure 2.2.4). Parameters from the best flex-fit heterotetramer models are also shown with theoretical Rg values 
and overall 2 goodness of fit (mean ± SD) against the reduced scattering dataset (Figure 2.2.5 and Figure 
2.2.6). 




et al, 2012). Comparison of the theoretical I(0)/c values with those determined from the (above) 
experimental Guinier analysis facilitated experimental protein complex MW estimation (Table 
2) — which was in good agreement with a heterotetrameric 2:2 complex of FICD•BiP-AMP.  
Based on the calculated protein deuteration values the contrast at each %D2O can also be 
calculated. A Stuhrmann plot (derived from plotting the square of the Rg data against the 
reciprocal of the contrast) provides information on the internal arrangement and size of the 












2 represent the Rg of the complex if it had a homogenous SLD;  reflects the radial 
distribution of SLD and  reflects the distance of the centre of the complex’s SLD from the 
complex’s centre of mass. Through this analysis (in concert with MULCh-derived individual 
component match points), a number of experimental Rg parameters were extracted (Figure 
2.2.4). The Rg provides an indication of protein component/complex size and, in the context of 
SANS, is a measure of the average contrast weighted distance from the centre of mass to each 
scattering element. The Stuhrmann derived Rg parameters are in good agreement with the 
theoretical values calculated from the input heterotetramer model using CRYSON analysis 
software (Svergun et al, 1998) (Table 2).  
Figure 2.2.4: Stuhrmann plot. Best-fit curves are displayed with 
dashed lines and 95% confidence interval bands in colour-matched 
solid lines. The determined match points of the individual complex 
components are indicated on the x-axis. Error bars are derived from 
SE of Guinier fits (Figure 2.2.2). 
 
 
In the case of the Stuhrmann plot of dFICD•hBiP-AMP a linear best-fit line (suggesting 
  ) was a considerably better fit to the data (shown in Figure 2.1.6; R2 = 0.93) than the 
fitting of a quadratic curve (R2 = 0.66). This suggests that the dFICD•hBiP-AMP complex has 
an SLD centre which is very close to the complex’s centre of mass (COM). The converse is 
true for the Stuhrmann fit of the deuterated BiP-AMP complex, which is much more quadratic 
(R2 = 0.95 for    versus 0.89 for  = ) — revealing little overlap between the hFICD•dBiP-




AMP complex’s SLD centre and COM. As semi-deuteration of a component increases its 
relative contribution to the overall SLD, these findings are consistent with a heterotetramer in 
which the centre of mass lies in the plane of the FICD dimer and above the plane of the majority 
of the BiP mass. This arrangement fits well with the structural model of the heterotetramer 
presented in Figure 2.1.6. Moreover, the value of  also provides valuable information about 
the structural organisation of the complex, with values of    suggesting that the higher 
contrast component of the complex is located towards the outside of the complex. Thus, it can 
be inferred from the Stuhrmann analysis, of both hFICD•dBiP-AMP and dFICD•hBiP-AMP, 
that FICD is on the inside and BiP-AMP towards the outside of the complex; this is again 
entirely consistent with the modelled heterotetramer structure (Figure 2.1.6).  
Figure 2.2.5: Goodness of fit from SANS structure 
modelling. Heat-map of the 2 goodness of fit of the 
theoretical scattering curve derived from each flex-fit model, 
against all observed experimental scattering datasets. The 
major NW to SE diagonal illustrates the optimised 2 of each 
flex-fit model from its progenitor dataset. For example, 
output structure 2 is derived from normal mode flex-fitting of 
the input structure (Figure 2.1.6) so as to minimise its 2 
relative to the scattering data obtained from hFICD• 
dBiP-AMP in 10% D2O. Note, the *flanked dataset resulted in anomalously poor model fits. 
By analysing the data across the entire q-range it is possible to extract further information about 
the internal arrangement of the heterotetramer. Across all D2O concentrations, the theoretical 
scattering profile of the heterotetramer (modelled in Figure 2.1.6) correlated well with the 
experimental scattering, with an overall average 2 of 3.4 ± 4 (mean ± SD) or 2.4 ± 2 following 
anomalous dataset removal (black dotted lines in Figure 2.2.1, quantified in Figure 2.2.5). 
This was true even at D2O concentrations close to the CMP for each deAMPylation complex, 
where the scattering profile is very sensitive to both the shape and stoichiometry of the particles 
in solution. Furthermore, the best flex-fit structure (generated for each scattering dataset by 
allowing the input structure to undergo normal mode analysis (NMA) flexing of its domains in 
order to minimise the 2 of the output flex-fit structure from that scattering dataset) did not 
cause significant changes in the predicted scattering profile (green dashed lines in Figure 
2.2.1). The SANS data thus indicate that the vast majority of particles in solution are engaged 
in a heterotetramer with neutron scattering properties closely aligned to those predicted by a 
heterotetramer model based on the heterodimer crystal structure (Figure 2.1.6). 





Figure 2.2.6: Evaluation of input and flex-fit heterotetramer models. a, Comparison of the average 2 for each 
model. The ‘reduced data’ average 2 (green) is derived from fitting to all data excluding the anomalous scattering 
observed for dFICD•hBiP-AMP in 100% D2O (*in Figure 2.2.5). Error bars represent SEM. b, Comparison of 
Stuhrmann analysis derived Rg (coloured, horizontal dotted lines) with the calculated Rgs of the input and output 
structures. In c and d symmetric output structures are underlined and flex-fit structures highlighted in bold have 
2 SDs (derived from the analysis of the reduced SANS dataset; green in a) which are less than and significantly 
different to the input model’s 2 SD (P < 0.05 by F-test). 
As mentioned above, no individual flex-fit structure produced a significantly reduced average 
2 across all datasets. The initial flex-fitting strategy (and that displayed in Figure 2.2.1) 
permitted non-linear rigid block NMA at all interdomain boundaries with the exception of the 
FICD dimer interface, which was constrained on account of its very low (nanomolar) in vitro 
KD (Perera et al, 2019). However, the experimental FICD Rg values derived from the 
Stuhrmann analysis were slightly higher than that possessed by the input heterotetramer model 
and the dimer interface-restrained flex-fit output models (Figure 2.2.6). Therefore, a flex-
fitting strategy with the dimer interface left unconstrained was also employed. This did not 
result in an overall improvement in output model quality (2) relative to the dimer interface-
constrained strategy (Figure 2.2.6). However, a number of flex-fit output structures (from both 
flex-fit strategies) did have significantly different and reduced 2 variances relative to that of 
the input model (Figure 2.2.6a, underlined). The majority of flex-fit structures possessed Rg 
parameters which were in good agreement with the Stuhrmann derived Rg values (Figure 
2.2.6b). Moreover, when the dimer interface was constrained, the principal variation in the 
flex-fit structures was evident in BiP(NBD) and FICD(TPR) domain reorientation and in the 
BiP lid region (Figure 2.2.7).  





Figure 2.2.7: Comparison of flex-fit structures. Structures are derived from normal mode (inter-domain) flex-
fitting with constraints only placed on the very tight dimer interface of FICD. All structures are aligned to FICD 
of the input heterotetramer structure (orthogonal view to that displayed in Figure 2.1.6), with FICDs in red and 
BiP-AMPs in magenta. Also, as in Figure 2.1.6, the centre of mass of the input model is indicated (cyan sphere). 
a, Superposition of all 12 flex-fit output structures. b, As in a but only displaying the top 5 flex-fit structures 
aligned to the input heterotetramer — those which produce statistically significant reductions in scattering 2 SDs 
relative to the input model. 
Previous Michaelis-Menten analysis of FICD deAMPylation produced no evidence of 
(negative or positive) enzyme cooperativity (Preissler et al, 2017a), which suggests that the 
two BiP binding sites of an FICD dimer operate independently from one another. 
Consequently, symmetry is to be expected from an average solution structure of a 
heterotetrameric deAMPylation complex which has an FICD dimer (which itself possesses C2 
rotational symmetry) at its core. Surprisingly, only around half of the flex-fit output structures 
maintained the C2 rotational of the input heterotetramer structure (Figure 2.2.7, highlighted in 
bold in Figure 2.2.6).  





Figure 2.2.8: Kratky plots of a best-fit dimer-restrained solution structure. Kratky plots of selected scattering 
curves highlighting the relative fits of the input model, dimer constrained best-fit structure and a poorer fitting 
rigid-body docking model (dashed lines). Inset, colour-matched models aligned by the FICD dimer, shown in 
orthogonal views. As expected, the rigid body dock model produces a poorer fit to the scattering data, which is 
especially evident when the buffer D2O content approaches the complex CMP (60% D2O datasets). Note, the 
Kratky plot scattering intensity profiles (with internal scattering features and slowly descending right-hand-side 
tails) are consistent with FICD•BiP-AMP being a flexible protein complex. 
Thus, each flex-fitting strategy yielded only one best-fit structure that possessed both symmetry 
and a significantly reduced 2 SD (Figure 2.2.8, Figure 2.2.9 and Figure 2.2.6, bold and 
underlined). The best-fit structure derived from leaving the high affinity FICD dimer interface 
unconstrained (mean 2 goodness-of-fit across the reduced data set 1.7 ± 0.4) is closer in 
conformation to the input structure than that obtained with a restrained dimer interface (mean 
2 2.4 ± 0.8) (Table 2), with an RMSD from the input heterotetramer structure of 5.4 and 7.1 
Å (across all 1,892 C pairs), respectively (Figure 2.2.9). Both output structures demonstrate 
good Rg agreement with the Stuhrmann analysis. Importantly, the best-fit complexes’ FICD 
Rgs are increased and in better agreement with the experimentally derived values, relative to 
the input structure (Table 2 and Figure 2.2.6b, bold and underlined). Moreover, the observed 
model deviations (from input to best-fit models) are indicative of additional deAMPylation 
complex flexibility in solution, in particular in the composite FICD(TPR)-BiP(NBD) interface 
and in the disposition of the BiP lid (SBD subdomain) (Figure 2.2.9). This flexibility is 
inaccessible to crystallographic analysis of BiP (complexes) but is consistent with previous 
observations of Hsp70 conformational dynamics (Zhuravleva et al, 2012; Wieteska et al, 
2017).  





Figure 2.2.9: Optimal best-fit solution structures. Optimal flex-fit structures with respect to overall agreement 
(of their theoretical scattering profile) with all experimental contrast-variation SANS datasets. Output structures 
are aligned to FICD of the input heterotetramer model, itself derived by imposing the C2 symmetry of the FICD 
dimer (PDB 4U0U) onto the heterodimeric deAMPylation complex crystal structure (as shown in Figure 2.1.6). 
The structural deviation between the best-fit solution structures and the input model is indicative of inter-domain 
flexibility present in solution. 
 
Chapter 2.3: The TPR domain is essential for deAMPylation 
Having established the validity of the heterodimeric crystal structure, in the context of a 
heterotetrameric complex in solution, I was curious to understand the sensitivity of 
deAMPylation activity and complex assembly to perturbations in the observed contacts linking 
the FICD TPR domain to BiP (Figure 2.1.3 and Figure 2.1.4). The ability of different FICDs 
to bind either modified or unmodified BiP can be assayed via the immobilisation of a protein 
ligand (BiP) onto a biosensor. Analyte (FICD) association and dissociation can then be 
monitored in real time utilising BioLayer Interferometry (BLI). By the introduction of a 
His363Ala mutation into all tested FICD variants that contain a catalytic domain, all analytes 
can be rendered catalytically dead and the effects of any given mutation on FICD•BiP±AMP 
complex assembly and disassembly can be monitored (without the possibility of any 
convoluting effects of covalent ligand modification).  





Figure 2.3.1: Immobilised BiP ligand can respond to and be saturated by ATP. a, BLI traces of the interaction 
between FICDL258D‐H363A and immobilised biotinylated BiPT229A‐V461F in different nucleotide states. Before 
exposure to FICDL258D‐H363A immobilised BiP:Apo was subjected to two consecutive incubation steps (activation 
and wash) in the presence or absence of ATP as indicated. FICD association and dissociation steps (shown) were 
then conducted in a nucleotide (Nt.)‐free solution. Note that BiP only interacts with FICDL258D‐H363A when pre‐
saturated with ATP. Importantly, ATP pre‐bound BiP retains its affinity for FICDL258D‐H363A even if subsequently 
washed in a buffer lacking ATP (compare red and green traces). Thus, the majority of BiP remains in its ATP-
state for the duration of the kinetic experiment, experimentally uncoupling the effect of nucleotide on the FICD 
analyte from its effect on the immobilised BiP ligand. b, Cartoon schematic of the BLI assays presented in a. The 
pre‐AMPylation complex is formed between the immobilised BiP:ATP ‘ligand’ and the FICD ‘analyte’. 
As FICD has a preference for ATP-state BiP as an AMPylation substrate (Preissler et al, 
2015b), it was important to establish that immobilised BiP could still respond allosterically to 
ATP. To this end, N-terminally avi-tagged, in vitro biotinylated, non-AMPylated, ATPase dead 
and substrate binding deficient apo BiP (BiPT229A-V461F:Apo), was loaded onto the BLI 
streptavidin biosensor. Preincubation of the immobilised BiP with MgATP resulted in a 
significant increase in its ability to interact with monomeric and catalytically dead FICD 
(FICDL258D-H363A) (Figure 2.3.1). This suggests that immobilised BiP is able to bind and 
respond allosterically to ATP and that FICD has both a preference for binding (as well as 
AMPylating as previously demonstrated) the ATP-state of BiP. Moreover, BiP’s binding and 
response to ATP was saturable and the allosteric effect of ATP-binding was long lasting, even 
when incubated for a prolonged period of time in a buffer lacking ATP (Figure 2.3.1), a 
phenomenon presumably potentiated by BiP’s ATPase activity–inhibiting Thr229Ala 
mutation.  




As AMPylation of BiP both intrinsically biases the Hsp70 towards its ATP-state and decreases 
its intrinsic ATPase activity (Preissler et al, 2015b, 2017b; Wieteska et al, 2017); BiPT229A-
V461F-AMP once bound to ATP will release ATP at a much slower rate than its unmodified 
form. This is attested to by the observation that it becomes much more difficult to remove 
nucleotide from BiP, by dialysis, once the BiP is AMPylated (as measured by A260/280 ratio, 
data not shown).  
 
Figure 2.3.2: FICD’s TPR domain is essential for binding BiP. Association and dissociation traces of FICD 
analytes (concentrations indicated in the legend) from immobilised BiP bound to ATP (either AMPylated or 
unmodified), are shown. Shown, is a single set of representative BLI curves from n = 3 independent experiments. 
Removal of the TPR1 motif (∆TPR1) from FICDH363A abrogates the ability of the FICD to bind either ATP-state 
BiP or BiP-AMP. The TPR domain alone (FICD residues 104–186) can interact with both BiP:ATP and BiP-
AMP:ATP. The ability for full analyte dissociation suggests that there is little non-specific binding of analyte to 
the biosensor. 
It was found that BiP bound more tightly to monomeric FICDL258D-H363A than to dimeric FICD 
(Figure 2.3.2). The converse was true for the binding to AMPylated BiP. Complex dissociation 
was further accelerated by the addition of ATP to the dissociation buffer; in the case of 
dissociation from immobilised BiP-AMP this is presumably via direct competition of ATP with 
the BiP’s covalently linked AMP moiety for the active site of FICD, during a multi-step 
dissociation of the analyte. Crucially, upon removal of the TPR1 motif, dimeric FICD lost all 
ability to bind either BiP ligand (Figure 2.3.2). As predicted by the mode of TPR binding in 
the crystal structures, the isolated TPR domain measurably interacted with the ATP-bound BiP 
ligands in a manner that was not affected by BiP’s covalent modification status. 





Figure 2.3.3: Biophysical characterisation of FICD mutants. a, Representative normalised differential 
scanning fluorimetry (DSF) melt curves (top curves and left y-axis) with corresponding negative first derivatives 
of the melt curves (bottom curves and right y-axis). Global minimums of the latter were used to calculate the 
melting temperature. Melt curves were collected in technical duplicate. RFU, relative fluorescent units. b, The 
derived protein melting temperatures (Tm, mean ± 95% CI) derived from n = 3 independent DSF experiments. 
Note, all FICD variants (like FICDL258D-H363A) are stabilised by nucleotide binding. Most FICD mutations do not 
cause large changes in Tm. The most destabilised FICD variant is in fact FICDL258D-H363A(TPRox) despite the 
presence of a disulphide bond fixing the TPR domain in place. c, PEG 2000 maleimide-based electrophoretic 
mobility assay analysis of the oxidation status of monomeric FICDL258D-H363A(TPRox), demonstrating almost 
complete disulphide-stapling of the FICD’s TPR domain to its -helical linker/C-terminal capping helix (Figure 
2.1.3). d, Schematised model of the BLI protocol (for immobilised BiP ± AMP) preceding the association and 
dissociation phases displayed in Figure 2.3.2 and subsequent BLI figures. 
The introduction of point-mutations into residues at the FICD(TPR1)-BiP interface (mutated 
residues highlighted in Figure 2.1.3 and Figure 2.1.4), whilst not perturbing the structural 
integrity of the FICD variants (Figure 2.3.3), significantly affected the kinetics of FICD 
association and dissociation of both monomeric and dimeric FICD variants (Figure 2.3.4). This 




agrees with the notion (suggested by the solution structure analysis) that monomeric and 
dimeric FICD similarly engage AMPylated BiP. Moreover, in keeping with the 
crystallographically observed multivalent nature of the deAMPylation complex, the kinetics of 
FICDL258D-H363A•BiP-AMP interaction appears biphasic and becomes increasingly monophasic 
upon disruption of FICD(TPR1)-BiP contacts (Figure 2.3.4a).  
 
Figure 2.3.4: FICD(TPR1) mutations disrupt deAMPylation complex assembly. a, Representative BLI 
analysis of TPR domain mutants of monomeric FICDL258D-H363A binding to immobilised AMPylated BiP, from n 
= 3 independent experiments. Note, TPR domain oxidation (TPRox) appears to increase the affinity of FICDL258D-
H363A for BiP-AMP. b, As in a but the tested analytes are all derivates of (dimeric) FICDH363A. In a and b, as in 
Figure 2.3.2, the beginning of each dissociation phase is indicated with vertical dashed lines and the second 
dissociation buffer is supplemented with 2 mM ATP.  
To address the role of interdomain contacts between FICD’s TPR and catalytic Fic domain in 
deAMPylation complex stability, one of two contacting residues within FICD’s TPR2 motif 
(Asp160) was mutated (highlighted in Figure 2.1.3). However, FICD’s TPR domain has also 
been observed to fully disengage from the capping/linker helix, exhibiting a ‘TPR-out’ 
conformation (PDB 6I7K and 6I7L). To analyse the effect of perturbed interdomain contacts, 
whilst maintaining the BiP binding–competent ‘TPR-in’ conformation, Asp160 and Thr183 
(the latter located within FICD’s capping/linker helix; Figure 2.1.3) were both mutated to 
cysteines and oxidised to stoichiometrically form an intramolecular disulphide bond (TPRox, 
Figure 2.3.3c). TPR oxidation within monomeric FICDL258D-H363A resulted in more biphasic 
kinetics and a significant decrease in dissociation rate from BiP (Figure 2.3.4a), suggesting 
that the covalent fixation of the ‘TPR-in’ conformation outweighs the destabilising effects of 
perturbing an intramolecular Fic-TPR domain contact (also see the destabilising effect of TPR 
oxidation evident in terms Tm depreciation, Figure 2.3.3a–b). Notably, the effect on dimeric 




FICD was less pronounced (Figure 2.3.4b). These measurements are consistent with the fact 
that the ‘TPR-out’ conformation has only been observed in monomeric FICD structures and 
suggests that dimeric FICD has an intrinsically less flexible TPR domain. Nevertheless, TPR 
oxidation does alter dimeric FICD binding kinetics. The increased FICD dissociation rate, 
which is further exaggerated by the addition of ATP in the second dissociation phase, 
implicates intramolecular Fic-TPR domain communication in the regulation of complex 
association-dissociation kinetics.  
In order to assess the effects of the above TPR domain mutations on the ability of FICD to 
deAMPylate its substrate (BiP-AMP), a fluorescence polarisation (FP)-based assay was 
employed (based on the methodology originally published in Preissler et al, 2017a). In a 
previous study the effects of various FICD mutations (including the monomerisation inducing 
Leu258Asp mutation) were measured under substrate limiting conditions (Perera et al, 2019). 
That is to say, with micromolar concentrations of enzyme and only nanomolar concentrations 
of AMPylated BiP (labelled with a FAM fluorophore derivatised AMP molecule; BiP-
AMP(FAM)). Such conditions are not consistent with quasi-steady state kinetics as the 
following relationship is not met: [E]0 << [S]0 + KM; where [E]0 and [S]0 are the concentrations 
of enzyme and substrate at t = 0 and KM is the Michaelis constant — (koff + kcat)/kon.  
So as to facilitate approximate quasi-steady state kinetics at early reaction progress time points, 
BiPT229A-V461F-AMP(FAM) was used as a (nanomolar) tracer for a much larger concentration 
of BiP-AMP (with [E]0 = 0.5 µM FICD variant, [S]0 = 5 µM BiP
T229A-V461F-AMP). Such a 
method was also previously employed in order to carry out a full Michaelis-Menten analysis 
of initial deAMPylation rate versus [BiPV461F-AMP], catalysed by an N-terminally glutathione 
S-transferase tagged, dimeric, wild type FICD (GST-FICD) protein (Preissler et al, 2017a). In 
this work by Preissler et al, it was found that the KM of GST-FICD for its substrate (BiP
V461F-
AMP) was 16 ± 3 µM (best-fit ± SE). Therefore, assuming that the FICD variants tested here 
have KM ≥ 16 µM, [S]0 may be considered small enough relative to the KM such that, by 
derivation from the Michaelis-Menten equation (Michaelis et al, 2011), the following 









where v is the measured initial deAMPylation rate or enzyme velocity. The value of kcat/KM, 
which can thus be derived from the measured initial reaction rate, reflects the catalytic 
efficiency or specificity of an enzyme.  
With the aforementioned conditions of enzyme and substrate concentrations, the FICD 
deAMPylation reactions do not go to completion within the permissible time frame of the time 
course (which is limited by technical obstacles such as evaporative losses from the assay wells). 
Thus, in order to convert changes in mFP caused by liberation of AMP(FAM) from the BiP-
AMP(FAM) tracer probe by FICD-mediated deAMPylation, the difference in FP (at t = 0) 
between the (0.5 µM) FICDL258D FP time course and the same reaction preincubated for 5 h 
(and therefore fully deAMPylated) was considered to reflect the ∆FP equivalent of 5 µM 
deAMPylated BiP (Figure 2.3.5a). Initial (linear) FP deAMPylation rates (in units of mFP/s) 
were, in this way, converted to deAMPylation rates (in units of nanomolar BiP 
deAMPylated/s). Using this technique, by enzyme dilution, it could also be demonstrated that 
the FP-deAMPylation assay had a linear dynamic range down to 6.3% (1/16th) of the rate of 
0.5 µM FICDL258D (Figure 2.3.5b–c). 
 
Figure 2.3.5: Establishing an in vitro FP deAMPylation assay. a, The FP curves from which Figure 2.3.7 was 
derived illustrating the data processing carried out to facilitate deAMPylation rate calculation from FP time course 
data. The difference (in mFP units) at t = 0 between the FICDL258D deAMPylation time course of BiP-AMP(FAM) 
and the pre-incubated and fully deAMPylated reaction was taken to represent the ∆FP corresponding to complete 
substrate deAMPylation (5 µM BiP-AMP). Fits of the linear enzyme velocities are overlaid. b, The FP-converted 
time course of BiP-AMP(FAM) deAMPylation with different concentrations of FICDL258D. c, Quantification of 
the assay represented in b, from n = 4 independent experiments — demonstrating the minimum linear dynamic 
range of the assay. The dashed line illustrates the unconstrained best-fit linear relationship between the observed 
deAMPylation rate and enzyme concentration. 
 





Figure 2.3.6: FICD(TPR1) mutation impairs deAMPylation activity. Left, representative deAMPylation time 
course (after conversion of mFP units into µM of enzyme product, deAMPylated BiP). Fits of the initial linear 
enzyme velocities are overlaid (dashed lines). From the calculated initial deAMPylation rates approximate values 
for catalytic efficiency can be derived (kcat/KM, right). Mean values are shown ± SD from n = 4 independent 
experiments. More accurately the presented ~ kcat/KM values represent the values of kcat/(KM+[S]0).  
 
Figure 2.3.7: Disruption of FICD’s TPR to catalytic domain communication impairs deAMPylation 
activity. As in Figure 2.3.6 but the effect of FICD interdomain disruption (via TPR oxidation) is analysed. Note, 
the deAMPylation catalytic efficiency of monomeric FICDL258D is also impaired with respect to wild type 
(dimeric) FICD.  
Having established the basis of an in vitro deAMPylation assay, it was found that mutation or 
removal of the TPR1 motif (in the context of FICDL258D) significantly reduced the catalytic 
efficiency (kcat/KM) of in vitro deAMPylation (Figure 2.3.6). This is consistent with the 
essential role played by the TPR domain in deAMPylation complex assembly. Moreover, of 
the set of TPR1 mutants only His131Ala still falls within the (tested) linear sensitivity range of 
the assay. Formally, the deAMPylation assay allows me to conclude that the other TPR1 
mutants and deletion of the TPR1 motif (∆TPR1) decrease the initial deAMPylation rate (and 
thus the approximate kcat/KM) to a value less than 6.3% of that exhibited by FICD
L258D (see 
Figure 2.3.5c).  




Monomerisation of FICD was observed to diminish the rate of deAMPylation under a steady-
state kinetic regime (Figure 2.3.7), with a 46% decrease in kcat/KM from dimeric to monomeric 
FICD (630 ± 50 to 340 ± 30 s–1 M–1, mean ± SD, respectively). Coincidentally, this is a very 
similar to the depreciation in enzyme velocity that was previously attributed to the same 
monomerising Leu258Asp mutation, under a substrate-limited kinetic regime (Perera et al, 
2019). Moreover, the kcat/KM value calculated here for wild type (dimeric) FICD is in good 
agreement with the value derived from a ‘traditional’ Michaelis-Menten analysis of GST-
FICD: 600 ± 100 s–1 M–1 (best-fit ± SE) (Preissler et al, 2017a). This agreement between the 
calculated kcat/KM values, at least in the case of wild type FICD, validates the assumptions made 
in the use of Equation 6 for FP-deAMPylation assay data processing (Figure 2.3.6 and Figure 
2.3.7).  
Interestingly, disruption of FICD’s TPR to Fic domain interaction (via TPR domain oxidation, 
TPRox) significantly compromised the deAMPylation activity of both monomeric and dimeric 
FICD (Figure 2.3.7), despite not appreciably decreasing the observed affinity for AMPylated 
BiP (Figure 2.3.2). The effect on catalytic efficiency presumably reflects a contribution of TPR 
flexibility or intra-FICD interdomain communication towards the deAMPylation turnover 
number (kcat).  
 
Chapter 2.4: The role of Glu234 in deAMPylation 
The deAMPylation complex crystal structure contains well-resolved electron density for BiP’s 
AMPylated Thr518 residue within FICD’s (Fic domain) active site (Figure 2.4.1). Note, prior 
to deAMPylation complex assembly and copurification, the BiP protein is in vitro AMPylated 
by prolonged (16 h) incubation with millimolar concentrations of (excess) MgATP alongside 
the AMPylation hyperactive and deAMPylation defective GST-FICDE234G (see Materials and 
Methods). Despite the extensive (preparative) in vitro BiP AMPylation, no extra density 
(corresponding to even partial AMPylation) was identified on a relatively buried (and very 
well-resolved) BiP NBD residue Thr366, which has been suggested as an alternative BiP 
AMPylation site (Ham et al, 2014; Sanyal et al, 2015; Casey et al, 2017; Moehlman et al, 
2018) (Figure 2.4.2). Furthermore, this alternative modification is observed (to an unknown 
degree) upon in vitro modification of the isolated NBD (Casey et al, 2017) and appears 
completely incompatible with the mode of intact BiP engagement by FICD, as 
crystallographically observed in this study.  






Figure 2.4.1: BiP’s Thr518-AMP bound to FICD. Left, the arrangement of BiP’s AMPylated Thr518 and Mg2+ 
cation within the Fic domain active site is shown. Thr518-AMP and important catalytic residues are overlaid with 
an unbiased polder OMIT electron density map (contoured at 4). All residues interacting with Mg2+ and the AMP 
moiety are shown as sticks and annotated (see Figure 2.4.3). Additionally, all potential hydrogen bonds formed 
by FICD’s Glu234 side chain are depicted with pink dashed lines. The putative catalytic water, coordinated by 
Glu234 and located within the Fic domain oxyanion hole, is annotated with a *. The Mg2+ coordination complex 
is shown by blue dashed lines. Right, a slightly rotated and clipped view of the active site, shown on the left, with 
the electron density map omitted for clarity. In addition, all hydrogen bonds formed between FICD and the 
catalytic water* and BiP’s Thr518-AMP are shown. Pink dashed lines represent strong hydrogen bonds, orange 
dashed lines are hydrogen bonds which only meet relaxed hydrogen bond criteria (in terms of angular range and/or 
distance).  
The phosphate of Thr518-AMP is coordinated by a Mg2+ held in position by FICD’s Asp367. 
A similarly-positioned Mg2+ coordinates the  and  phosphates of ADP in previous FICD 
structures and ATP in FICDE234G (Bunney et al, 2014). Moreover, the -phosphate is also 
located within the Fic domain oxyanion hole, with coordination both from the main-chain 
amino group and side chain of FICD Asn369 (Figure 2.4.1 [right] and Figure 2.4.3). The Fic 
domain oxyanion hole contributes towards the stabilisation of ATP’s  and  phosphates in the 
AMPylating enzyme. In the context of deAMPylation it is likely that the location of the -
phosphate, being both coordinated by Mg2+ and localised within the oxyanion hole, stabilises 
the -phosphate position and the extra negative charge development that occurs during the 
deAMPylation reaction. The resolved enzyme-substrate complex, therefore rationalises the 
observed dependence of FICD’s deAMPylation reaction on divalent cations (with a preference 
for Mg2+) (Veyron et al, 2019). 





Figure 2.4.2: Electron density surrounding putative BiP AMPylation sites. Left, BiP-AMP from the 
deAMPylation complex, coloured and labelled by (sub)domain organisation. In addition, Thr518 within ℓ7,8 of the 
SBD and Thr366 within the BiP NBD are shown as sticks and coloured in cyan. Note, unlike Thr518, Thr366 is 
not a particularly solvent exposed residue within the isolated ATP-state BiP structure. Right, blow-ups of the 
highlighted residues with neighbouring amino acids also shown as sticks and overlaid with 2Fo-Fc electron 
densities maps (contoured at 2). Note, there is no unaccounted-for electron density in the vicinity of the modelled 
Thr366 and Thr518-AMP residues. The hydroxyl group of Thr366 also forms a strong hydrogen-bond (pink 
dashed line) to the main-chain of its -helix. The location of Thr366, a largely buried NBD residue within an -
helix, would appear to render this amino acid inaccessible for the intermolecular -sheet engagement required for 
Fic domain-mediated AMPylation. 
As in other crystal structures of isolated FICD bound to nucleotides (Bunney et al, 2014), the 
adenosine is bound in a hydrophobic pocket which is covered by the Fic flap domain. Indeed, 
residues Val316 and His319 of the latter form direct hydrophobic contacts to the adenine 
nucleobase (Figure 2.4.1 and Figure 2.4.3). Moreover, a number of hydrogen bonds between 
the Fic domain and adenosine contribute to anchoring the AMP moiety (Figure 2.4.1 [right] 
and Figure 2.4.3).  





Figure 2.4.3: Intermolecular contacts between BiP’s Thr518-AMP and FICD. All intermolecular contacts 
between BiP’s Thr518-AMP, Mg2+ cation (green sphere) and FICD’s catalytic Fic domain (from the state 1 
deAMPylation crystal structure) are depicted (see Figure 2.4.1). Various Fic domain features and the distance 
between the putative catalytic water* and the AMP phosphorous atom (P) are also annotated. Note, the strong 
hydrogen bond schematised between FICD’s Arg374 and the ribose 3’OH group (a Glu234 to ribose 3’OH 
hydrogen bond is not identified by LigPlot+, using default constraints). Also note, the lack of base in the vicinity 
of BiP’s Thr518 C atom.  
An anchimeric-assisted mode of deAMPylation (also known as neighbour group participation), 
could theoretically generate the observed products of deAMPylation — AMP and unmodified 
BiP (Preissler et al, 2017a). However, the aforementioned coordination of the -phosphate and 
the binding mode of the adenosine region of the AMP moiety would make intramolecular 
cyclisation and nucleophilic attack (of the ribose 3’OH into the -phosphate) improbable. This 




unfavourable situation is further compounded by the fact that Thr518 is held in place by the 
intermolecular -sheet formed between BiP’s ℓ7,8 and the Fic domain flap. Moreover, aside 
from these steric considerations, an anchimeric-assisted deAMPylation reaction is also 
rendered infeasible on electrostatic grounds. Namely, the putative nucleophile (ribose 3’OH) 
only forms a very weak (3.44 Å and badly angled) hydrogen bond to FICD’s Glu234 and forms 
a much stronger (2.94 Å) hydrogen bond to the side chain or Arg374 (Figure 2.4.1 [right] and 
Figure 2.4.3). The latter will severely decrease the nucleophilicity of the 3’OH, which is also 
not within range of a potential base for 3’OH group deprotonation. 
A similar argument can be made on structural and chemical grounds to dismiss an elimination 
reaction-based deAMPylation mode (which could also generate the observed deAMPylation 
products). That is to say, there is a lack of base within the vicinity of BiP’s Thr518 C atom 
(Figure 2.4.1 and Figure 2.4.3). Such a base would be required in order to carry out the proton 
abstraction necessary to catalyse an E1cB-type elimination reaction.  
 
Figure 2.4.4: FICD’s Glu234 coordinates a catalytic water molecule. A reduced active site view from the (state 1) 
deAMPylation complex, as in Figure 2.4.1. The same (4) polder OMIT map is displayed along with selected 
FICD residues (yellow) that contribute towards hydrolysis of BiP’s AMPylated Thr518 (purple). The position of 
the catalytic water, which appears well-positioned for in line nucleophilic attack, is highlighted*. In addition, the 
putative general acid, FICD’s His363, is modelled based on an alignment of the catalytically competent FICD 
structure PDB 6I7K (by residues 213–426 of the Fic domain). The view on the left is rotated relative to the left 
panel of Figure 2.4.1, approximately as indicated on the lower left-hand side, and displays the P-O(Thr518) 
phosphodiester bond directly into and perpendicular to the plane of the page. The right panel displays an 
orthogonal view, with the phosphodiester bond parallel to the plane of the page. Pink dashed lines represent 
potential hydrogen bonds formed by Glu234 and also (in the right-hand side panel) the catalytic water. 




Conversely, Glu234 (located atop the inh) tightly engages a water molecule within FICD’s 
oxyanion hole (Figure 2.4.1 and Figure 2.4.3). The aforementioned Glu234-coordinated water 
molecule sits almost directly in-line with the P-O(Thr518) phosphodiester bond (Figure 
2.4.4) and likely participates in catalysis. Moreover, the putative catalytic water-P distance 
observed in the deAMPylation complex crystal structure (3.73 Å; Figure 2.4.3) is consistent 
with this water’s potentially nucleophilic role. For example, the attacking nucleophile (a serine 
oxygen atom) was found to be 3.86 Å from its target P(ATP), in a quantum mechanically 
optimised model of reactants within the active site of protein kinase A (Valiev et al, 2003).  
In Figure 2.4.4 the active site is also modelled with a catalytic histidine from a catalytically 
competent FICD structure (PDB 6I7K), which was chosen on the basis of its very close 
similarity in C and C position with the crystallographically observed His363Ala residue 
(also 0.45 Å RMSD over 214 C pairs of the Fic domain residues 213–426). The resulting 
deAMPylation complex active site structure is highly suggestive of an acido-basic hydrolytic 
mechanism of eukaryotic deAMPylation; with FICD’s N2(His363) within comfortable 
hydrogen bonding distance (2.84 Å) of BiP’s O(Thr518) atom (Figure 2.4.4). In this 
hypothetical regime Glu234 aligns and activates a water molecule for an SN2-type nucleophilic 
attack into the -phosphate, with His363 positioned to facilitate a concerted protonation of the 
Thr518 alkoxide leaving group (generating unmodified BiP and AMP as observed 
experimentally (Preissler et al, 2017a)). As Glu234 is also forms salt bridges with FICD’s 
Arg371 and Arg374 (Figure 2.4.1 and Figure 2.4.4), it would seem unlikely that it would also 
be able to act as a general base in the above reaction scheme. Indeed, based on the crystal 
structure of monomeric FICDL258D:Apo (PDB 6I7J), the pKa of Glu234 is estimated to be 
depressed from an intrinsic value of 4.4 down to 3.0 [calculated using the Rosetta pKa server 
(Kilambi & Gray, 2012; Lyskov et al, 2013)]. In the case of a number of protein kinases that 
contain a catalytic aspartate (which also has a low pKa), quantum mechanical and molecular 
mechanical computational techniques have identified a role for the conserved aspartate as a 
catalytic (but not a general) base. The catalytic aspartate is thought to accept the attacking 
hydroxyl group proton at a late stage of the phosphorylation reaction, after the formation of the 
transition state (Valiev et al, 2003; Cheng et al, 2005). Such a role, as a late-stage proton trap, 
may also be played by FICD’s Glu234. 
 




Chapter 2.5: Conclusions 
Through a structure-led approach I have demonstrated (by X-ray crystallography and SANS) 
that both monomeric and dimeric FICD proteins engage AMPylated BiP in a bivalent fashion: 
utilising both the catalytic Fic domain and the FICD(TPR) domain. The former engages the 
target residue region of BiP-AMP, principally via an intermolecular -sheet formed between 
the Fic domain flap and BiP’s SBD ℓ7,8. Such an interaction was anticipated based on the 
identified location of BiP AMPylation [Thr518 within ℓ7,8 (Preissler et al, 2015b)] and the 
previously observed sequence independent mechanism of Fic-target recognition, afforded by 
the flap region of other Fic proteins for their AMPylation substrates or pseudo-substrates (Xiao 
et al, 2010; Goepfert et al, 2013).  
Conversely, the role of FICD’s TPR domain is specific to the enzyme-substrate relationship of 
FICD and BiP. The crystal structure of a trapped heterodimeric deAMPylation complex, 
resolved in great detail the ability of FICD’s TPR1 motif to bind a tripartite BiP surface 
composed of its NBD, interdomain linker and SBD. Solution structure analysis validated the 
overall conclusions derived from the heterodimeric crystal structure, in the context of a 
heterotetrameric deAMPylation complex with dimeric FICD at its core, and also hinted at the 
presence of increased intra-TPR domain flexibility and inter-domain flexibility existing in 
solution.  
Furthermore, mutational analysis highlighted the sensitivity of deAMPylation complex 
assembly and BiP-AMP deAMPylation ability, to the disruption of specific FICD(TPR1)-BiP 
intermolecular contacts. Here, again, between monomeric and dimeric FICD the conserved 
mode of BiP-AMP engagement was highlighted. Moreover, catalysis of FICD-mediated 
deAMPylation (but not substrate binding) was also perturbed by the disruption of 
intramolecular contacts between FICD’s TPR domain and catalytic domain.  
Finally, the crystal structure presented in this work provides strong support for a mechanism 
of eukaryotic deAMPylation that is acido-basic in nature, rationalising the essential role of 
FICD’s Glu234 in facilitating deAMPylation of BiP (Preissler et al, 2017a). It can be inferred 
that Glu234 serves to align a catalytic water molecule in-line for nucleophilic attack into -
phosphate of Thr518-AMP (Figure 2.5.1). Moreover, this acidic residue may act as a catalytic 
base, through a mechanism involving late proton transfer analogous to the role played by the 
catalytic aspartates of some protein kinases (Valiev et al, 2003; Cheng et al, 2005). The 
proposed deAMPylation mechanism (which also rationalises the essential role for a divalent 




cations and FICD’s His363) is far removed from the binuclear metal-catalysed reactions 
catalysed by the other two known (bacterial) deAMPylases (Xu et al, 2010; Chen et al, 2013). 
 
 
Figure 2.5.1: Proposed hydrolytic BiP deAMPylation mechanism. FICD’s Glu234 activates and aligns a 
catalytic water molecule for in-line nucleophilic attack into the backside of AMPylated BiP’s P-O(Thr518) 
phosphodiester bond. The -phosphate group coordination by Mg2+, and localisation within FICD’s electron 
withdrawing oxyanion hold (Figure 2.4.1 and Figure 2.4.3), stabilises the position of P and increases its 
electrophilicity. His363 can exist in either a protonated or deprotonated state. The former is required for 
deAMPylation and is shown. The reaction likely proceeds via a nucleophilic SN2-type pathway with concerted 
protonation of BiP’s Thr518 alkoxide leaving group (catalysed by FICD’s His363 acting as a general acid). A 
potential role for FICD’s Glu234 acting as a catalytic (but not general) base, accepting a proton from the 
nucleophilic water at a late stage of the reaction after formation of the pentacoordinate transition state (‡), is 
shown. Glu234 acting as a proton trap is consistent with its interaction with Fic motif Arg371 and Arg374 (not 
shown), which will depress its pKa. The schematised hydrolytic reaction generates BiP (with an unmodified 
Thr518) and AMP. Following product release Glu234 and His363 could facilely exchange protons with the solvent 
to regenerate the original FICD active site. Ionic or hydrogen bond interactions are denoted with hashed lines, 
dashed lines represent partial covalent bonds and partial charges are indicated by . BiP’s Thr518 residue is 
annotated in purple. 




As a bacterial Fic protein (EfFic) has also been observed to possess gatekeeper glutamate-
dependent deAMPylation activity (Veyron et al, 2019), it is likely that the mechanism of 
deAMPylation outlined above is conserved across this class of proteins. Furthermore, other 
mechanisms of phosphodiester bond cleavage, including anchimeric assistance or an E1cB-
type elimination reaction, which are capable of generating the products of FICD-mediated 
deAMPylation (AMP and unmodified BiP), are also rendered extremely unlikely by the 
resolved structure of the deAMPylation complex.  
This body of work clarifies the mechanism of eukaryotic deAMPylation which, at the time of 
writing, is only exemplified by FICD. Notably, the disparate enzymatic mechanisms attributed 
to the two previously identified (bacterial) deAMPylators were both inferred based on the 
known products of their catalysed deAMPylation reactions and by similarity with enzymatic 
mechanisms defined in the context of evolutionarily related enzymes (Xu et al, 2010; Chen et 
al, 2013). Therefore, to the best of my knowledge the structures presented here represent the 
only deAMPylation (enzyme-substrate) complex structures yet solved. The unique FICD•BiP-
AMP complex, elucidated here, also provides intriguing clues towards understanding the 
nature of FICD substrate engagement in the context of BiP AMPylation.  
  




Chapter 3: FICD’s TPR domain recognises the ATP-state of 
unmodified BiP 
Chapter 3.1: The engagement of FICD and BiP-AMP is incompatible with 
the ADP-state of BiP 
The importance of contacts between FICD’s TPR domain and BiP to deAMPylation, 
demonstrated above, explains previous observations that the isolated AMPylated BiP SBD is 
refractory to FICD-mediated deAMPylation (Preissler et al, 2017a). It is noteworthy that FICD 
also specifically binds (Figure 2.3.1) and AMPylates ATP-state BiP with a preference for more 
domain-docked BiP mutants and fails to AMPylate the isolated BiP SBD (produced by SubA 
proteolysis of the interdomain linker of AMPylated intact BiP; Preissler et al, 2015b). 
Furthermore, the observation that FICD’s interaction with unmodified BiP:ATP was abrogated 
by TPR1 deletion (Figure 2.3.2) hints at the possibility that FICD recognises the domain-
docked ATP-state of unmodified BiP (for AMPylation) in a similar fashion to ATP-state biased 
BiP-AMP (for deAMPylation).  
 
Figure 3.1.1: FICD binds the ATP-state of BiP. The deAMPylation complex (coloured as in Figure 2.1.3 with 
subdomains labelled) is aligned via its NBD (a) or SBD (b) with an ADP-state BiP (PDB 7A4U; grey). As in 
Figure 2.1.3 the TPR1 mutants mutated in this study are shown with ball and stick representation and coloured 
in green. The respective BiP interacting partners are also shown, labelled and coloured according to their 
subdomain localisation (in the deAMPylation complex structure) and grey in the BiP:ADP structure. a, Inset, a 
closeup view of FICD(TPR1)-BiP(NBD) contacts. Changes in NBD conformation (from ATP to ADP-state) 
would disrupt the intermolecular contacts present in the deAMPylation structure. b, The intermolecular -sheet 
region of ℓ7,8 (highlighted in green) is shortened in ADP-state BiP. Inset, disposition of Thr518 is highlighted. In 
the BiP:ADP structure the shortened ℓ7,8 forms an intramolecular hydrogen bond network which includes the 
Thr518 hydroxyl group — making this region inaccessible for intermolecular interaction with the catalytic Fic 
domain (pink lines; hydrogen bonds). 




Structures of unmodified BiP indicate that a domain-undocked ADP-state BiP loses the 
tripartite NBD-linker-SBD surface that is recognised by FICD’s TPR1 motif in the context of 
deAMPylation (Figure 3.1.1). Furthermore, even if FICD were able to bind the NBD or the 
ℓ7,8 SBD region (which also becomes less accessible in BiP’s ADP-state) of a nucleotide-free 
(apo) or ADP-bound BiP, the Hsp70’s heavy bias towards the domain-undocked conformation 
(Marcinowski et al, 2011; Wieteska et al, 2017) would render engagement of the other FICD-
BiP interaction surface unlikely (Figure 3.1.1).  
 
Figure 3.1.2: FICD's TPR domain and the J-domain recognise similar ATP state–specific Hsp70 surfaces. 
All structures are aligned via the Hsp70 NBD. The deAMPylation complex and BiP:ADP are coloured as in 
Figure 3.1.1. In addition, the DnaK:ATP•DnaJ cocrystal structure (PDB 5NRO) is also superposed (coloured in 
light and dark blue, respectively). The former displays excellent agreement with the ATP-state BiP from the 
deAMPylation complex. The JDP binds in a similar location to FICD’s TPR1, with both molecules recognising 
an Hsp70 ATP state–specific, tripartite surface of NBD-linker-SBD. Blow-up, right-hand side, the aspartate of 
the characteristic and ubiquitously conserved J-domain ‘HPD’ motif is shown with its DnaK interaction partner 
(Arg167); this contact is conserved in all JDP-Hsp70 interactions. The same salt bridge is mimicked in the 
FICD(TPR1)-BiP(NBD) interaction, shown. Upon ATP hydrolysis, conformational changes in the NBD of an 
unmodified BiP (grey), including in the NBD -sheet bearing BiP’s Arg197 (arrow) will disrupt the FICD(TPR1)-
BiP(NBD) contacts. Note, the curly arrow depicts the undocking of the BiP linker upon BiP ATP- to ADP-state 
transition.  
These alignments suggest that the FICD’s TPR1 motif recognises an ATP-state specific Hsp70 
surface in order to catalyse deAMPylation. If this mode of binding was also common to a pre-
AMPylation complex and was, therefore, also required for the engagement of FICD with 
unmodified BiP for AMPylation, this would rationalise the observed selectivity of FICD for 
the ATP-state of unmodified BiP. Indeed, the tripartite Hsp70 surface by which FICD’s TPR1 
motif is observed to engage BiP-AMP is in the same Hsp70 region known to be engaged by J-
domain proteins (JDPs) (Figure 3.1.2). Like FICD (in the context of AMPylation) JDPs also 




specifically engage ATP-state Hsp70s (Kityk et al, 2017; Preissler et al, 2017b) — suggesting 
a possible convergent evolution towards a similar mechanism of ATP state–specific Hsp70 
recognition.  
 
Chapter 3.2: FICD’s TPR domain is essential for AMPylation complex 
assembly 
In order to test the hypothesis that FICD’s TPR domain may also be responsible for the 
engagement of unmodified BiP and thus in the formation of a (pre-)AMPylation complex, we 
returned to the BLI setup of Figure 2.3.4. In this instance, rather than BiP-AMP being 
immobilised on the biosensor, ATP-bound unmodified BiP was used as a ligand (see Figure 
2.3.3d for a schematised methodological comparison). In this context the effect of TPR1 motif 
mutations on (catalytically dead) FICD binding were magnified relative to their effect on the 
deAMPylation complex (Figure 3.2.1, and for comparison Figure 2.3.4). This is consistent 
with the absence of a covalently BiP-linked AMP moiety engaging FICD’s active site. This 
absence would increase the relative contribution of (wild type) TPR-BiP contacts to the net 
interaction across the entire complex.  
 
Figure 3.2.1: FICD’s TPR domain is essential for recognition of unmodified BiP. Representative BLI analysis 
of TPR domain mutants of monomeric (a) and dimeric (b) FICD binding to immobilised ATP-bound BiP, from n 
= 3 independent experiments. This BLI experiment is a parallel to those conducted with BiP-AMP:ATP as an 
immobilised ligand in Figure 2.3.4. The ability of FICD to bind BiP:ATP is very sensitive to mutations in 
contacting FICD(TPR1) residues. Note, that disruption of the intramolecular FICD contact (TPRox) appears to 
increase the affinity for BiP:ATP, especially enhancing monomeric FICDL258D-H363A association and slowing its 
dissociation. Also, consistent with Figure 2.3.2, monomeric FICDL258D-H363A binds more tightly to the BiP:ATP 
ligand (resulting in a greater binding displacement) than dimeric FICDH363A.  




It should be noted that, in a parallel to the analysis of FICD variants binding to an AMPylated 
BiP ligand (Figure 2.3.4), disruption of an intramolecular (interdomain) contact between 
FICD’s TPR and Fic domain (whilst locking the TPR domain in a TPR-in conformation 
compatible with the observed BiP-AMP binding mode; TPRox), appears to increase the affinity 
of both monomeric and dimeric FICD for unmodified BiP:ATP (Figure 3.2.1). As in the case 
of BiP-AMP:ATP binding, the ability of TPR domain oxidation to stimulate FICD binding is 
much more pronounced for monomeric FICD (Figure 3.2.1a). This (again) suggests that the 
effects of TPR domain stabilisation (by disulphide stapling) may, in the context of an otherwise 
more dynamic monomeric FICD(TPR) domain, outweigh the effects of disrupting FICD 
interdomain communication. Conversely, in the context of a potentially less dynamic TPR 
domain within dimeric FICD, upon TPR oxidation a more subtle effect on binding kinetics and 
increased FICD dissociation rates are observed (Figure 3.2.1b).  
 
Chapter 3.3: In vitro and in vivo BiP AMPylation is dependent on FICD’s 
TPR domain 
In order to assess the role of FICD’s TPR domain in catalysing in vitro AMPylation, in an 
analogous fashion to the FP-derived in vitro deAMPylation assay (Figure 2.3.6 and Figure 
2.3.7), the utility of fluorescent FAM-labelled nucleotide analogues was once again harnessed. 
Moreover, as previously characterised in the context of vitro AMPylation reactions using [‐
32P]‐ATP (Perera et al, 2019), the assay presented here also benefited from the addition of an 
excess (7.5 µM) constitutively dimeric and catalytically dead (disulphide-linked) FICD 
(S-SFICD
A252C‐H363A‐C421S; trap). This trap binds BiP-AMP for a prolonged period of time and 
thereby inhibits its deAMPylation by the catalytically (and deAMPylation) competent FICD 
under investigation. By providing 10 µM ATP(FAM) as the sole nucleotide, with 5 µM BiP 
and 0.5 µM (catalytically competent) monomeric FICDL258D (the same concentration of 
substrate and enzyme that was used in the in vitro deAMPylation assay) it was found that the 
AMPylation reaction progress was linear over an extended time period (Figure 3.3.1a–b). 
Importantly, at the 1 h time point selected for endpoint measurement of the various FICD 
variants (Figure 3.3.1c), the amount of accumulated BiP-AMP is directly proportional to the 
initial rate of FICDL258D-mediated AMPylation. It should also be noted that the difference in 
BiP AMPylation between overnight incubation of the AMPylation reaction at 4 and 20 °C, 
reflects the increased rate of BiP-AMP trap escape and deAMPylation (as evidenced by the 




conspicuous increase in free AMP(FAM) nucleotide analogue resolved in Figure 3.3.1b). 
Moreover, BiP-AMP (presumably on account of being a specific FICD deAMPylation 
substrate) is much more sensitive to FICD-mediated deAMPylation than the (much less 
efficiently accrued) FICD autoAMPylation signal (Figure 3.3.1a).  
 
Figure 3.3.1: FICD(TPR1) mutation impairs in vitro AMPylation. Fluorescence and Coomassie gel images 
of in vitro AMPylation assays utilising ATP(FAM) as an AMPylation co-substrate, in the presence of excess 




product trap (Trap(ox)) to discourage BiP-AMP(FAM) deAMPylation. a, Representative FICDL258D (0.5 µM) 
BiP-AMPylation time course with quantification of two independent experiments (dashed lines; directly 
proportional fits). Proteins were resolved using a 10% SDS-PAGE gel. b, The FICDL258D (0.2 µM) BiP-
AMPylation time course that is also quantified in a. Using a 4–12% SDS-PAGE gel, free AMP(FAM) nucleotides 
can be resolved from the gel front (which contains a large amount of excess ATP(FAM)). Note, the increased 
AMP(FAM) production upon 25 °C overnight incubation of the AMPylation reaction, relative to the same reaction 
incubated at 4 °C (lane 8 [non-reducing SDS-PAGE] or lane 9 [reducing SDS-PAGE] versus lane 7). c, An in 
vitro AMPylation assay analysing the effects of deleting the TPR1 motif (∆TPR1), mutating TPR1 motif residues 
or perturbing FICD intramolecular contacts (TPRox). All FICD perturbations cause significant depreciations in 
the rate of AMPylation catalysed by both dimeric FICD (dFICD) and monomeric FICDL258D (mFICD). A gel from 
a representative experiment is shown with the initial rates (mean ± 95% CI) of BiP-AMPylation (in relative 
fluorescent units/s normalised to the rate of FICDL258D-mediated BiP AMPylation), from n = 4 independent 
experiments. Note, the lack of correlation between FICD (cis)autoAMPylation and BiP substrate AMPylation 
visible in the high exposure (High Exp.) fluorescence gel image. 
As previously observed, using trace amounts of [‐32P]‐ATP with ATP and by monitoring BiP-
AMP production by autoradiograph (Perera et al, 2019), monomerisation of FICD resulted in 
a considerable BiP AMPylation rate enhancement — 32-fold in this instance (Figure 3.3.1c). 
Moreover, in agreement with the observed deleterious effects on pre-AMPylation complex 
affinity afforded by FICD(TPR1) mutations, loss of TPR-BiP contacts also impaired BiP 
AMPylation by monomeric FICD in vitro (Figure 3.3.1c). That is to say, surface mutations in 
TPR1 and deletion of the TPR1 motif paralleled the effects of these mutations on 
deAMPylation complex assembly and in vitro deAMPylation activity (Figure 2.3.4–Figure 
2.3.7). Of note, impairment of interdomain (TPR-Fic) communication by TPR oxidation, 
although stabilising the pre-AMPylation complex of monomeric FICD and BiP:ATP (Figure 
3.2.1), decreased the in vitro AMPylation rate of both monomeric and dimeric FICD (Figure 
3.3.1c). This is consistent with a role for TPR to Fic domain communication in contributing 
both towards deAMPylation and AMPylation turnover number (kcat). 
It should also be noted that Figure 3.3.1c nicely illustrates that monomeric FICDL258D (and 
derivates thereof) have a strong preference for (cis)autoAMPylation. It has previously been 
demonstrated that FICDE234G can catalyse (trans)autoAMPylation (Bunney et al, 2014). 
However, the observation that the high concentration and very large molar excess of 
catalytically dead trap FICD (over catalytically active FICD) is almost imperceptibly modified, 
suggests (trans)autoAMPylation is a much less likely outcome relative to the cis reaction. 




Furthermore, as previously observed (Perera et al, 2019), monomerisation does increase FICD 
autoAMPylation activity. Although, importantly, this experiment also demonstrates that 
amongst variants of monomeric FICDL258D there is no correlation between (specific) 
AMPylation activity towards BiP and FICD (cis)autoAMPylation. In fact, in the case of TPR1 
removal (∆TPR1) and TPR domain oxidation (TPRox), (cis)autoAMPylation and BiP-
AMPylation levels appear anti-correlative — with these FICD modifications resulting in 
increased autoAMPylation whilst simultaneously drastically reducing the rate of BiP 
AMPylation (Figure 3.3.1c). 
 
Figure 3.3.2: TPR1 mutated FICDs are deficient in their ability to promote a pool of AMPylated BiP in 
cells. Representative native-PAGE immunoblot analysis of the accumulation of AMPylated (B-form) BiP in 
FICD–/– CHO cells transfected with FICD variants, as indicated. Major non-AMPylated BiP species (monomeric 
A, dimeric II and trimeric III) are also annotated. Right, quantification of AMPylated B-form BiP from n = 3 
independent experiments (mean ± SD). The eIF2 immunoblot acts as a loading control. Note the inverse 
relationship between the FICD expression levels and the ability of each respective FICD variant to catalyse BiP 
AMPylation.  
To further corroborate the role of FICD’s TPR domain in facilitating AMPylation we sought 
to test the effect of FICD(TPR1) mutations on in vivo BiP AMPylation. In agreement with 
previous studies (Preissler et al, 2017a) overexpression of wild type dimeric FICD into CHO 
cells lacking endogenous FICD (FICD–/–) did not induce the accumulation of BiP-AMP (which 
migrates as the B-form of monomeric BiP on a native-PAGE gel) (Figure 3.3.2). Conversely, 
transient expression of an AMPylation unrestrained and deAMPylation defective, monomeric 
FICDE234G-L258D induced large amounts of BiP-AMP accumulation. Levels of AMPylated BiP, 
detected by its mobility on native-PAGE, were significantly lower in cells targeted with the 




FICDK124E-E234G-L258D and FICDK124E-H131A-E234G-L258D TPR1 mutations (Figure 3.3.2). 
Moreover, the higher levels of expression of the TPR1 mutant FICDs (compared to FICDE234G-
L258D) is consistent with previous observations of FICD expression levels inversely correlating 
with the variant’s AMPylation activity (within transiently transfected FICD–/– cells) (Perera et 
al, 2019). The lesser effect of His131Ala corresponds with the fact that this mutation exhibited 
the least effect of any tested TPR1 mutation with respect to in vitro complex assembly and 
AMPylation (Figure 3.3.2).  
The nature of the above assay is quite crude, in that it relies on analysing the lysate from the 
entire cell population (which includes both transfected and untransfected cells). 
Overexpression of FICDE234G-L258D in FICD–/– cells is documented to cause a considerable 
amount of ER stress and possibly, as a result, cell death (Perera et al, 2019). Moreover, 
overexpression of FICDE234G in FICD–/– cells, which causes a similar amount of ER stress and 
in vivo BiP-AMP accumulation to FICDE234G-L258D (Perera et al, 2019), has also been observed 
to reduce cell colony outgrowth (Preissler et al, 2017a). It is therefore likely that the above 
strategy for quantifying in vivo AMPylation of BiP underestimates the effect of FICD(TPR1) 
mutation (by underrepresenting the AMPylation induced by FICDE234G-L258D).  
 
Figure 3.3.3: Dot-plot from FACS-based in vivo AMPylation assay. A representative dot-plot from n = 4 
independent experiments. The mCherry signal acts as a transfection marker, being expressed in trans from the 
same plasmid as the transiently expressed FICD constructs (in FICD–/– CHO cells). Cells with mCherry+ signal 
≤ 104 were gated, thus eliminating the distorting effects of very high FICD and/or mCherry expression on the 
XBP1::Turquoise signal (an ER stress reporter). The gated mCherry+ subset is further analysed in Figure 3.3.4. 
Cell population quadrant percentages are also annotated. FI, fluorescence intensity. 




In order to circumvent these technical issues, and to provide a more quantitative means of 
assessing the effects of TPR1 motif mutations on in vivo AMPylation, the ability for FICD-
mediated BiP AMPylation to induce ER stress was exploited in an orthogonal flow cytometry-
based assay (Figure 3.3.3).  
As previously observed, overexpression of FICDE234G-L258D, but not wild type FICD, induced 
considerable ER stress (as indicated by the XBP1::Turquoise ER stress reporter signal). From 
this more nuanced analysis of single, live and transfected cells, it is clear that the majority of 
FICD(TPR1) mutations reduce the percentage of cells undergoing ER stress (Figure 3.3.4). In 
instances where the decrease in the proportion of stressed cells is less obvious (Glu105Arg, 
His131Ala), it is obvious both from the representative histogram and from the quantification 
of the high stress median values that the severity of ER stress is reduced within the ‘high stress’ 
cell population (Figure 3.3.4). Moreover, the UPR reporter activity induced by various TPR1 
mutant FICD derivatives correlated well with the hierarch of the mutations’ effects on BiP 
binding (Figure 2.3.4). 
 
Figure 3.3.4: FICD(TPR1) mutations reduce BiP AMPylation-induced ER stress. Representative FACS histograms 
of the XBP1::Turquoise UPR reporter signal levels, in FICD–/– CHO cells expressing the indicated FICD 
derivatives. The overall histogram areas (derived from the respective mCherry+ subpopulations annotated in the 
representative Figure 3.3.3 dot-plot) are each normalised to an arbitrary unit area. Note, the bimodal distribution 
of the fluorescent signal in FICD-transfected cells. Quantification of the fraction of cells that are stressed 
(XBP1::Turquoise fluorescent intensity > 600 fluorescent units; vertical dashed line), as well as the median FACS 
signal of the low and high stressed cell populations are shown from n = 4 independent experiments (mean values 
± SD). Bars and datapoints are (colour) coded according to the histogram legend. 
  




Chapter 3.4: Conclusions 
Together, these observations parallel the effects of TPR1 mutations which were 
crystallographically predicted and experimentally demonstrated to affect deAMPylation 
complex assembly and deAMPylation activity. The same deAMPylation affecting 
FICD(TPR1) mutations robustly enfeebled pre-AMPylation complex assembly, in vitro 
AMPylation and in vivo AMPylation of BiP. This coherent ensemble of data leads me to 
conclude that TPR surface mutations in residues that contact BiP in the deAMPylation complex 
also contribute to enzyme-substrate interaction during FICD-mediated AMPylation.  
This finding rationalises the observed selectivity possessed by FICD for AMPylating and 
binding to ATP-state BiP and provides a plausible and relatively intuitive mechanism for 
substrate-level regulation of BiP AMPylation in vivo. By this token, changes in unfolded 
protein load within the ER are transduced into changing levels of BiP AMPylation by the 
former binding to BiP’s SBD and titrating these BiP species away from the ATP-state and into 
the ADP-state. The latter state is incompatible with the mode of FICD•BiP interaction (Figure 
3.1.1) and thus not a substrate for FICD-mediated AMPylation. This mechanism of substrate-
level regulation explains the residual response to cycloheximide treatment (in terms of a further 
increase in BiP-AMP level) observed in FICD–/– cells overexpressing constitutively 
monomeric FICDL258D (Perera et al, 2019).  
  




Chapter 4: The mechanistic basis of FICD state switching 
Chapter 4.1: AMPylation competent binding of MgATP 
The above results are entirely consistent with those previously published, that monomerisation 
is able to reciprocally regulate FICD’s bifunctionality (Perera et al, 2019). Namely, under the 
same enzyme and substrate (steady state kinetic) conditions FICD monomerisation induced ~ 
64-fold bias towards BiP AMPylation and away from its mutually antagonistic deAMPylation 
activity. Under the tested enzyme and substrate concentrations this change is predominantly 
due to a 32-fold increase in AMPylation activity of monomeric FICDL258D over dimeric wild 
type FICD (Figure 3.3.1c); the rest of the difference being made up for by a 46% decrease in 
the rate of monomeric FICDL258D-catalysed deAMPylation (Figure 2.3.7). 
 
Figure 4.1.1: Monomeric and dimeric FICD bind ATP. Left, quantified protein melt temperatures of the 
indicated FICD proteins in absence (Apo) or presence of nucleotides (as indicated). Shown are the mean Tm values 
± SD from n = 3 independent DSF experiments. Monomeric FICDL258D (mFICD) and FICDL258D‐E234G (mFICDE/G) 
as well as dimeric wild type FICD (dFICD) and FICDE234G (dFICDE/G) were tested. ADP and ATP concentrations 
in mM are given in parentheses. The ATP titration was carried out in a buffer containing 25 mM MgCl2. Right, 
plot of the derived increase in FICD melting temperature (∆Tm) against ATP concentration, as measured by DSF. 
Note the similarity in the K½s of ATP‐induced Tm increase (annotated) between mFICD and dFICD. Although the 
K½ of mFICD is slightly lower than that of dFICD, the difference is not statistically significant (P > 0.05 by a 
two-tailed Welch’s t-test). Shown are mean ∆Tm values ± SD from n = 3 independent experiments with the best‐
fit lines from a one‐site binding model. 
As MgATP is known to be the co-substrate required for BiP AMPylation, it is possible that 
there may be a difference in either the mode of ATP binding between dimeric and monomeric 




FICD or in the alibility of the two FICDs to bind ATP. The binding of small ligands can be 
monitored through their propensity to stabilise the native (folded) state of its binding partner 
protein. This increase in stability is often translated into a positive shift in the (melting) 
temperature required for protein unfolding. In order to measure changes in protein melt 
temperature differential scanning fluorimetry (DSF) was employed.  
In agreement with earlier work (Bunney et al, 2014) it was found that both ADP and ATP were 
able to cause a significant change in protein melt temperature (∆Tm) in the absence of the inh 
glutamate — in the context of a Fic domain Glu234Gly mutation (Figure 4.1.1, left). The 
ability for ATP to stabilise/bind FICD was drastically reduced by the presence of Glu234, 
although a seemingly saturable increase in Tm was still observed. Quantification of the thermal 
shift data indicated that both monomeric and dimeric FICD were both able to bind ATP in a 
buffer containing excess Mg2+ ions, displaying similar K½s of ATP‐induced Tm increase 
(Figure 4.1.1, right). 
These results suggested that the variation in enzyme activity of different FICD mutants may 
arise not from variation in their affinity for nucleotide but rather from their particular manner 
of ATP binding. To explore this possibility, I set out to cocrystallise FICD variants (with 
varying BiP AMPylation abilities), with and without MgATP. 
X‐ray crystal structures of monomeric and dimeric FICD were obtained in assorted nucleotide‐
bound states (Table 3 and Table 4). The tertiary structure of the Fic domain of both the apo, 
monomeric FICDL258D and the apo, dimer-relay mutant FICDK256S deviated little from that of 
the nucleotide‐free wild type dimer structure (FICD:Apo; PDB: 4U04) (Figure 4.1.2). 
Moreover, cocrystallisation of FICDL258D, FICDK256A or the wild type dimer with ATP or an 
ATP analogue (AMPPNP) also did not result in any significant conformational changes in the 
Fic domain (Figure 4.1.2). Accordingly, the greatest RMSD between the Fic domain of the 
FICD:ATP structure (over 195 C pairs across residues 213–407) and any other monomeric or 
dimer-relay FICD structure is 0.53 Å (observed between FICD:ATP and FICDL258D:Apo). The 
only conspicuous change in global tertiary structure occurred in the TPR domain of FICDL258D 
cocrystallised with ATP or AMPPNP, which are isostructural outside of the active site region, 
in which the TPR domain is flipped almost 180° from its position in other FICD structures 
(Figure 4.1.2). Notably, in all FICD structures the inh remains firmly juxtaposed to the core 
Fic domain. 
 




Table 3: Data collection and refinement statistics of FICD ± nucleotide complexes. Values in parentheses 
correspond to the highest-resolution shell, with the following exceptions: aThe number of molecules in the 
asymmetric unit cell (a.u.), the number of molecules in the biological unit is shown in parentheses; bMolProbity 
percentile score is shown in parentheses (100th percentile is the best among structures of comparable resolutions, 












   Data  
   collection 
      
Synchrotron 
stations 
DLS I04 DLS I04 DLS I03 DLS I04 DLS I03 DLS I03 
Space group P21212 P22121 P22121 P3121 P6422 P6422 




43.82, 76.51,   
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 0.163 (0.717) 0.109 (0.385) 0.107 (0.636) 0.176 (0.856) 0.167 (1.009) 0.071 (0.611) 
<I/(I)> 19.2 (1.8) 6.8 (2.4) 5.6 (1.0) 8.6 (2.2) 13.0 (2.5) 10.3 (1.8) 
CC1/2 0.999 (0.720) 0.993 (0.547) 0.995 (0.567) 0.996 (0.549) 0.999 (0.503) 0.998 (0.523) 
Unique 
reflections 
31293 (4091) 21825 (1978) 18543 (1712) 18963 (1380) 26617 (3188) 34573 (3351) 
Completeness, % 100.0 (100.0) 99.9 (99.5) 99.4 (97.3) 100.0 (100.0) 100.0 (100.0) 99.4 (99.1) 
Redundancy 6.4 (6.5) 4.4 (4.4) 3.7 (3.7) 9.7 (10.0) 16.1 (16.5) 4.6 (4.6) 





 0.280 / 0.319 0.208 / 0.259 0.282 / 0.325 0.228 / 0.283 0.232 / 0.252 0.214 / 0.251 
Atoms (non-H) 5650 2851 2731 2951 2828 2940 
Average B-
factors, Å2 
55.3 42.5 54.6 50.9 58.2 56.4 
RMS Bond 
lengths, Å 
0.002 0.003 0.003 0.003 0.002 0.003 
RMS Bond 
angles, ° 




96.5 98.5 98.2 97.9 98.5 99.4 
Ramachandran 
outliers, % 
0 0 0 0 0 0 
MolProbity 
scoreb 
1.33 (100th) 0.86 (100th) 0.74 (100th) 0.99 (100th) 0.97 (100th) 0.99 (100th) 
PDB code 6I7G 6I7H 6I7I 6I7J 6I7K 6I7L 
 
 




Table 4: Crystallisation conditions of FICD ± nucleotide complexes. Where applicable the crystallisation 
conditions (and seed dilution) of the crystals used for micro-seeding are also shown. Seeds stock suspensions were 











Seed Crystal Conditions 
(Seed Dilution) 
FICD:ATP 6I7G 
0.1 M Tris pH 7.5; 20% PEG 
300; 5% PEG8K; 10% 
Glycerol (150:50:100) 
FICD 
0.2 M (NH4)2SO4, 0.1 M 
NaCacodylate, 30% PEG 
8000 (1/3) 
FICDK256S:Apo 6I7H 
0.1 M Tris pH 8.5; 0.05 M 




0.1 M Bis-Tris pH 6.5; 0.2 M 
MgCl2; 25% PEG3350 
(100:25:100) 
FICDK256A 
0.1 M Na3Citrate pH 5.5, 40% 
PEG 600 (1/10) 
FICDL258D:Apo 6I7J 
0.1 M Tris pH 8.5; 2.0 M 
(NH4)2SO4 (150:50:100) 
FICDL258D 
0.1 M Tris pH 8.5, 0.2 M 
Li2SO4, 40% PEG 4000 (1/2) 
FICDL258D:MgATP 6I7K 









1.5 M NaCl; 10% EtOH 
(150:50:200) 
FICDK256A 
0.1 M Na3Citrate pH 5.5, 40% 
PEG 600 (1/500) 
 
t 





Figure 4.1.2: Monomerisation or dimer-relay disruption does not cause large-scale changes in the Fic 
domain. Superposition of FICD asymmetric unit molecules with FICD:Apo (PDB 4U04; purple) are presented, 
aligned by Fic domain residues 213–407. Glu234, His363 and ATP are shown as sticks with the Mg2+ cation as a 
green sphere (where applicable). The Fic domain inhibitory alpha helix (inh) and gross domain architecture are 
annotated. a, Wild type FICD and monomeric FICDL258D ± ATP are superposed. Note, the only significant 
deviation in tertiary structure is the flipping of the TPR domain in the FICDL258D:ATP structure. The 
FICDL258D:AMPPNP structure is identical to FICDL258D:ATP outside of the Fic domain active site and is not 
shown. b, FICDs mutated at the dimer-relay residue Lys256 ± ATP are superposed. Mutation of this residue also 
does not result in large conformational changes in FICD structure (relative to FICD:Apo). 





Figure 4.1.3: Electron density of FICD Glu234 and MgATP. FICD active sites are shown overlaid with 
unbiased polder OMIT maps (using mesh representation) in the region of MgATP and Glu234. a, The wild type 
dimer FICD structure displays a lack of density corresponding to a Mg2+ ion. The ATP density is contoured at 
3.5 and the Glu234 at 5.0. b, The dimeric dimer-relay mutant FICDK256A displays a clear MgATP density up 
to and including the γ‐phosphate phosphorous atom. The ATP density and Glu234 densities are both contoured at 
3.0. c, The MgAMPPNP nucleotide analogue bound to monomeric FICDL258D is clearly coordinated by a Mg2+ 
ion. The polder OMIT density does not cover the entirety of AMPPNP’s -phosphate (in the region of O1 and 
O2). The ATP density is contoured at 3.0 and the Glu234 at 5.0. d, Monomeric FICDL258D contains a clear 




MgATP density although it is still not complete over the -phosphate’s O3. The ATP density is contoured at 3.0 
and the Glu234 at 5.0. 
However, upon closer inspection of the ATP-bound cocrystal structures differences between 
the FICD variants are apparent. Namely, although all structures that crystallised in the presence 
of millimolar concentrations of MgATP contained electron density attributable to the 
nucleotide, only the AMPylation‐biased FICD mutants (Leu258Asp and Lys256Ala) also 
contained discernible, octahedrally coordinated Mg2+ ion density (Figure 4.1.3). As noted in 
other AMPylating Fic enzymes, this Mg2+ was coordinated by the ‐ and ‐phosphates of 
ATP/AMPPNP and the conserved aspartate (FICD’s Asp367) of the Fic motif (Khater & 
Mohanty, 2015b; Bunney et al, 2014). Conversely, the only possible candidate for Mg2+ in the 
dimeric, wild type FICD:ATP structure was a water density, located between all three 
phosphates, that fell in the Fic motif's oxyanion hole — a position incompatible with divalent 
cation coordination (Zheng et al, 2017). 
The FICD:ATP structure (which lacks a coordinating Mg2+ ion) has a polder OMIT electron 
density which fully covers the region of the ATP molecule (Figure 4.1.3a). Conversely, none 
of the MgATP containing FICD structures contained polder OMIT density that completely 
covered the modelled ATP γ‐phosphate (Figure 4.1.3b–d). Of these three structures 
FICDL258D:ATP has the most well-defined density for both its ATP molecule and Glu234 
(Figure 4.1.3d). The presumably lower occupancy regions, especially in the area of the ATP 
γ‐phosphate, potentially speak towards the MgATP-bound active sites representing relatively 
high energy states and possibly sampling a number of different γ‐phosphate (and Glu234) 
conformations.  
Alignment of the nucleotide-bound structures revealed that ATP or AMPPNP were bound very 
differently by the wild type dimer and the AMPylation-biased monomeric or dimer-relay FICD 
mutants (Figure 4.1.4a–b). Concordantly, the RMSD of ATP between the wild type FICD and 
monomeric FICDL258D was 2.17 Å, and 2.23 Å between the ATPs bound to wild type FICD 
and FICDK256A. As previously observed in other ATP-bound Fic proteins that possess an 
inhibitory glutamate, the nucleotide in FICD:ATP is not stably coordinated by a Mg2+ (Engel 
et al, 2012; Goepfert et al, 2013); a cation necessary for FICD-mediated AMPylation (Ham et 
al, 2014). Moreover, the closest interatomic distance between wild type FICD’s ATP -
phosphate the Fic domain flap residue Val316 is markedly reduced relative to that observed in 
FICDK256A and FICDL258D (Figure 4.1.4a–b).  





Figure 4.1.4: Monomeric FICD’s Glu234 permits AMPylation competent MgATP binding. a–b, 
Superposition of the structures presented in Figure 4.1.3 (upper panels). In b the FICDK256A:ATP structure is 
replaced by the FICDL258D:MgAMPPNP structure. ATP interacting residues are shown as sticks and annotated. 
Mg2+ and ATP are coloured to match the corresponding ribbons. Active site waters are omitted for clarity. 
Between active sites the only significant side chain deviation is in Glu234 position. Note, the FICD:ATP His363 
side chain is also flipped. This assignment is based on the formation of a His363 hydrogen bond to a ribose 
interacting water, presumably enabled by the disposition of the -phosphate which can no longer compete for the 
interaction with His363 (also see Figure 4.1.3a). Inset, blow‐up displaying the smallest interatomic distances (i–
iv) between ‐phosphates and Glu234 residues. Note, distances (i) and (ii) are hypothetical and are not 
experimentally observed. These represent the distances (pink) between catalytically competent ‐phosphates and 
FICD:ATP’s Glu234. Distances between the closest point of the Fic domain flap [Val316(C1)] and the 
corresponding Pα atom are shown in the right‐hand side panel. Non-favourable Glu234-Glu263 interactions 
(present in all structures apart from FICDL258D:ATP are also annotated. c, A focussed view of the ‐phosphate and 
Glu234 regions of the alignments in a and b, annotated with the greatest ‐phosphate to Glu234 Van der Waals 
radii overlap. A Van der Waals overlap < 0.6 Å is not generally considered to represent a steric clash. The much 




greater hypothetical overlaps (pink) suggest that the Glu234 deviation observed within dimeric wild type FICD 
would be insufficient to accommodate the position of a catalytically competent ‐phosphate.  
By overlaying 3 Å radius centroids centred on P and the nearest Val316 (non-hydrogen) atom 
C1, it becomes clear that the space afforded by the ATP conformation in wild type FICD is 
insufficient to accommodate a putative attacking nucleophile (Figure 4.1.5a). Furthermore, an 
attacking nucleophile (BiP’s Thr518 hydroxyl group) in-line with P-O3 would be at a 
considerable distance from the catalytic His363 (required to deprotonate Thr518’s hydroxyl 
group) (Figure 4.1.4a–b and Figure 4.1.5a).  
 
Figure 4.1.5: In-line nucleophilic attack is sterically occluded in the dimeric FICD:ATP structure. a, Semi‐
opaque 3 Å centroids centred on Pα and Val316(C1) are shown. The putative BiP Thr518 nucleophile (depicted 
by the cross) is positioned in‐line with the scissile phosphoanhydride (parallel to the plane of the paper) and 3 Å 
from P. This nucleophile position lies within the Val316 centroid (indicating a steric clash) and far away from 
His363, which would be required for nucleophile deprotonation. For clarity, the FICD:ATP structure is overlaid 
with a thin slice of the FICD:ATP structure in the plane of the P‐O3 bond. b, As in a except without an overlaid 
slice within the plane P‐O3 phosphoanhydride bond and rotated for clarity. In the monomeric AMPylation‐
competent FICDL258D:ATP structure, the putative nucleophile (cross) lies outside the Val316 semi-opaque centroid 
(indicating a lack of steric clash with the Fic domain flap) and also in proximity to His363 (the general base).  
In contrast, within FICDK256A or FICDL258D MgATP and MgAMPPNP are bound such that the 
interatomic P-C1(Val316) distance is relatively large (Figure 4.1.4a–b). As a result, there 
is no steric overlap between Val316 and a potential nucleophile primed for in-line nucleophilic 
attack into the ATP -phosphates bound to FICDK256A or FICDL258D (Figure 4.1.5b). 
Moreover, the -phosphate position in these structures is the same as that assumed by 
AMPylation-active Fic proteins lacking inhibitory glutamates (Engel et al, 2012; Goepfert et 
al, 2013; Bunney et al, 2014) (Figure 4.1.6). In this position, as illustrated above, in-line 
nucleophilic attack into the --phosphoanhydride bond of ATP is not sterically hindered and, 




furthermore, the N2 of His363 is well positioned for general base catalysis (Figure 4.1.6). 
Together these data suggest that both monomeric and dimer-relay mutant FICDs bind MgATP 
in an AMPylation competent conformation, whereas dimeric FICD does not. The latter finding 
is consistent with previous observations of inhibitory glutamate containing, AMPylation-
autoinhibited Fic proteins bound to ATP (Engel et al, 2012; Goepfert et al, 2013). 
 
Figure 4.1.6: AMPylation competent MgATPs share a common P position. The ATP ‐phosphates of 
monomeric or dimer-relay FICD mutants are in the same position as that of a MgATP molecule competently 
bound to the AMPylation unrestrained, dimeric FICDE234G (dark blue, PDB: 4U07). All AMPylation competent 
MgATP structures are superposed as in Figure 4.1.4. All ‐phosphates sit within the Fic domain oxyanion hole 
(formed by the Fic (sub)motif GN369G) and are coordinated by a Mg2+ ion, which is also complexed by the 
respective ‐phosphates and the Fic motif Asp367. 
The presence of ATP in both dimeric, wild type FICD and monomeric FICDL258D (although in 
different binding modes) is consonant with the DSF data (Figure 4.1.1). Apart from Glu234, 
the residues directly interacting with ATP are similarly positioned in all structures (maximum 
RMSD 0.83 Å). However, considerable variability is observed in Glu234, with an RMSD of 
4.20 Å between monomeric and dimeric wild type ATP structures. The large disposition in 
Glu234 conformations may hint at the basis of monomerisation-induced AMPylation 
competency.  
In all ATP-bound structures the inhibitory glutamate is displaced from the respective apo 
ground-state position, in which it forms an inhibitory salt bridge with Arg374 (R2 of the Fic 
motif). However, the displacement of the Glu234 side chain observed in the FICD:ATP 
structure (from its position in FICD:Apo; PDB 4U0U) would be insufficient to accommodate 
the -phosphate of an ATP/AMPPNP bound in an AMPylation competent conformation (see 
distances i and ii in Figure 4.1.4a–b and Figure 4.1.4c). In the FICDL258D and FICDK256A 
structures the maximum Van der Waals radii overlap between the bound -phosphate and the 
respective Glu234 side chain is less than the default value considered to represent a steric clash 
(< 0.6 Å overlap). Conversely the Van der Waals overlap between any AMPylation competent 




ATP -phosphate and the wild type FICD:ATP structure’s Glu234 (despite being displaced 
relative to its apo state position) is > 0.88 Å (Figure 4.1.4c, pink dashed lines). The differences 
between AMPylation competent conformations of Glu234 and ATP -phosphate (within 
FICDL258D and FICDK256A) may reflect the ability to trap diverse states of a dynamic system 
and/or may be indicative of variability in the protonation state of the -phosphate — pKa 7.1 
for the terminal phosphate proton of ATP and 7.7 for AMP-PNP (Yount et al, 1971). Moreover, 
changes in the charge borne by the ATP -phosphate may be facilitated by the different 
crystallisation conditions (pH 6.5 buffered condition for FICDK256A:ATP crystal growth; in the 
FICDL258D:nucleotide crystals the pH was likely dominated by the Tris-HCl present in the 
protein preparation [~ pH 8.0]; see Table 3). It is therefore possible that -phosphate within 
both the FICDK256A:ATP and FICDL258D:AMPPNP may be protonated (thereby reducing the 
electronic repulsion between the -phosphate and Glu234). Furthermore, there may also be 
differences in the flexibility or range in attainable bond angles between the --phosphate P-
O-P and P-N-P linkages of ATP and AMPPNP, respectively, which may affect the propensity 
of the -phosphate to bind in a certain conformation. With these factors in mind the cocrystal 
structure of FICDL258D:ATP should represent the most physiological AMPylation competent 
active site — with crystallisation conditions ~ pH 8.0 the bound ATP should have a net charge 
of –4 (the likely charge state of ATP at physiological pH).  
 
Chapter 4.2: The role of Glu234 flexibility in AMPylation 
The findings above suggest that the AMPylation-biased FICD mutants attain their ability to 
competently bind MgATP by increased flexibility at the top of the inh and by extension 
through increased Glu234 dynamism. This assertion is supported by analysis of average residue 
B-factors which provide a measure of the degree of molecular motion or static disorder. It was 
found that the temperature or B-factors in the vicinity of the dimer interface and Glu234 (of 
ATP-bound FICD structures) appears to correlate with AMPylation activity (Figure 4.2.1). 
This is despite similar crystal structure resolutions, overall B-factor averages (Table 3) and 
similar protein/crystal packing environments in the region of the dimer interface and Glu234 
(Figure 4.2.2 and Figure 4.2.3). 





Figure 4.2.1: B-factors are suggestive of monomerisation increasing Glu234 flexibility. The residue average 
B‐factors, for the four FICD complexes co‐crystallised with ATP, are shown [in (i–iv)] with a cold to hot colour 
code. For clarity, the TPR domain (up to residue 182) is not shown. Selected residues involved in the putative 
hydrogen bond, dimer-relay network are shown and labelled. 
 





Figure 4.2.2: The dimer-relay hydrogen bond network is maintained in FICD crystal structures. An 
alignment of FICD structures in the region of the principal dimer interface. The hydrogen bond network linking 
the dimer interface to Glu234 is also shown (blue dashed lines). Where indicated, single molecules from the 
asymmetric unit (*) are displayed with their respective crystal symmetry mates (Sym1). Note, the side chains of 
Asp258 and (Sym1)Arg250 of the monomeric FICDL258D:nucleotide structures, form a crystallographically 
induced intermolecular salt bridge (magenta dashed line). The salt bridges between Glu234 and the Fic motif 
Arg374 (magenta dashed lines) in the FICDL258D:Apo and FICDK256S:Apo structures, as observed in previous 
inhibitory glutamate-containing Fic crystal structures, are also shown. 
Moreover, it is notable that the differences in nucleotide triphosphate binding, Glu234 
disposition and average residue B-factors were observed despite all FICD:nucleotide structures 
crystallising with intact dimer interfaces (Figure 4.2.2). In the case of FICDL258D, which 
appears completely monomeric even at concentrations in the order of hundreds of micromolar 
(Perera et al, 2019), a crystallographically induced salt bridge (which incorporates Asp258) in 
the structures of FICDL258D:ATP and FICDL258D:AMPPNP restores the canonical dimer 
interface. Moreover, with the exception of direct hydrogen bonds to the Lys256 side chains 
(which are lost upon mutation of this residue), in all FICD crystals the putative dimer-relay 
hydrogen-bond network (linking the dimer interface to the inh and FICD active site) was 
maintained (Figure 4.2.2). This is also the case even in the FICDL258D:Apo crystal structure, 
which crystallised as a monomeric protein with a free dimer interface (Figure 4.2.2 and Figure 
4.2.3iii). 
 





Figure 4.2.3: Crystal packing around inh is similar in all FICD structures. FICDs with similar crystal 
packings are grouped into panels (i-iv). The inhibitory alpha helix (inh) is denoted with an asterisk (*) and 
Glu234s are shown as sticks. The wild type, dimeric FICD:Apo structure (FICD:Apo; PDB: 4U0U) is provided 
in all panels for reference. Symmetry mates within 4 Å of the FICD dimer interface (Sym1) or the inh (Sym2/3) 
are also displayed. Note, the crystals structures of Lys256 mutant FICDs (ii) contain a single molecule in their 
asymmetric unit but are packed as dimers, crystallographically reconstituting the dimeric biological unit (see 3). 
The asymmetric unit of FICDL258D bound to ATP (or an ATP analogue) (iv) contain a single molecule and thus 
corresponds to the biological unit of this monomeric protein. However, packing against the symmetry mate 
(Sym1), crystallographically reconstitutes a dimer interface that is highly similar, but not identical, to that 
observed in the wild type protein (see 2). In (iv) there are no crystal contacts in the vicinity of the inh. Instead, 
Sym2 in (iv) is included to highlight the intermolecular TPR domain swap, in which the intramolecular TPR 




domain contacts (broken by the ‘TPR out’ conformation in the asymmetric unit) are compensated for by a 
symmetry related TPR domain. 
Therefore, it seems likely that much of the monomerisation-linked conformational flexibility 
that facilitates binding of MgATP in solution cannot be trapped by the static snapshots which 
are obtainable crystallographically. Nonetheless, further circumstantial evidence for the 
increase in FICD AMPylation activity resulting from increased Glu234 flexibility arises from 
analysis of FICD protein melt temperatures, which provides an indication as to general protein 
stability and may be sensitive to increased flexibility in (the region of) the inh. At 
concentrations were the tested FICD variants (apart from FICDL258D and FICDG299S) were all 
principally dimeric (2 µM; KDs calculated by SEC in Perera et al, 2019) there is an inverse 
correlation between AMPylation ability (see Figure 1.5.1) and protein Tm (Figure 4.2.4a). This 
trend is present under various nucleotide conditions (Figure 4.2.4b).  
 
Figure 4.2.4: AMPylation biased FICD variants exhibit greater thermally lability. a, Melting temperatures 
(Tm) of the indicated FICD mutants (in the absence of nucleotide) were measured by differential scanning 
fluorimetry (DSF). Shown is the mean Tm ± SD from n = 3 independent experiments. The inset shows colour-
matched melt curves with their negative first derivatives, from a representative DSF experiment conducted in 
technical triplicate. The Tm for each protein sample was calculated from global minimum analysis of the melt 
curve negative first derivative. RFU, relative fluorescence units. See Figure 1.5.1 for quantification of respective 
FICD mutant AMPylation activities. b, Quantification of the indicated FICD variant Tms in the presence of either 
no nucleotide (Apo), 5 mM ATP or 2.5 mM ADP. All FICD variants respond similarly to the binding of ATP and 
ADP. For reference, the data in a is also duplicated in b. 
 




Chapter 4.3: Increased Glu234 flexibility decreases BiP deAMPylation 
activity 
In Chapter 2.4, through analysis of the state 1 deAMPylation complex crystal structure, the 
mechanistic basis of the essential role played by the gatekeeper Glu234 residue in Fic domain-
catalysed deAMPylation was elucidated. The above inferences regarding a monomerisation-
induced increase in inh and Glu234 flexibility, suggests that such a change may also explain 
the ~ 50% reduced deAMPylation efficiency of monomeric relative to wild type, dimeric FICD 
(Figure 2.3.7). The second (state 2) sub-2 Å deAMPylation complex-crystal structure, which 
is almost identical to that previously presented (Table 1 and Figure 2.1.2), appears to provide 
direct support for this assertion.  
 
Figure 4.3.1: Monomerisation increases Glu234 flexibility in the deAMPylation complex. a, A second 
deAMPylation complex structure (state 2, orange) is overlaid with an unbiased polder OMIT electron density 
map, contoured at 6. The view is the same as that presented in Figure 2.4.1. The OMIT map was calculated over 
regions of Fic domain catalytic residues of particular interest (Asp367 and Glu234), the Mg2+ coordination 
complex, BiP’s Thr518-AMP (green) and the approximate position of the state 1 catalytic water (marked with *). 
Hydrogen bonds formed by Glu234 are shown as pink dashed lines. Residues interacting with the AMP moiety 
are shown as sticks. b, A rotated and reduced view of the active site visible in a, aligned with the active site of the 
(deAMPylation competent) state 1 complex (yellow). His363 is modelled by superposition of a catalytically 
competent FICD (PDB 6I7K, as in Figure 2.4.2). The catalytic water (from state 1) is annotated with *. The 
distance between the closest Mg2+ first-coordination sphere water (red) from the state 2 complex and the (state 1) 
catalytic water* is annotated.  
As in the state 1 structure (Figure 2.4.1 and Figure 2.4.2), the FICD active site contains 
obvious electron density for BiP’s Thr518-AMP, Fic domain catalytic residues and a 
coordinated Mg2+ cation (Figure 4.3.1a). However, alignment with the state 1 structure reveals 
a clear difference in the orientation of Glu234 (Figure 4.3.1b). In the second, state 2, structure 




the Glu234 sidechain points further away from the position of the catalytic water molecule, 
that was so clearly visible in state 1, and more towards the Mg2+ cation.  
 
Figure 4.3.2: Increased Glu234 flexibility enfeebles positioning of the catalytic water. The same polder OMIT 
map is displayed over a reduced active site, as in Figure 4.3.1, highlighting the extended electron density covering 
the state 2 Mg2+ coordinating water and the position of the putative (state 1) catalytic water*. The orthogonal 
view, right, also helps to illustrate the shifted position of the Mg2+ coordination complex, which is presumably 
linked to the altered disposition and hydrogen bond contacts of the state 2 Glu234. Hydrogen bonds formed by 
both state 1 and 2 Glu234 residues are annotated with pink dashed lines.  
As observed in the monomeric FICDL258D:nucleotide structures it is possible that the state 1 
and state 2 deAMPylation complexes capture different snapshots of a dynamic Glu234 and Fic 
domain active site. However, in the case of the deAMPylation complexes, these changes are 
much better resolved. The reorientation of Glu234 noted in the state 2 complex appears to 
directly affect the ability of the state 2 active site to carry out the proposed deAMPylation 
mechanism (Figure 2.5.1), through stabilising a slight shift in the position of the Mg2+ 
octahedral coordination complex (Figure 4.3.2). Glu234 in the state 2 conformation forms a 
hydrogen bond with a different Mg2+ coordinated water, which facilitates a movement in the 
entire metal ion coordination complex in the direction of the (state 1) catalytic water. Although 
there is some remaining electron density in the catalytic water molecule region, this density is 
merged with the electron density of a Mg2+ coordinating water molecule (Figure 4.3.2). 
Moreover, this elongated density is incompatible with the modelling of two water molecules 
(accommodating the Mg2+ coordination geometry requirements would necessitate an infeasible 
inter-water distance of 1.89 Å) and suggests that there may be a dynamic shuttling of a water 
to and from the primary Mg2+ coordination sphere into a position more conducive to catalysis. 




Thus, it is clear that the Glu234 position observed in the state 2 crystal structure does not permit 
the stable positioning of a catalytic water molecule in-line for nucleophilic attack.  
A corollary of the two tenets, that Glu234 is necessary for coordinating a catalytic water 
molecule for deAMPylation and that Glu234 flexibility increases upon monomerisation, is the 
prediction that FICD deAMPylation activity should decrease upon monomerisation. This has 
already been demonstrated in terms of a decrease in catalytic efficiency (Figure 2.3.7). 
However, an increase in Glu234 flexibility is expected to intrinsically affect the ability of the 
FICD active site to catalyse deAMPylation and should thus lower the kcat. 
In order to directly measure the turnover number (kcat) for monomeric and dimeric FICDs both 
enzymes must be saturated with deAMPylation substrate, this necessitated adaptation of the 
previous FP-based in vitro deAMPylation assay. In order to compensate for the much-increased 
amount of substrate, the assay was modified to incorporate 10 µM rather than the previous 0.5 
µM of FICD enzyme. This enabled near complete substrate deAMPylation in all samples, 
within the permissible time course of the assay, and therefore permitted an ability to convert 
(for each reaction) the observed changes in FP signal into units of µM BiP produced or 
(equivalently) µM BiP deAMPylated (Figure 4.3.3).  
 
 
Figure 4.3.3: FP-based measurement of FICD deAMPylation kcat. a, Representative background drift-
subtracted FP deAMPylation time course. Linear best-fits are overlaid illustrating the initial reaction progress 
(from which y0 values were obtained) and final plateau value (y∞). The ∆FP between y0 and y∞ (for each sample) 
was taken to represent [BiP-AMP]0. b, Using the calculated ∆FP to ‘µM BiP deAMPylated’ conversion factors, 
deAMPylation time courses are presented. This provides a visual indication that the initial rates for each enzyme 
(best fit dashed lines) are similar at both BiP-AMP substrate concentrations. 





Figure 4.3.4: Monomerisation decreases FICD's deAMPylation kcat. a, Quantification of the initial 
deAMPylation rates (mean ± SD) with either 100 or 150 µM BiP-AMP substrate at t = 0, derived from analysis 
as presented in Figure 4.3.3. Results are presented from n = 4 independent experiments. b, The resulting kcat 
parameters were calculated using all initial enzyme velocities presented in a. The mean kcat value ± SD is shown 
with the P-value from a two-tailed Welch’s t-test annotated. 
In this fashion, it was found that the initial rates of deAMPylation were indistinguishable at 
initial substrate concentrations of 100 and 150 µM BiP-AMP (Figure 4.3.3 and Figure 4.3.4a), 
implying that FICD and FICDL258D are saturated at both BiP-AMP concentrations. Therefore, 
the initial deAMPylation rates, observed at both substrate concentrations for each enzyme, 
represent maximal enzyme velocities from which a kcat parameter can be extracted (Figure 
4.3.4b). As expected for the less-flexible Glu234-bearing, dimeric, wild type FICD its 
deAMPylation kcat ({10 ± 1} × 10
–3 s–1, mean ± SEM) was significantly greater (by a factor of 
1.8 ± 0.2) than that of monomeric FICDL258D ({5.7 ± 0.4} × 10–3 s–1). The monomerisation-
induced (proportional) decrease in kcat is very similar to that observed for the respective 
decrease in kcat/KM (Figure 2.3.7). 
A comparison of the turnover numbers calculated here and the previously derived 
deAMPylation catalytic efficiencies also facilitates calculation of monomeric and dimeric KM 
values for BiP-AMP substrate — suggesting approximate Michaelis constants of 16 ± 2 µM 
for dimeric, wild type FICD and 17 ± 2 µM for monomeric FICDL258D (mean ± SEM). One can 
also extrapolate that monomerisation of FICD must increase the effective KD for BiP-AMP by 
a factor of 1.9 ± 0.4 (mean ± SEM of the estimated fold-change). This accords with the poorer 
binding of FICDL258D-H363A, relative to FICDH363A, to immobilised BiP-AMP measured by BLI 
(Figure 2.3.2). Furthermore, the kcat and KM values derived for dimeric FICD are in good 
agreement with those previously obtained from substrate titration and Michaelis-Menten 




analysis of GST-FICD: kcat {9.9 ± 0.9} × 10
–3 s–1 and KM
 16 ± 3 µM (best-fit ± SE) (Preissler 
et al, 2017a). This adds credibility to the methods of kcat/KM and kcat determination employed 
in the present study. 
 
Chapter 4.4: Monomerisation regulates differential substrate binding 
kinetics 
The monomeric FICD-containing AMPylation complex is particularly sensitive to ATP-
mediated destabilisation 
The enzymatic analysis conducted above suggests that FICD is able to modulate its 
deAMPylation kcat in response to changes in its oligomeric state, whilst maintaining a relatively 
consistent KM. It therefore appears that differential substrate affinities may help potentiate the 
changes enacted at the level of FICD’s active site by monomerisation and dimerisation. For 
example, if a dimerisation-induced increase in deAMPylation kcat were to occur without a 
compensatory decrease in the KD for BiP-AMP, this would result in a proportional increase in 
deAMPylation KM. If enzyme substrate concentrations were not much greater than the (new) 
KM value this would also mean that a 1.8-fold increase in kcat would translate into less than a 
1.8-fold increase in deAMPylation activity. The differential substrate binding affinities 
possessed by monomeric and dimeric FICD may, therefore, contribute to the oligomerisation 
state-dependent reciprocal regulation of BiP AMPylation/deAMPylation.  
The FP-based in vitro deAMPylation assays, discussed above, were conducted in conditions of 
no excess ATP or other nucleotide. As revealed in the BLI assays, addition of ATP to the buffer 
solution is able to stimulate dissociation of both monomeric and dimeric FICD from 
immobilised BiP-AMP (Figure 2.3.2 and Figure 2.3.4). Destabilisation of the complex 
presumably occurs via competition of the exogenous nucleotide with the BiP-linked AMP 
moiety for the Fic domain active site, during a multi-step dissociation process.  
However, it was also observed that the dissociation of both monomeric and dimeric FICD from 
unmodified BiP:ATP was stimulated by the presence of ATP (Figure 2.3.2 and Figure 3.2.1). 
In this instance there is no possibility for a mechanism involving direct competition of 
nucleotide with a covalently attached AMP moiety, suggesting that there may be some form of 
allosteric mechanism at play. Moreover, it appeared from these BLI experiments that 
monomeric FICD was more sensitive to the addition of ATP in the (second) dissociation phase 




than dimeric FICD. As ATP is the co-substrate for BiP-AMPylation, a reaction massively 
favoured by FICD monomerisation, this phenomenon warranted further investigation. 
 
Figure 4.4.1: The binding of nucleotide to FICD enfeebles AMPylation complex formation. a, BioLayer 
interferometry (BLI) derived association and dissociation traces of monomeric FICDL258D‐H363A (mFICDH363A) or 
dimeric FICDH363A (dFICDH363A) from immobilised biotinylated BiPT229A‐V461F in absence or presence of 
nucleotides. Unless indicated (*), BiP was saturated with ATP before exposure to FICD variants. A representative 
set of traces from n = 3 independent experiments is shown. Note, the binding of mFICDH363A was more affected 
by presence of (saturating concentrations of) ATP (8 mM) and ADP (2 mM). b, Schematic of the BLI protocol 
used for testing the BiP:ATP binding response of FICD analytes to the presence of different nucleotides (as used 
to analyse the non-* samples in a).  
I previously demonstrated that immobilised BiP can be bound to ATP and remain in its ATP-
state for prolonged periods of time whilst immersed in nucleotide free buffer (Figure 2.3.1). 
This enables a deconvolution of the effect of nucleotide, on protein binding kinetics, mediated 
through BiP nucleotide binding and FICD nucleotide binding. Consistent with Figure 2.3.1 
and the revelation that FICD recognises the ATP-state of its AMPylation substrate, the binding 
of both apo monomeric or dimeric FICD to unmodified apo BiP was considerably accentuated 
by activation of the BiP ligand with ATP (Figure 4.4.1). As previously noted in the absence of 
extra nucleotide apo monomeric FICDL258D-H363A bound more tightly to immobilised BiP:ATP 
than apo dimeric FICDH363A. Saturating concentrations of both ATP and ADP impaired the 
ability of both FICDs to bind the BiP ligand. However, this impairment was much more 
pronounced for FICDL258D-H363A. Moreover, ATP actually had a reproducibly greater effect on 




monomeric FICD binding than ADP (which contrasts with the corresponding nucleotide 
responses of dimeric FICD analyte binding).  
It is clear that both ATP and ADP binding to FICD can elicit a diminution in its affinity for 
BiP:ATP, which is appreciable both in the association and dissociation phase of either FICD 
analyte. However, as noted previously, the kinetic profiles of FICD binding are multiphasic, 
which makes extraction of meaningful KDs (or other kinetic binding parameters) problematic. 
Therefore, in an effort to quantify the different sensitivities towards nucleotide, exhibited by 
monomeric and dimeric FICD, the effect of addition of nucleotide to a preformed pre-
AMPylation complex (as in Figure 2.3.2 and Figure 3.2.1) was revisited with modifications.  
In this instance a single dissociation event was analysed in order to increase the analysable 
dissociation signal and to facilitate more reliable exponential decay curve fitting (Figure 4.4.2). 
Where indicated 8 mM ATP was used to supplement the dissociation well buffer solution. This 
concentration was assumed to be saturating (being considerably above the low millimolar K½s 
of ATP-induced Tm increase, Figure 4.1.1) and non-rate limiting for the dissociation reactions 
under investigation. That is to say, at a sufficiently high concentration such that the association 
rate of ATP into any exposed FICD active sites should be considerably faster than the rate of 
FICD dissociation from BiP:ATP. This later assumption is reasonable given the very high on 
rates generally associated with small molecule binding events and the sizeable concentration 
of ATP. The use of ATP during the dissociation phase also biases the analysis against any 
potential of confounding effects of the nucleotide on the status of the BiP ligand. As BiP:ATP 
has already been demonstrated to be a much better FICD binding partner, the addition of ATP 
to the dissociation well should actually strengthen the interaction from the point of view of the 
immobilised ligand (either by direct nucleotide exchange of any NBD-bound ADP, resulting 
from the small amount of residual BiPV461F-T229A ATPase activity, with the excess ATP in 
solution or replenishment of any ATP losses from the BiP NBD).  
 





Figure 4.4.2: ATP destabilises the pre‐AMPylation complex. a, A representative BLI experiment is shown. 
Similar to the setup employed in Figure 4.4.1, apo FICD analytes (all at 250 nM) were loaded onto BiP:ATP in 
the association phase (all in a no nucleotide buffer). At the start of the dissociation phase (indicated by the dashed 
vertical line), the pre-AMPylation complexes were transferred into wells containing only buffer (no analyte) ± 
ATP (as indicated). b, Quantification of the biphasic dissociation traces from a. The start of the dissociation phase 
in a was taken as t = 0. The best-fit biexponential decay curves are overlaid with dashed black lines. c–e, The 
parameters extracted from biphasic fitting of the FICD dissociation traces, all presented as mean values ± SD from 
n = 3 independent experiments. In c and d, bars are colour-matched to the BLI traces presented in a and b. Note, 
the koff,fast, the percentage of the dissociation phase attributable to fast dissociation (%Fast) and the koff,slow 
parameters of both monomeric and dimeric FICD were all increased by ATP. However, the proportional effect of 
ATP (highlighted in e) was considerably greater for monomeric FICD with more pronounced sensitivity in terms 
of dissociation %Fast and koff,slow. 




The resulting analysis demonstrated a clear effect of ATP on the disassembly of dimeric and 
monomeric FICD-containing pre-AMPylation complexes (Figure 4.4.2). The overall rate of 
dimeric FICD dissociation is faster (relative to monomeric FICD dissociation) both with and 
without ATP in the dissociation buffer. This is consistent with previous results that monomeric 
FICD binds its AMPylation substrate more avidly than dimeric FICD (Figure 3.2.1). In light 
of Figure 4.4.1, this suggests that ATP also has a very significant effect on the on rate(s) of 
monomeric FICD. Furthermore, although the overall dissociation rate in the presence of 
MgATP is greater for dimeric than monomeric FICD, the relative response of monomeric FICD 
dissociation to ATP is much greater than that exhibited by dimeric FICD (Figure 4.4.2e). The 
effect of MgATP was especially significant with respect to modulating monomeric FICD’s rate 
of slow dissociation (koff,slow) and the percentage of the dissociation attributed to the fast phase 
(%Fast). 
Modelling the active site of the AMPylating Michaelis complex 
As the overall manner of FICD•BiP-AMP engagement (captured crystallographically) is shared 
by the AMPylation complex, it stands to reason that AMPylation complex active sites can be 
approximated by alignment of the deAMPylation complex (after removal of the AMP moiety) 
and ATP-bound FICDs (Figure 4.4.3). BiP Thr518 can be accommodated by the active site of 
MgATP-bound, monomeric FICD and the resulting state appears conducive to AMPylation 
(Figure 4.4.3a). This supports two previous assertions — firstly, that FICD similarly engages 
BiP:ATP and BiP-AMP and, secondly, that monomeric FICD binds MgATP in an AMPylation 
competent conformation. Conversely, as anticipated, Thr518 does not bind in a position in line 
with the --phosphoanhydride bond of ATP bound to dimeric, wild type FICD (Figure 
4.4.3b). Moreover, Thr518 in the modelled dimeric FICD system would result in a significant 
steric clash with the ATP -phosphate (Figure 4.4.3b inset). Therefore, it is feasible that there 
may be some degree of direct competition between the binding of BiP’s unmodified Thr518 
target residue and ATP within the active site of wild type FICD.  





Figure 4.4.3: BiP's Thr518 can be accommodated in the active site of ATP-bound monomeric FICD. a, A 
pseudo AMPylation complex created by structural alignment, illustrating the ability of monomeric FICD bound 
to MgATP (yellow with purple nucleotide) to accommodate BiP’s Thr518 in a catalytically competent 
conformation. The model is derived by alignment of FICDL258D:ATP with the state 1 deAMPylation complex 
(FICD in orange; BiP in purple), over the Fic domain residues 213–426. O of BiP’s Thr518 (restored to its non-
AMPylated state by in silico removal of the AMP moiety) is in-line with the P-O3-phosphoanhydride bond 
and can be deprotonated by His363. Though not modelled here, flexibility in the Fic flap, FICD’s Val316 and 
BiP(ℓ7,8) likely permit P and O(Thr518) to attain a distance consistent with an initial substrate engagement state. 
b, As in a but with alignment of dimeric FICD bound to ATP in a catalytically incompetent mode. Note the severe 
clash between Thr518 and the ATP -phosphate. Inset, interatomic distances between BiP’s Thr518 and the -
phosphate are annotated (* and **). Small rearrangements in the position of Thr518 will not be able to generate a 
sterically permissible and catalytically competent active site.  
However, the observation that monomeric FICD-containing pre-AMPylation complexes are 
more sensitive to nucleotide (than dimeric FICD) speaks against direct substrate competition 
being the mechanism responsible for the nucleotide sensitivity observed in the above BLI 
experiment (Figure 4.4.2). Moreover, the fact that ADP can also elicit a similar response to 
ATP in both monomeric and dimeric FICD (Figure 4.4.1) is further evidence against an 
appreciable role for direct competition with BiP within the active site — as ADP binds  dimeric, 
wild type FICD with high affinity (KD 1.5 µM) and with its -phosphate in the canonical 
position (see PDB 4U0U; Bunney et al, 2014), as exemplified by the ATP molecule in Figure 
4.4.3a. 





Figure 4.4.4: A putative AMPylation complex active site. The starting structure presented in Figure 4.4.3a 
(purple ‘unmodified’ BiP from the deAMPylation complex and yellow FICDL258D:MgATP) was energy-
minimised to produce the modelled AMPylation complex active site (FICD•BiP with MgATP). The derived local 
energy minimum is also superposed with the original state 1 deAMPylation complex (FICD•BiP-AMP with the 
AMP moiety removed, orange). Selected intermolecular hydrogen bonds (pink dashed lines) and interatomic 
distances (black dashed lines) are annotated. Note, unmodified BiP is able to form an intermolecular -sheet with 
the flap of FICDL258D whilst position its target reside Thr518 in line for nucleophilic attack into the ATP -
phosphate, within hydrogen bonding distance of the general base His363 and without any steric clashes. In the 
AMPylation complex Glu234 may form direct intermolecular contacts. Minimisation was carried out with the 
original position of ATP and FICD’s Arg374 fixed. A portion of both FICDs’ -helical linkers and the complete 
TPR domains (in the background in Figure 4.4.3) are omitted for clarity. 
Through minimisation of the hybrid AMPylation complex modelled in Figure 4.4.3a, 
speculative inferences about the nature of oligomerisation and FICD-nucleotide dependent 
changes in BiP substrate affinity can be made. In the deAMPylation complex, FICD’s Tyr400 
forms a hydrogen bond to BiP’s SBD ℓ5,6 Asn496. The energy minimised FICD is based on 
the FICDL258D:MgATP structure, in which Glu234 faces away from the active site and no 
longer forms the AMPylation inhibiting salt bridge to the Fic motif Arg374 (Figure 4.4.4). As 
such Glu234 in the minimised AMPylation complex forms a hydrogen bond to BiP’s Asn496 
and an intramolecular hydrogen bond to FICD’s Tyr400 (Figure 4.4.4). This in turn permits 
Tyr400 to form a different intermolecular hydrogen bond to the main chain of BiP’s Ly516 
(within ℓ7,8 of the SBD). The position of the displaced monomeric FICD Glu234 is potentially 
stabilised by being within salt bridge forming distance of FICD’s Arg396. The modelled end 
result is an intramolecular salt bridge-stabilised, intermolecular hydrogen bond network in 
which there is a net addition of one intermolecular hydrogen bond in the protein-protein 




interface relative to the deAMPylation complex (Figure 4.4.4). This may be able to provide 
extra stabilisation of the target residue bearing BiP SBD ℓ7,8.  
Speculation on the nature of FICD’s oligomeric state–linked pre-AMPylation complex 
affinity and nucleotide sensitivity  
If monomeric FICD possesses a more flexible inh and Glu234, as proposed in Chapter 4.2, it 
is plausible that the bolstered intermolecular hydrogen bond network (modelled in Figure 
4.4.4) may also be favoured by monomerisation. This could explain the observed increase in 
BiP:ATP affinity induced by monomerisation of FICD (Figure 2.3.2). Conversely, in the 
context of binding BiP-AMP, Glu234 has a direct role in stabilisation of the Mg2+ coordination 
complex (Figure 4.3.2). This is not a role played by Glu234 during AMPylation as the divalent 
cation is tightly coordinated between the  and -phosphates of ATP and likely enters the 
active site with the nucleotide. It is therefore plausible that the binding of BiP-AMP (and a 
Mg2+ ion) disfavours the hypothetical AMPylation complex-favouring Glu234 conformation. 
Correspondingly, increased Glu234 flexibility may also directly destabilise the deAMPylation 
complex by weakening the ionic interactions afforded by stable divalent cation positioning (as 
well as causing the aforementioned reduction in deAMPylation kcat through less efficiently 
coordinating a catalytic water). This logic could indeed rationalise the observed 
monomerisation-induced decrease in FICD affinity for BiP-AMP (Figure 2.3.2). 
Inspired by the modelled AMPylation complex active site, one could speculate further as to the 
nature of the allosteric pre-AMPylation complex destabilisation induced by nucleotide. The 
narrow ATP -phosphate to FICD Glu234 tolerances, and incomplete -phosphate electron 
density within the isolated FICDL258D:ATP crystal structure (Figure 4.1.3 and Figure 4.1.4) 
suggests that MgATP binding may itself induce greater displacement of FICD’s inh and 
Glu234 (via steric and electronic repulsion) than that captured crystallographically. Addition 
of MgATP to the active site of monomeric FICD may, in this way, reduce the propensity for 
intermolecular Glu234 contacts. This hypothesis is also consistent with the similar, albeit 
reduced, response of monomeric FICD-containing pre-AMPylation complexes to ADP, as 
MgADP binding has previously been observed to have some electronically repulsive effect on 
the disposition of Glu234 (causing the population of two alternative Glu234 conformations in 
dimeric FICD soaked with MgADP; PDB 4U0U).  
If dimeric wild type FICD is also able to sample the Glu234 flipped out state, as evidenced by 
PDB 4U0U (Bunney et al, 2014), it is possible that a small (potentially transient) population 




of dimeric FICD-containing pre-AMPylation complexes is similarly affected by nucleotide 
binding in the active site. This would rationalise the (reduced) sensitivity of dimeric FICD-
containing AMPylation complexes to nucleotide. 
FICD’s Tyr400 residue also forms direct hydrophobic contacts to the adenosine portion of 
nucleotides bound in FICD’s active site in all nucleotide-bound FICD structures. Furthermore, 
the hydrophobic contacts to the adenosine are more pronounced in isolated FICD:nucleotide 
complexes than in the deAMPylation complex, where Tyr400 moves away from the adenosine 
to also form an intermolecular hydrogen bond with BiP (Figure 4.4.4). Thus, it is also a 
possibility that nucleotide may directly affect pre-AMPylation complex binding kinetics by 
directly affecting the conformation of nucleotide/BiP interacting residues in the active site. 
Furthermore, as contacts between the Fic domain and TPR domain have already been 
demonstrated to affect AMPylation and deAMPylation activity it would not be surprising if 
more long-range allosteric mechanisms also contribute to the particular sensitivity of the 
monomeric FICD-containing pre-AMPylation complex to ATP.  
 
Chapter 4.5: ER energy status may modulate FICD’s monomer-dimer 
equilibrium 
The crystal structures of FICD:nucleotide complexes revealed that FICD's oligomeric state can 
impact significantly on the mode of ATP binding. Figure 4.4.1 and Figure 4.4.2 indicate that 
nucleotide binding within FICD can induce allosteric effects on FICD conformation (which are 
able to affect AMPylation complex stability). Together, these observations suggest that 
bidirectional intramolecular signalling from the FICD dimer interface to the nucleotide‐binding 
active site may be possible and that ATP binding in FICD's active site may also influence the 
oligomeric state of the protein. Furthermore, I also speculated above that the relationship 
between inh/Glu234 flexibility and ATP binding may be bidirectional. That is to say, that 
monomerisation-induced Glu234 flexibility facilitates AMPylation competent MgATP binding 
and, reciprocally, that ATP binding may also stimulate greater deviation of the Glu234/inh 
position from the basal AMPylation inhibiting conformation of the side chain. If ATP binding 
does indeed contribute to destabilising the inh, this may then feedback through the same dimer-
relay to weaken the dimer interface. 





Figure 4.5.1: The FICD dimer off rate is increased by ATP. a, Above, representative BLI traces of an FICD 
dimer dissociation experiment. 3 nM of either N-terminally biotinylated dimeric FICDH363A (dFICD) or 
biotinylated monomeric FICDL258D-H363A (mFICD) were incubated with a 100‐fold molar excess of non-
biotinylated FICDH363A prior to biosensor loading. The legend indicates the ligand present in the dissociation 
buffer (at 5 mM), if applicable. Below, schematised version of dFICD loading and dissociation steps. b, Above, 
representative FICD dimer dissociation experiment derived from the traces in a following subtraction of the 
respective mFICD background drift traces. Best-fit single exponential decay curves are overlaid (black dashed 
lines). Below, quantification of the dimer dissociation rates in different nucleotide buffer conditions from n = 4 
independent experiments. Statistical analysis was performed using a one-way ANOVA followed by a Tukey test 
for post hoc analysis. P-values are annotated (n.s.; not statistically significant, P > 0.05).  
To investigate the hypothesis of nucleotide-modulated oligomerisation, N‐terminally 
biotinylated FICDH363A was incubated with a 100-fold molar excess of non‐biotinylated 
FICDH363A. This permitted all biotinylated FICDH363A molecules to release and exchange their 
homodimeric binding partner for non-biotinylated FICDH363A protomers. The resulting semi-
biotinylated heterodimeric FICDH363As were loaded onto a BLI streptavidin biosensor. The 
dissociation of non‐biotinylated FICDH363A from its immobilised partner was then observed by 
quasi‐infinite dilution into buffers varying in their nucleotide composition (as illustrated in 
Figure 4.5.1a). Biotinylated, monomeric FICDL258D-H363A was similarly incubated with the 
same excess of non‐biotinylated FICDH363A and also loaded onto the BLI tip (in order to provide 




internal controls for baseline drift). It was found that ATP but not ADP induced a 3‐fold 
increase in the dimer dissociation rate (koff, Figure 4.5.1b). This is suggestive of a mechanism 
whereby changing ATP/ADP ratios in the ER may modulate the oligomeric state of FICD but 
does not preclude the possibility of a compensatory increase in dimer association rate (kon). 
In order to establish whether ATP is indeed able to modulate FICD’s monomer-dimer 
equilibrium (and not simply cause proportional increases in dimer koff and kon), I developed a 
dimerisation‐sensitive fluorescent FICD probe. Various residues were trialled for their ability 
to either permit a FRET or fluorophore self-quenching based readout of FICD oligomerisation 
state. Cysteines were introduced by site directed mutagenesis into the background of a 
dimerisation‐competent, cysteine‐free, catalytically inactive FICDH363A‐C421S. Mutated residues 
at surface‐exposed positions predicted to lie within a FRET distance across the dimer interface 
were decorated with cysteine-reactive fluorophore derivatives. Residues on the N‐terminal 
extension of the Fic domain (Ser241Cys, Lys256Cys) were either very poorly labelled or 
caused destabilisation of the protein upon being labelled, resulting in significant aggregation 
(see Figure 1.3.2 for an illustration of the core Fic domain and its less conserved extensions). 
Stable and monodisperse fluorescent probes were engineered by the introduction of cysteine 
substitutions into the surface of the core Fic domain (Ser288Cys and Arg308Cys). FICDS288C-
H363A‐C421S was found to label efficiently with tetramethylrhodamine (TMR)-maleimide and to 
produce the greatest signal-to-noise optical readout of FICD's oligomeric state. Moreover, the 
original serine side chain was not observed to be engaged in inter‐protomer contacts.  
To validate the ability of FICDS288C-H363A‐C421S-TMR (FICD-TMR) to report on FICD’s 
oligomerisation status, the probe was incubated with an escalating concentration of unlabelled 
dimerisation‐competent FICDH363A. It was found that dimeric (unlabelled) FICDH363A, but not 
unlabelled monomeric FICDL258D-H363A, led to a progressive increase in the fluorescence of 
FICD‐TMR (Figure 4.5.2a). This observation is consistent with a reduction in fluorophore 
self‐quenching as FICD‐TMR homodimers are converted to heterodimers containing only one 
labelled protomer.  
The dimerisation‐sensitive probe was used to investigate the ability of ATP and ADP to 
modulate the FICD monomer‐dimer equilibrium in solution. In agreement with the BLI 
experiment that reported on an ATP-stimulated FICD dimer dissociation rate from an 
immobilised FICD protomer (Figure 4.5.1), ATP was observed to increase the proportion of 
monomeric FICD-TMR in a concentration‐dependent fashion (Figure 4.5.2b). Conversely, 




supplementing the dissociation buffer with ADP appeared to push the FICD equilibrium 
towards the dimer and also effectively antagonised the monomerising effect of ATP (Figure 
4.5.2b). Moreover, the apparent nucleotide-dependent modulation of FICD’s oligomeric state 
occurs within a plausible physiological range of ER-luminal ATP and ADP concentrations. 
Together, these observations attest to an allosteric coupling of FICD's oligomeric state to the 
identity of the bound nucleotide and suggest a means of physiologically transducing changing 
levels of ER stress to alterations in overall BiP modification status. 
 
Figure 4.5.2: ATP stimulates FICD monomerisation. a, Validation of the fluorescent dimerisation probe. The 
dimerisation‐sensitive TMR fluorescence of the labelled dimer (2.5 nM FICD-TMR) is dequenched specifically 
by equilibration with excess unlabelled dimerisation‐competent FICDH363A but not monomeric FICDL258D‐H363A. 
Mean values ± SD, from n = 3 independent experiments, are shown. RFU, relative fluorescence units. b, ATP 
increases, and ADP decreases, the proportion of monomeric FICD. Fluorescence measurement of nucleotide‐
dependent modulation of the FICD monomer‐dimer equilibrium. The probe signal at each nucleotide condition is 
presented as a fraction of the completely monomeric FICD fluorescent signal (in other words, as a fraction of the 
fluorescent intensity of complete fluorophore dequenching). Regression lines from a one-site binding model are 
overlaid (black dashed lines in both a and b). *Plateaus were constrained to a shared best‐fit value. Data shown 
are the mean ± SD from n = 4 independent experiments. a.u., arbitrary units. 
 
Chapter 4.6: Conclusions 
Here, I have dissected the mechanistic basis of the oligomerisation state-dependent switch in 
FICD enzymatic activity. In its dimeric state FICD can bind ATP (but not with a coordinating 
Mg2+ ion), although it will not do so in an AMPylation competent conformation. 
Monomerisation of FICD permits the binding of MgATP such that the ATP -phosphate is 
conducive to the in-line nucleophilic attack required for BiP AMPylation. It appears that the 
change in AMPylation permissibility of the FICD active site stems from a monomerisation-




induced increase in gatekeeper Glu234 flexibility (and possibly also increased dynamism in 
the inh). These observed changes likely play a very significant role in the considerable 
AMPylation rate-enhancement of monomeric FICD over dimeric FICD (summarised in Figure 
4.6.1). 
 
Figure 4.6.1: FICD monomerisation increases AMPylation activity. Monomerisation of FICD increases inh 
and gatekeeper Glu234 flexibility. This permits AMPylation competent binding of MgATP within the active site 
of monomeric FICD (mFICD; left-hand side). The dimeric FICD (dFICD) enzyme, with its more rigid Glu234, 
inhibits the positioning of the ATP -phosphate, which would otherwise engage the Fic motif Arg374. If ATP 
binds to the dimeric FICD active site it does so without the coordination of a Mg2+ cation and in an AMPylation 
incompetent conformation — incompatible with in-line nucleophilic attack into the scissile P-O3 
phosphoanhydride bond (right-hand side). Monomeric FICD is therefore a much better BiP AMPylase than 
dimeric FICD. Changing levels of ER stress (possibly through indirect modulation of ER energy status) alters the 
monomer-dimer equilibrium so as to match the levels of inactive, AMPylated BiP to the burden of unfolded 
proteins. 
Moreover, it seems likely that the process of crystallisation may mask the full effects of the 
monomerisation-induced increase in inh and Glu234 flexibility in solution — leading to 
crystallographically induced dimerisation within the monomeric FICDL258D:nucleotide 




structures and (presumably) also to the stabilisation of the dimer-relay hydrogen bond network. 
Such considerations could explain the comparatively small differences in the position of 
Glu234, but stark differences in nucleotide conformation, observed between the wild type and 
monomeric or dimer-relay mutated FICD structures. In solution, disruption of the dimer-relay 
network (either by mutation and/or monomerisation of FICD) may well induce partial 
unfolding of inh from the catalytic Fic domain. This then permits AMPylation competent 
binding of MgATP and results in the observed (considerable) relief of Glu234-mediated 
AMPylation autoinhibition. Conversely, the crystallisation process quite possibly favours 
rearrangements, including inh refolding and crystallographic reconstitution of the dimer 
interface, and convergence towards a low energy state (the one stabilised in solution by 
dimerisation). This then outweighs the energetic penalty of the resulting (crystallographically-
induced) electronically or sterically strained carboxylate-carboxylate (Glu234-Glu263) or 
glutamate-phosphate contacts observed in the AMPylation competent structures (Figure 
4.1.4).  
Somewhat unsurprisingly, the increased Glu234 flexibility of monomeric FICD also reduces 
the catalytic efficiency and maximal velocity of BiP deAMPylation. As elucidated in Chapter 
2.4, Glu234 plays an essential role in the catalysis of the deAMPylation reaction, aligning and 
activating an attacking catalytic water molecule for in-line nucleophilic attack into the 
phosphodiester bond linking BiP to its AMP moiety. In this chapter, I present a 
crystallographically captured corollary of decreased Glu234 stability in the context of FICD-
mediated deAMPylation — an increased likelihood of Glu234 causing a shift in the Mg2+ 
coordination complex and being unable to effectively stabilise a catalytic water molecule 
(summarised in Figure 4.6.2). As in the case of the FICD:nucleotide crystal structures, the 
nature of the crystallisation process may underestimate the destabilising effect of 
monomerisation on the inh and gatekeeper Glu234.  





Figure 4.6.2: FICD dimerisation increases deAMPylation activity. BiP deAMPylation requires the positioning 
and activation of a catalytic water molecule in-line with the P-O(Thr518) phosphodiester bond. These ends can 
only be met by Glu234 (see right-hand side). As monomerisation increases the flexibility of this gatekeeper 
residue, which sits atop the inh, it also decreases the ability for Glu234 to stably position a water molecule 
conducive to deAMPylation (left-hand side). Coordinated modulation of the FICD pool between more monomeric 
(mFICD) and more dimeric (dFICD) states therefore serves to reciprocally regulate the two functionally opposite 
enzymatic reactions catalysed by FICD, despite a similar mode of ATP-state BiP(±AMP) substrate binding.  
It was also initially revealed in Chapter 2.3 that monomeric FICD was able to bind unmodified 
BiP:ATP more avidly than dimeric FICD and, conversely, that dimeric FICD was able to bind 
BiP-AMP more tightly than monomeric FICD (Figure 2.3.2). These reciprocal substrate 
binding affinities align with the division of labour between monomeric and dimeric FICD; the 
former being a good AMPylase (binding unmodified BiP:ATP as its substrate) and the latter 
being a good deAMPylase (binding BiP-AMP as its substrate). Indeed, in the case of 
deAMPylation I have experimentally demonstrated that despite dimerisation increasing the 
deAMPylation kcat, the concomitant increase in BiP-AMP affinity enables the KM to remain 
unchanged. Moreover, the AMPylation complex affinity appears to be influenced by FICD-




bound nucleotide, with monomeric FICD particularly sensitive to the allosteric, destabilising 
effect of ATP.  
Allosteric affinity-modulation induced by ATP, may stem from feedback between FICD’s 
Glu234 or Tyr400 and the bound ATP molecule — depreciating potential intermolecular 
contacts with BiP’s SBD that are made or stabilised by these Fic domain residues. There is 
also the additional possibility that long range allostery may also contribute to this observed 
nucleotide sensitivity phenomenon. For example, ATP binding within the Fic domain may 
affect other BiP contacting areas of FICD such as the dimer interface adjacent Glu260 region 
which forms hydrophobic contacts to parts of BiP’s SBD ℓ5,6. Moreover, communication 
between the Fic domain and TPR domain has already been shown (in Chapters 2 and 3) to be 
important for FICD-mediated AMPylation and deAMPylation. It is therefore also plausible that 
the allosteric effect of FICD nucleotide binding may exploit this axis. Interestingly, based on 
molecular dynamics simulations, long range allostery extending from the ATP binding site to 
a distal target recognition module (affecting AMPylation substrate affinity) has also been 
implicated in the functioning of another Fic protein — IbpA (Khater & Mohanty, 2015b). 
As ATP is the co-substrate for FICD-mediated AMPylation the utility of this ATP-induced 
destabilisation could be twofold. Firstly, by increasing the AMPylation complex KD, the 
presence of ATP within the ER will increase the effective KM for unmodified ATP-state BiP 
(the other AMPylation co-substrate). Having a high KM (given that the total concentration of 
BiP in the ER may be in the order of hundreds of micromolar) may allow FICD-mediated 
AMPylation to be responsive to changing concentrations of ATP-state BiP in the ER. A KM in 
the order of or greater than the range of luminal BiP:ATP concentration is necessary for the 
hypothesised existence of substrate-level regulation of BiP AMPylation, discussed earlier. 
Conversely, if the BiP:ATP concentration were considerably greater than the AMPylation KM 
the rate of FICD-mediated AMPylation would cease to be sensitive to the amount of BiP:ATP 
(with the enzyme simply working at or close to its maximum velocity). Secondly, tight binding 
of an enzyme-substrate complex can be anti-catalytic (by increasing the Gibbs free energy of 
activation). It is therefore plausible that enzyme co-substrate (ground state) destabilisation, 
observed to be prevalent in the monomeric FICD-containing AMPylation complexes, may 
serve a catalytic function — reducing the Gibbs free energy of activation for the AMPylation 
reaction as observed in a number of other enzymes (Andrews et al, 2013; Ruben et al, 2013). 
As it is very likely that the co-substrates for BiP AMPylation will/must bind in a sequential 




fashion, selective enzyme-substrate destabilisation in the context of both substrates may greatly 
increase both the efficiency and kcat of monomeric FICD catalysed AMPylation.  
In further support of the potential for long range and bidirectional allostery being prevalent 
across FICD, it was found that ATP and ADP were able to reciprocally modulate FICD’s 
monomer-dimer equilibrium. Binding of ATP within the active site of dimeric FICD pushed 
the FICD equilibrium towards the monomeric state and also increased the dimer dissociation 
rate. Contrarily, a low (nanomolar) concentration of FICD binding ADP actually increased the 
proportion of homodimeric molecules in solution. In addition, the observed sensitivity of the 
FICD monomer-dimer equilibrium to nucleotide occurred within a plausible dynamic range of 
ER luminal ATP and ADP concentrations.  
The major ER-resident ATPase proteins are all chaperone proteins (BiP, Hsp90 and Hsp110 
family proteins). Moreover, the chaperoning capacity and, by extension, ATPase content of the 
ER is dominated by BiP (Bakunts et al, 2017). As the ER lumen is spatially and presumably 
temporally delineated (by the ER membrane) from the ATP buffering systems which are 
prevalent within the cytosol of eukaryotic cells, it is plausible that the ATP/ADP ratio may 
respond to changing levels of unfolded protein load in the ER. For example, an increase in co-
translational protein translocation into the ER will raise the concentration of unfolded nascent 
chain protein able to be bound by BiP molecules and other protein chaperones. Binding of these 
unfolded proteins by BiP molecules will stimulating the intrinsic ATPase activity of these 
chaperone proteins and potentially induce a drop in the luminal ATP/ADP ratio. In this model 
the decreased ATP/ADP ratio is directly sensed by the FICD pool, as a proxy of ER stress, and 
translated into a more dimer biased FICD equilibrium. This, in turn, facilitates increased 
deAMPylation of any inactive reserves of BiP (BiP-AMP) and thus increases BiP chaperoning 
capacity (without the need for the induction of the transcriptional and translational machineries 





Chapter 5: Discussion 
Chapter 5.1: General Summary 
In this study I have discovered that both monomeric and dimeric FICD recognise BiP through 
specific engagement of the FICD target recognition module (its TPR domain) with a tripartite 
Hsp70 ATP state–specific surface (composed NBD-linker-SBD). Both oligomeric states of 
FICD also form additional contacts between their catalytic Fic domains and BiP’s SBD (ℓ5,6 
and ℓ7,8) BiP’s SBD ℓ7,8 contains the target residue (Thr518) which is both AMPylated and 
deAMPylated by FICD in its single, bifunctional active site.  
FICD scaffolds a very similar mode of BiP engagement in order to catalyse both BiP 
AMPylation and deAMPylation. This facilitates the selective binding of ATP-state unmodified 
BiP (BiP:ATP) and the intrinsically ATP-state biased AMPylated BiP (BiP-AMP), 
respectively. The ability for FICD to discriminate between BiP:ATP and BiP in a domain 
undocked ADP-state potentially facilitates substrate-level regulation of BiP AMPylation. Such 
a regulatory mechanism would allow the rate of BiP AMPylation to inversely correlate with 
the protein folding demand in the ER — by binding to BiP’s SBD unfolded peptides stimulate 
BiP’s ATPase activity and will therefore titrate BiP out of the ATP-state and into the client-
bound ADP-state. 
These findings rationalise previous observations pertaining to the exquisite selectivity of 
FICD-mediated AMPylation for BiP. For example, it has been demonstrated that FICD is only 
able to AMPylate BiP proteins that are allosterically coupled or, in other words, respond to 
ATP binding in the BiP NBD by domain docking. Moreover, FICD has an AMPylation 
preference for BiP mutants that are more biased towards the ATP-state and, in addition, FICD 
is unable to AMPylate the isolated SBD of BiP (which cannot assume the ATP-like 
conformation of the SBD subdomain) (Preissler et al, 2015b). Likewise, although full-length 
BiP-AMP is intrinsically biased towards the ATP-state, FICD is also unable to deAMPylate 
the isolated BiP SBD (Preissler et al, 2017a).  
FICD’s gatekeeper glutamate is well characterised for its AMPylation autoinhibiting role as 
part of a inhibitory -helix (inh) conserved throughout the Fic protein family (Engel et al, 
2012; Goepfert et al, 2013). However, it is also necessary for the catalysis of Fic domain-
mediated deAMPylation (Preissler et al, 2017a; Veyron et al, 2019). Here, I 





water in-line for nucleophilic attack into the backside of the phosphodiester bond covalently 
linking BiP and the AMP moiety.  
Monomerisation of FICD reciprocally regulates the mutually antagonistic activities of FICD, 
facilitating rapid and stable modulation of the inactivated BiP-AMP pool within the ER, in 
response to varying conditions of unfolded protein load. Monomerisation converts FICD from 
a strong homodimeric deAMPylase (and poor AMPylase) into a good AMPylating enzyme 
with diminished deAMPylation activity. Through a hydrogen bond network linking the FICD 
dimer interface to inh and Glu234, FICD monomerisation increases Glu234 (and potentially 
also inh) flexibility. Increased Glu234 flexibility serves two important functions which induce 
the described reciprocal regulation of FICD bifunctionality. The increased flexibility of this 
AMPylation-inhibiting residue permits the -phosphate of ATP to bind in a position 
coordinated by the Fic motif Arg374. In turn, this facilitates AMPylation competent binding of 
MgATP in the Fic domain active site. In a similar vein, increased Glu234 flexibility also 
reduces the likelihood of efficient catalytic water positioning, required for BiP-AMP 
deAMPylation. Conversely, wild type, dimeric FICD has a less flexible Glu234 which is more 
capable of positioning and activating the catalytic water molecule required for deAMPylation. 
Dimerisation therefore increases both the catalytic efficiency and turnover number of FICD-
mediated deAMPylation. The more rigid nature of wild type, dimeric FICD’s gatekeeper 
glutamate also does not permit the binding of MgATP in an AMPylation competent 
conformation within the Fic domain active site. Instead, the conformation of dimeric, wild type 
FICD-bound ATP sterically occludes the engagement of an attacking BiP Thr518 nucleophile 
in a position in-line for nucleophilic attack.  
Further support for a monomerising switch existing in vivo comes from an appraisal of 
regulatory mechanisms employed by other evolutionarily related Fic proteins. For example, 
oligomerisation of the class III bacterial Fic protein from Neisseria meningitides (NmFic) 
antagonises both auto-AMPylation and NmFic catalysed AMPylation of its substrate, DNA 
gyrase (Stanger et al, 2016). In this instance, monomerisation of NmFic is proposed to facilitate 
unfolding and cis-autoAMPylation of the protein’s C-terminal inh, which is thus prevented 
from folding back onto the Fic domain active site. Though the surface involved in 
oligomerisation of this class III Fic protein is different from that of FICD, the repressive 





Interestingly, the principal FICD dimerisation surface (which contains Leu258 and is situated 
at the boundary of the Fic domain core and the N-terminal Fic domain extension) also acts as 
a structurally conserved dimer interface in other class II bacterial Fic proteins. For example, 
this conserved dimer interface is present in the Fic proteins belonging to Clostridium difficile 
(CdFic; PDB 4X2C; Dedic et al, 2016) and Bacteroides thetaiotaomicron (BtFic; PDB 3CUC), 
but not in the Shewanella oneidensis Fic protein (SoFic; Das et al, 2009; Goepfert et al, 2013). 
Moreover, in a parallel to the effect of disrupting FICD’s dimer-relay network a His57Ala 
mutation in CdFic (structurally homologous to FICDK256A) results in increased solvent 
accessibility and auto-AMPylation activity towards CdFic’s Thr38 (Dedic et al, 2016). This 
auto-AMPylation target residue is homologous to FICD’s Thr237, a residue within the dimer-
relay network and situated on the loop immediately following Glu234. The modulable solvent 
accessibility of the Clostridium difficile Fic homologue, upon His57Ala mutation, speaks to an 
evolutionary conserved Fic network, which terminates at the inh, whose dynamic nature is 
regulated by the stabilising effect of dimerisation.  
To this end, it seems likely that inh, whose presence is largely ubiquitous throughout all Fic 
proteins, is in fact (in the absence of Fic domain engagement) intrinsically disordered. This 
was experimentally demonstrated to be the case for the inhibitory PhD antitoxin (homologous 
to inh) which only gains -helicity upon engagement of its Fic-like binding partner, Doc 
(Garcia-Pino et al, 2008). Moreover, simultaneous mutation of both the inhibitory glutamate 
of NmFic (Glu186Ala) and a serine one turn N-terminal to the glutamate (Ser182Ala), causes 
a complete loss of electron density for inh (Engel et al, 2012). This disorder in the inh region 
appears to be caused by mutation of the serine, as the crystal structure of NmFic only mutated 
at the inhibitory glutamate (Glu186Gly) contains clearly defined electron density 
corresponding to the inh (Goepfert et al, 2013).  
The –4 position, relative to the AMPylation inhibiting glutamate, is highly conserved 
throughout Fic proteins as a hydroxyl group containing amino acid (predominantly serine and 
sometimes threonine; Thr230 in FICD) (Engel et al, 2012). In available Fic protein structures 
bearing an inh, the serine/threonine residue forms a hydrogen bond to the conserved Fic 
domain arginine (R2 of the Fic motif). It therefore seems likely that this contact to the Fic 
domain plays a role in stabilising and maintaining a folded state of the inh. This further 
supports the plausibility of evolutionarily conserved Fic protein regulation which focuses on 





Fic proteins, via divergent mechanisms, to regulate their AMPylation activities selectively and 
dynamically and (possibly in the case of a number of Fic proteins) reciprocally their 
deAMPylation activities, in response to appropriate physiological cues.  
 
 
Figure 5.1.1: The post-translation UPR is mediated through regulation of FICD bifunctionality. FICD 
recognises (AMPylated or unmodified) BiP’s linker-docked NBD and the ℓ7,8 region of the SBD, via its TPR 
and catalytic domain, respectively. This is only possible when BiP is in a domain-docked ATP-like state. Dimeric 
FICD has a relatively rigid gatekeeper Glu234 which facilitates efficient alignment of an attacking water for BiP 
deAMPylation whilst prohibiting AMPylation competent binding of ATP (right-hand side). Conversely, 
monomeric FICD has a more flexible Glu234 which decreases its deAMPylation efficiency whilst permitting 
AMPylation competent binding of MgATP (left-hand side). The FICD monomer-dimer equilibrium is adjusted in 
response to changing levels of unfolded proteins within the ER. This occurs, possibly in part, through direct 
(FICD) sensing of the ER luminal energy status — with low levels of unfolded protein causing an increase in the 





In addition to the effects of monomerisation and dimerisation noted above, I also present 
experimental evidence of bidirectional and long range allostery transmitted from the nucleotide 
within the active site of FICD. This allostery manifests itself as destabilisation of the pre-
AMPylation complex that is particularly prominent in monomeric FICD-containing 
complexes. I speculate that this may contribute to an additional level of monomerisation-
induced stimulation of AMPylation activity, through catalytic co-substrate-mediated ground 
state destabilisation. Additionally, the oligomeric state of FICD can be directly manipulated by 
the identity of the adenine nucleotide bound within its Fic domain. The resulting picture of the 
dynamic and regulatable cycle of BiP AMPylation and deAMPylation, catalysed by FICD, is 
illustrated in Figure 5.1.1. 
 
Chapter 5.2: Potential physiological regulators of FICD activity 
The endogenous concentration of FICD 
In vitro the predicted structured portion of human FICD, residues 104–445 with an additional 
N-terminal cysteine site-specifically labelled with a fluorescent dye, was measured by 
analytical ultracentrifugation to have a dimerisation KD of 1.2 nM (95% CI: 1.1 to 1.4 nM) 
(Perera et al, 2019). This value was consistent with the dilution (into the low nanomolar range) 
required to observe accumulation of AMPylated BiP catalysed by wild type FICD (Perera et 
al, 2019). Likewise, in order to assess the capacity for nucleotide to modulate the monomer-
dimer equilibrium of the fluorescent oligomeric-state probe a similarly sparse dilution of FICD 
was required (2.5 nM FICD-TMR).  
It has been estimated that FICD is a relatively low abundance protein both in cell lines and 
across human tissue. For example, the inability to detect wild type FICD immunoblot signal 
from AR42j cell lysate derived from ~ 5 µl packed cell volume (without immunopurification 
of FICD), coupled with the detection sensitivity of the tested anti-FICD antibodies for 
recombinant E. coli FICD protein, produced an estimated upper bound of endogenous FICD 
concentration ~ 1 µM (Preissler et al, 2015b). In addition, proteomic analyses have in the past 
routinely failed to reliably detect FICD. For instance no FICD was identified in an analyses of 
HeLa cells conducted to relatively comprehensive (but not saturating) depths of ~ 9,000 and ~ 
10,300 proteins (Hein et al, 2015; Nagaraj et al, 2011). FICD peptides were also non-detectable 
across a wide range of human tissues measured to a median depth of 6,400 proteins per tissue 





However, in a more recent proteomic and transcriptomic analysis conducted across a large 
number of human tissues with a median depth per tissue ~ 11,000 proteins, FICD peptides were 
identified (Wang et al, 2019). It was found that FICD was enriched in the bone marrow and 
secretory tissues, particularly in the pancreas, pituitary and salivary glands. On a per tissue 
basis FICD was most prevalent in the pancreas, with expression levels very close to the median 
protein expression level for this tissue. It should also be noted that protein expression levels 
across the measured pancreatic proteome ranged across 7 orders of magnitude and that the 
relative FICD protein expression level was considerably higher than the relative abundance of 
its RNA transcript. By applying the proteomic ruler approach (Wiśniewski et al, 2014) this 
study also provided label-free protein copy number estimates — including an estimate of ~ 
29,000 FICD copies per pancreatic cell (Wang et al, 2019). Assuming the same volume (~ 
1,000 µm3) as a rat pancreatic  cell (Pipeleers & Pipeleers-Marichal, 1981) of which 10–30% 
of the total cell volume is ER (Stefan et al, 1987), gives an approximate FICD concentration 
(within the human pancreatic ER) of ~ 240 nM. This is consistent with the upper limit derived 
from immunoblot sensitivity, noted above. 
In this same proteomic analysis, protein copy number estimates were also calculated for BiP 
(with an estimated 36 million BiP molecules per pancreatic cell). Using the same cell parameter 
assumptions, this suggests a total BiP concentration within the ER of 300 µM. This value of 
ER luminal BiP concentration is consistent with BiP copy number and ER volume estimates 
from budding yeast cells (Ghaemmaghami et al, 2003; West et al, 2011). Moreover, it has been 
observed on numerous occasions and by multiple methods (IEF, SILAC-based mass 
spectrometry and intact protein mass spectrometry) that a substantial proportion of the total 
BiP pool can be AMPylated, ranging from 40–60% (Chambers et al, 2012; Preissler et al, 
2015b). Importantly, the changes in BiP modification status can occur over a relatively short 
time scale. For example, in the mouse pancreas the levels of AMPylated BiP increased from ~ 
15 to 40%  of the total pancreatic BiP content (as measured by IEF) in the space of 2 h following 
cycloheximide injection (Chambers et al, 2012). Note, the calculated 15% basal AMPylated 
BiP value is actually an upper limit as it is in fact derived from mouse pancreases which were 
fasted over-night and then analysed 1 h after refeeding; although, the basal estimate is similar 
in IEF gel appearance to the level of AMPylated BiP present in a number of untreated cell lines 
(Chambers et al, 2012; Preissler et al, 2015b).  
Given the previous calculation of total pancreatic BiP concentration based on the above 





AMPylation of 10 nM/s. Assuming that the AMPylating FICD protein in this regime is working 
continuously at its Vmax this necessitates an AMPylation kcat of 4 × 10
–2 s–1. This kcat value 
appears reasonable given that the AMPylating FICD species (monomeric FICD) is less active 
than FICDE234G (Perera et al, 2019) which has been measured to possess a kcat ~ 6 × 10
–1 s–1 
(Sanyal et al, 2018), an order of magnitude greater than that estimated to be required for 
endogenous FICD. In the 2018 study by Sanyal et al, which measured BiP AMPylation through 
radioactive signal incorporation from an [‐32P]‐ATP source, the Km of FICD
E234G for (ATP-
state) BiP was also derived and calculated to be in the low micromolar range (~ 5 µM), albeit 
in a non-physiological buffer (5 mM HEPES pH 7.5, 1 mM MnCl2, 0.5 mM EDTA and 1 mM 
ATP). If the Km of endogenous monomeric FICD (in a physiological ionic strength and 
nucleotide content environment) is also in the low micromolar range for ATP-state BiP, this is 
consistent with FICD being able to operate close to Vmax except under conditions where a 
considerable pool of BiP is not free and in the ATP-state (either extensively occupied with 
unfolded client protein and/or depleted of ATP). However, given that the switch to an 
AMPylating state cannot occur instantaneously upon cycloheximide injection it stands to 
reason that the maximal rate of BiP AMPylation must be considerably higher than the average 
(10 nM/s) estimated across the entire 2 h time period post-injection. Therefore, for 240 nM 
endogenous FICD the kcat must be markedly greater than 4 × 10
–2 s–1 but also significantly less 
than the kcat of FICD
E234G (~ 6 × 10–1 s–1). At concentrations ≤ 240 nM this does not provide a 
particularly wide window for the FICD AMPylation kcat to fall within. With these consideration in 
mind, it seems plausible that the estimated ER luminal FICD concentration of 240 nM must, if 
anything, underestimate the endogenous pancreatic concentration.  
Moreover, the rate of deAMPylation has been observed in the mouse pancreas to be faster still 
— with a return from 40% AMPylated BiP after over-night fasting to 15% AMPylated BiP 
within 1 h following refeeding (Chambers et al, 2012). With FICD’s KM for BiP-AMP 
measured, in this study and previously (Preissler et al, 2017a), to be ~ 16 µM it is again possible 
that FICD deAMPylation could proceed close to or near Vmax; with the level of BiP-AMP at 1 
h post-refeeding (~ 15% of the total BiP pool) representing around 45 µM residual 
deAMPylation substrate. Furthermore, there is less opportunity for sequestration of BiP-AMP 
as it is intrinsically ATP-state biased (Preissler et al, 2017b; Wieteska et al, 2017), and 
enfeebled with respect to ATPase activity and stable binding of unfolded proteins (Preissler et 
al, 2015b). This means that the total (final) concentration of BiP-AMP (~ 45 µM) will be very 





infer (at an effective deAMPylating FICD concentration of 240 nM) a lower limit for 
deAMPylation kcat of 8 × 10
–2 s–1. This is in the order of, but still considerably greater than, the 
kcat measured (here) for dimeric, wild type FICD (1 × 10
–2 s–1).  
 
Figure 5.2.1: N6-FAM conjugated nucleotides are likely poor FICD substrates. a, Above, surface view of the 
deAMPylation complex crystal structure with FICD (yellow) bound to BiP-AMP (purple). Below, the complex 
from the same perspective as above but displayed with surface capping just above the plane of the adenosine. 
Inset, the structure of ATP(FAM) [full name N6-(6-Aminohexyl)-ATP-6-FAM]. b, The adenosine N6 position, 
which is modified in FAM labelled nucleotides, is highlighted with a *. Above, close-up view of the sliced surface 
view shown in a. Note that the nucleotide moiety is completely enclosed with little extra space in the adenosine 
binding pocket. Below, an orthogonal view of the nucleotide binding cleft illustrating the lack of room above and 
below the adenosine able to accommodate a linker or fluorophore. 
In this study, deAMPylation kcat measurement was based on an assay utilising AMP(FAM)-
labelled BiP as a tracer of the deAMPylation progress of an excess of unlabelled BiP-AMP. 
The resulting kcats will only be correct (in terms of absolute values) if BiP-AMP(FAM) is an 
equally good deAMPylation substrate as (unlabelled) BiP-AMP molecule. There is some 
evidence to suggest this is not the case. Namely, although it is generally a trivial matter to 
AMPylate BiP to completion (following incubation with FICDE234G in the presence of excess 





labelling efficiency of only 1.8% (see Materials and Methods). Furthermore, it is clear from 
the crystal structure of BiP-AMP•FICD that there is no room for the bulky adenosine FAM 
fluorophore extension within the FICD active site without necessitating some disruption of 
either the deAMPylation or AMPylation complex (Figure 5.2.1). On this basis, it is easy to 
imagine that around 10–100 BiP-AMP molecules could be deAMPylated per molecule of BiP-
AMP(FAM), this would result in an actual BiP-AMP deAMPylation kcat in the order of 10–
100-fold greater than that calculated in the FP-based deAMPylation assay (although the relative 
difference between the measured FICD variants should be accurate, as should the calculated 
KM values). In the context of such a kcat correction factor the estimated FICD ER concentration 
(in the order of hundreds of nanomolar) is compatible with the observed rate of murine 
pancreatic deAMPylation.  
Extremely dynamic transitions in BiP AMPylation status have also been observed in cell 
culture systems. For example, GH3 cells upon exposure to cycloheximide AMPylated 
approximately 50% of their BiP pool in a period of 90 min (from an untreated state of no or 
very little AMPylated BiP). Likewise, upon subsequent exposure to pharmacological stressors 
(ionomycin and dithiothreitol) the complete reserve of AMPylated BiP was also deAMPylated 
within 90 min (Laitusis et al, 1999). GH3 cells have been measured to have an approximate 
volume of ~ 2,000 µm3 (Nesin et al, 2011), as this cancer cell line is derived from a rat pituitary 
the relative expression levels of FICD and BiP in the human pituitary (Wang et al, 2019) give 
approximate total ER concentrations of 170 nM and 270 µM, respectively (assuming an ER 
volume that is 10% of the entire cell volume). Thus, in these GH3 cells both AMPylation and 
deAMPylation must be able to proceed at a rate > 25 nM/s, which implies that the kcats of 
AMPylation and deAMPylation must both be > 1.5 × 10–1 s–1. This lower limit for an 
AMPylation kcat (which assumes an FICD concentration of 170 nM, enzyme saturation and no 
counteracting substrate deAMPylation) is only 25% of the kcat measured for the AMPylation 
hyperactive FICDE234G (Sanyal et al, 2018). As monomeric FICDL258D has been observed to 
catalyse AMPylation at a considerably slower rate than FICDE234G, although not at saturating 
substrate concentrations (Perera et al, 2019), this again suggests that the calculated FICD 
concentration is an underestimate of the endogenous concentrations. This underestimation may 
be caused by an instability of the full-length (single-pass transmembrane) FICD protein. For 
example, if FICD is extremely labile following disruption of the cell/ER membrane, without 





a good proportion of the endogenous FICD protein may not be accessible to downstream 
analyses.  
Plausibility of FICD undergoing oligomeric state-dependent switching in vivo 
Having now established that endogenous FICD concentrations must be, at a minimum, in the 
order of hundreds of nanomolar this poses a fundamental issue for the proposed mechanism of 
reciprocal regulation through modulation of FICD’s monomer-dimer equilibrium. Specifically, 
appreciable monomerisation of an FICD, that possesses an unperturbed dimer interface, can 
only be achieved in vitro by dilution of the protein into the low nanomolar range (on account 
of a dimerisation KD ~ 1 nM). Moreover, at a very low concentration of 2.5 nM FICD, a 
saturating concentration of ATP (the only allosteric modulator yet identified to induce FICD 
monomerisation) was only able to induce an approximate 16% increase in fluorescent signal, 
to a value still less than 40% of the fluorescent signal of a completely (dequenched) 
monomerised FICD. If, FICD’s ER concentration is indeed only 100-fold greater than its 
dimerisation KD (which as noted above seems a conservative estimate) this would result in a 
93% dimeric FICD population. Even if one allowed for a 10-fold increase in the in vivo 
dimerisation KD, relative to the measured KD in vitro, this would only facilitate the 
monomerisation of 20% of the total FICD protomers. Therefore, for monomer-dimer 
transitions to play a role in the regulation of FICD activity in vivo, it is necessary that the 
effective dimerisation KD is increased by several orders of magnitude relative to that measured 
in vitro (at least under conditions of low ER protein folding load where appreciable BiP-AMP 
accumulation, and presumably FICD monomerisation, is induced).  
How then can we reconcile a requirement of an effective dimerisation KD in the order of 
hundreds of nanomolar with the measured KD of 1.2 nM? The first and most trivial possibility 
is that FICD is not regulated by oligomeric state-dependent switching in vivo. In this scenario, 
the ability of FICD–/– cells to accumulate BiP-AMP only under regimes of low-level expression 
of recombinant FICD (Perera et al, 2019) must reflect the presence of an unidentified 
(allosteric) regulator of FICD activity. This regulator must be expressed at similarly low levels 
to endogenous FICD and is thus unable to regulate a large molar excess of FICD (such as that 
which occurs upon overexpression in conventional transient cell transfection experiment). 
Furthermore, the coherent and extensive set of observations pertaining to the in vitro and in 
vivo reciprocity of dimeric and monomeric FICD enzymatic activity would then represent an 





an FICD monomer-dimer equilibrium have been avoided on the basis of the perceived technical 
difficulties. This is in part a function of the lab’s lack of technical expertise in the cell imaging 
techniques required to address such an issue, and also partly stems from concerns over the 
experimental tractability of being able to reliably assay the oligomeric state of an endogenous 
protein expressed at relatively low cellular concentrations.  
Co-translational FICD glycosylation 
In lieu of this somewhat troubling possibility, I believe that the balance of probabilities favours 
a situation where FICD’s monomer-dimer equilibrium is key to regulation of BiP AMPylation 
and deAMPylation. As such, the effective KD must be increased in vivo. Part of such an 
increase in effective dissociation constant (KD
eff) may stem from post translational modification 
of FICD. For instance, FICD expressed in the ER has one major glycosylated residue, Asn275 
(Sanyal et al, 2015). This glycosylation site is located within the Fic domain, on the opposite 
side to the active site and relatively close to the dimerisation interface. The asparagine in 
question is surface exposed in FICD crystal structures and does not form intramolecular 
hydrogen bonds via its side chain. It is therefore possible that the extended N-glycan floats 
relatively freely in solution, facing away from the surface of the protein (whilst covalently 
tethered to Asn275). In such a conformation it is difficult to imagine how Asn275 glycosylation 
would be able to effect FICD’s dimerisation KD
eff. However, upon inspection of the FICD 
surface in the vicinity of this residue, a conspicuous hole (followed by a groove) in the FICD 
structure became apparent (Figure 5.2.2).  
Given that N-linked glycosylation of ER proteins occurs co-translationally it is possible that a 
proportion of FICD actually has the N-linked glycan locked within this cavity — enforced by 
the folding of the C-terminal FICD helix over the glycan and onto the rest of the Fic domain 
(Figure 5.2.2e). The putative locked glycan would protrude into a relatively hydrophobic 
(electro-neutral) extended groove which appears (sterically) to be able to accommodate a large 
amount of the covalently attached glycan structure. As glycans have electro-negative 
coulombic potentials, and in this hypothesised situation a very high effective concentration for 
binding within the hydrophobic Fic domain groove, it is possible that a glycan docked in this 
way would cause considerable allosteric and/or destabilising effects throughout the Fic domain. 
This destabilisation may, in turn, extend to include a weakening of the dimer interface able to 
raise the dimerisation KD
eff closer to the luminal FICD concentration. Interestingly, the Asn275 






Figure 5.2.2: An FICD cavity for accommodating a glycan. a, View of an FICD dimer (using the FICD:ATP 
structure). On the right the ribbon representation is overlaid with a surface representation, coloured according to 
coulombic potential. *Indicates the position of the glycosylated reside Asn275 (in all applicable panels). The 
arrow represents the putative direction that the N-linked glycan may be locked in (co-translationally) by the C-
terminal Fic domain helix. Note, in this view the carboxy terminus (of the left protomer) is pointing out of the 
page in the lower left quadrant of the structure. b, A more focussed view of the surface representation in a, 
highlighting the tunnel-like cavity which is adjacent to the Asn275 side chain. c, An orthogonal view (of the left-
hand side) of b which illustrates the tunnel cavity exit. This cavity appears to open up into a relatively hydrophobic 
groove (the roof of which is formed by FICD’s C-terminal helix). d, i and ii, Zoomed in views of the boxed regions 
from b and c, respectively. i, Residue Pro388, from a Fic domain loop, forms part of the roof of the cavity and is 
annotated. Tyr223 which forms part of the helical floor is also labelled (see a). e, A basic glycan structure 
(Man3GlcNAc2Asn) was built into the protein, within covalent bonding distance of Asn275, and manually 
positioned through the cavity. The model was energy minimised, and the resulting local energy minimum is 
presented in i and ii (with identical perspectives as presented above in d). i, the rest of the roof of the tunnel cavity 





Moreover, the overall structure of the Fic domain appears conserved throughout FICDs (with 
almost identical crystal structures comparing human and C. elegans FICD homologues [C. 
elegans Fic-1; PDB 5JJ6]).  
The hypothetical increase in dimerisation dissociation constant brought about by N-linked 
glycosylation of Asn275, would likely represent a constitutive increase in KD
eff. Removal of 
the glycan from the aforementioned groove would require unfolding or disengagement of the 
C-terminal helix from the rest of the Fic domain. Moreover, enzymatic removal of the majority 
of the glycan cannot be catalysed within the secretory pathway. Likewise, a basal increase in 
KD
eff may also be afforded by the transmembrane nature of FICD in vivo.  
Membrane localisation 
It is a widely accepted principal that restricting protein binding partners to a 2-dimensional 
plane can increase their effective concentrations by orders of magnitude. However, if the 
surface area to volume ratio of a membrane in which two binding partners are localised is 
sufficiently large, reduced protein complexation (or in other words an increase in KD
eff) will 
occur. Based on empirical measurements of thermodynamic parameters which contribute to 
2D protein-protein binding, it has been estimated that colocalization to a membrane with a 
surface area to volume ratio greater than 50 will induce an increase in KD
eff (Yogurtcu & 
Johnson, 2018). Moreover, the rough endoplasmic reticulum (RER) has also been measured by 
high resolution electron microscopy-based cellular reconstructions to have a very large surface 
area to volume ratio. For example, the RER of a Syrian hamster (insulin secreting) pancreatic 
cell line was measured to have a surface area to volume ratio of 77 (Marsh et al, 2001), which 
is very similar to the ER surface area to volume ratio of 75 measured in budding yeast (Wei et 
al, 2012). As these represent average ratios across the entire measured volume of ER in each 
cell type, it is plausible that thinner, more tubular (and flat) sections of ER will have (locally) 
much greater ratios. Indeed, it has been demonstrated in yeast cells that there are multiple 
morphologically distinct ER domains, in which tubular ER was measured to have an elevated 
surface area to volume ratio relative to the bulk ER (West et al, 2011).  
It is therefore conceivable that if FICD were to endogenously reside in flattened tubular ER its 
local membrane environment may possess a surface area to volume ratio > 100 but presumably 
< 1000. Using these as limits, one would expect a 2–20-fold increase in dimerisation KD
eff 
(Yogurtcu & Johnson, 2018). However, like N-glycosylation, such a mechanism of increasing 
the in vivo dimerisation KD





cause a constitutive increase in KD
eff. That is to say, without their being extremely rapid 
morphological ER remodelling and/or active and dynamically regulatable mechanisms to 
redistribute FICD to different ER domains, FICD membrane localisation is unlikely to be able 
to contribute to the very dynamic enzymatic switching behaviour observed in vivo. 
Post-translational N-lysine acetylation 
Contrarily, a post-translational modification such as N-lysine acetylation may well be 
amenable to a regulatory switching mechanism that occurs on the time scales observed in vivo. 
Lysine acetylation of ER-resident and ER-transiting proteins has only been relatively recently 
discovered, and comparatively little is known about its prevalence or regulatability compared 
to, for example, N-glycosylation. However, a mechanism whereby N-lysine acetylation 
impairs the interaction of ER-resident binding partners has previously been proposed (Peng et 
al, 2018). In the case of FICD it is conceivable that the fairly surface exposed (N) amino group 
of Lys256 may be reversibly acetylated to regulate FICD activity. The backbone of Lys256 
forms part of the principal FICD dimerisation surface and its side chain forms an intrinsic part 
of the proposed dimer-relay hydrogen bond network (making a hydrogen bond/salt bridge to 
Glu242) linking the dimer interface to FICD’s active site (see Figure 1.5.1). It has also been 
shown that Lys256 mutation increases the dimerisation KD (~ 7-fold), decreases deAMPylation 
activity and significantly increases BiP-AMPylation activity (even at concentrations where 
Lys256-mutated FICD is predominantly dimeric) (Perera et al, 2019). Moreover, even at 
concentrations where Lys256 mutated FICDs are dimeric the Tm data suggest that the resulting 
FICD is destabilised/more flexible. In addition, although crystallising as a dimer, FICDK256A is 
able to bind MgATP in an AMPylation competent conformation. Acetylation of FICD’s 
Lys256 may therefore increase the KD
eff by a factor of 10 or more. However, by abrogating the 
ability to interact with Glu242 (which can only act as a proton acceptor) and also by virtue of 
being a relatively bulky modification, acetylation may result in a considerable switch in 
enzymatic activity (by the same mechanism as achieved in vitro by monomerisation) without 
an explicit requirement for in vivo monomerisation. Evidence for Lys256 modification being 
able to induce considerable destabilisation of FICD is also provided anecdotally by the 
observation that although FICDK256C forms a stable protein in solution, labelling of this cysteine 






In order to function as part of an FICD switching mechanism, given the time frames involved, 
the result of any such regulatory mechanism must be reversible. To this end, a number of ER 
acetyltransferase enzymes have been identified and deacetylation within the Golgi has also 
been observed (reviewed in Farrugia & Puglielli, 2018). Furthermore, a protein localised to the 
cis-Golgi and Golgi cisternae, has been characterised as possessing deacetylase enhancer 
activity (Lalioti et al, 2013). One could therefore speculate that under conditions of increased 
ER stress, where in the above model FICD deacetylation would be required, a decreased 
efficiency of the machinery required to retain FICD within the ER may allow transient escape 
of FICD into the cis-Golgi (where it could be rapidly deacetylated and become more dimeric 
and/or a better AMPylase) before retrieval back to the ER. The longer FICD spends 
(efficiently) retained within the ER (which may only occur for prolonged periods of time under 
low ER stress conditions) the more likely FICD is to be re-acetylated by ER-resident 
acetyltransferases and thus become more monomeric and/or a better AMPylase and poorer 
deAMPylase.  
Intriguingly, the mechanism by which FICD is retained in the ER is also not well understood. 
It was demonstrated that the portion of FICD up to the end of its (single-pass) transmembrane 
domain (residues 1–45) is sufficient to cause localisation of a C-terminally fused GFP to the 
ER (Sanyal et al, 2015). However, the cytosolic N-terminus of FICD lacks any recognisable 
di-arginine motif associated with type II membrane protein retention within the ER (Schutze 
et al, 1994). It is an inviting possibility, therefore, that BiP may itself be essential in facilitating 
FICD’s ER retention. It has been extensively demonstrated that BiP, by binding clients within 
its SBD, can perform such a role in retaining client proteins within the ER. Moreover, 
coordinated release of these clients from BiP can result in rapid and regulated trafficking out 
of the ER. For example, ER Ca2+ depletion, which results in a destabilisation of BiP-substrate 
complexes, is able to cause synchronised secretion of otherwise ER retained proteins (Preissler 
et al, 2020). This mechanism of BiP-coupled ER retention and reversible acetylation would 
also rationalise the observation that thapsigargin treatment (which depletes the ER Ca2+ stores) 
also rapidly induces BiP deAMPylation (Laitusis et al, 1999; Chambers et al, 2012; Preissler 
et al, 2015b) without necessarily inducing elevated levels of unfolded proteins (Preissler et al, 
2020). This latter point is especially true of the experiment conducted in (Preissler et al, 2015b) 
in which significant deAMPylation of BiP was observed within 60 min of thapsigargin 
treatment in the (continued) presence of cycloheximide (which was initially applied to the cell 





would the thapsigargin have limited time to induce potential protein unfolding, but the ER 
would already be depleted of labile clients and there would be no flux of newly synthesised 
proteins into the ER for the duration of the experiment.  
Active monomerisation of FICD catalysed by BiP 
As mentioned in Chapter 1.1 the substrate binding ability and chaperoning functionality of all 
Hsp70 proteins are intrinsically linked to the action of co-chaperone proteins, in particular 
NEFs and JDPs. There is considerable diversification of the latter, allowing different JDPs to 
catalyse the binding of Hsp70s with specific classes or subsets of proteins. In support of a role 
for BiP substrate binding in the regulation of FICD activity, and by extension in the regulation 
of BiP’s own activity, unpublished work from ex-lab members (Cláudia Rato da Silva and 
Martin J. Kamphuis) has shown that knockout of a particular ER-localised JDP abrogates the 
ability for CHO cells to induce BiP AMPylation. Moreover, this phenotype was dependent on 
the HPD motif, which is characteristic of all JDPs and is required for their interaction with 
Hsp70s and their ability to stimulate Hsp70 ATPase activity. In the case of the BiP AMPylation 
phenotype, mutation of the JDP’s endogenous HPD motif (to QPD) resulted in a phenocopy of 
the JDP knockout. This is reminiscent of the mechanism of Ire1 regulation, another ER-
localised transmembrane UPR transducer, which is responsible for the XBP1 branch of the 
canonical UPR.  
It has been demonstrated that the ER-localised JDP (ERdj4) is required in order to load BiP 
onto Ire1, causing monomerisation of the otherwise homodimeric UPR transducer (Amin-
Wetzel et al, 2017, 2019). Ire1 monomerisation is presumably driven by entropic pulling 
stimulated via JDP-mediated ultra-affinity and ATP hydrolysis, which stabilise a non-
equilibrium monomeric Ire1 steady-state (De Los Rios & Barducci, 2014; De Los Rios et al, 
2006). In this so-called chaperone inhibition model, the inhibition of Ire1 dimerisation (and 
the resultant UPR signalling) is released upon an increase in ER protein folding load, this 
titrates ERdj4 away from Ire1 and causes ERdj4 to instead load BiP onto the extra burden of 
unfolded proteins. A similar mechanism, wherein an ER-localised JDP and BiP act as ER stress 
sensors could, therefore, also operate to regulate the oligomeric state of FICD effectively and 
rapidly, either with or without additional mechanisms of dimerisation KD
eff enhancement. A 
further hint to this end is provided in the form of the particular crystal packing observed in the 





strengthened by each AMPylated BiP binding the unfolded C-terminal tail of a symmetry 
related FICD molecule (as a canonical substrate within the BiP SBD) (Figure 5.2.3).  
 
Figure 5.2.3: BiP can bind the unfolded C-terminus of FICD. The asymmetric unit protein molecules that 
comprise the heterodimeric deAMPylation complex are shown in blue and light grey. This structure has been 
discussed at length in Chapter 2.1. Additionally, as highlighted in this representation, an engagement of an 
unfolded C-terminal tail of a symmetry related FICD molecule (black) within the peptide binding groove of BiP-
AMP’s SBD is present in both the state 1 and state 2 deAMPylation complex crystal forms. This potentially 
represents a simple artefact of high protein concentrations and the particular crystal packing environment. 
However, it may also be suggestive of a role for BiP binding FICD, as a (partially unfolded) substrate, in enabling 
FICD monomerisation and thus in the reciprocal regulation of FICD activity. 
Any combination of the above speculative mechanisms may or may not exist and/or operate 
simultaneously to increase, either constitutively or in a regulatory fashion, the effective dimer 
equilibrium dissociation constant. The prospect of BiP actively participating in the regulation 
of FICD monomerisation is a particularly attractive one as it directly reconciles experimental 
observations pertaining to rapid thapsigargin-stimulated BiP deAMPylation and, particularly, 
the ER-localised JDP knockout phenotype. Moreover, a central role of a JDP and BiP in the 
reciprocal-regulation of FICD bifunctionality would also provide a means of sensing changing 
levels of ER stress. In this model an elegant negative feedback system would exist, whereby 
an increased burden of unfolded ER protein titrates JDP and BiP away from FICD, permitting 
FICD dimerisation and increased BiP deAMPylation so as to create increased ER chaperoning 
capacity (and vice versa). This also parallels a seemingly ubiquitous feature of Hsp70 proteins 





regulators within the eukaryotic ER, cytosol and nucleus (Amin-Wetzel et al, 2019; Kmiecik 
et al, 2020).  




Chapter 6: Materials and Methods 
Chapter 6.1: Plasmid construction 
The plasmids used in this study have been described previously or were generated by standard 
molecular cloning procedures and are listed in Table 5. 
 
Chapter 6.2:Protein purification 
His6-SUMO fused proteins 
The majority of proteins used in this study (both FICD and BiP) were expressed as N-terminal 
His6-Smt3 fusion constructs from either pET28-b vectors (expressed in T7 Express lysY/I
q 
(NEB) E. coli cells) or pQE30 vectors (expressed in M15 (Qiagen) E. coli cells). T7 Express 
cells were grown in LB medium containing 50 µg/ml kanamycin. M15 cells were grown in the 
same medium supplemented with an additional 100 µg/ml ampicillin. All cells were grown at 
37 C to an optical density (OD600nm) of 0.6 and then shifted to 18 C for 20 min, followed by 
induction of protein expression with 0.5 mM isopropylthio β-D-1-galactopyranoside (IPTG). 
Cells were eventually harvested by centrifugation after a further 16 h at 18 C. 
Following harvesting bacterial pellets were resuspended and lysed with a high-pressure 
homogenizer (EmulsiFlex-C3; Avestin) in buffer A (25 mM Tris-HCl pH 8.0, 500 mM NaCl, 
40 mM imidazole, 1 mM MgCl2, 0.1 mM tris(2-carboxyethyl)phosphine (TCEP)) containing 
protease inhibitors (2 mM PMSF, 4 µg/ml pepstatin, 4 µg/ml leupeptin, 8 µg/ml aprotinin), 0.1 
mg/ml DNaseI, and 20 µg/ml RNaseA. The lysates were clarified by centrifugation at 45,000 
 g for 35 min. The resulting supernatant was then incubated with 1 ml of Ni-NTA agarose 
(Thermo fisher) per 1 l expression culture, for 30 min at 4 C with rotation. The Ni-NTA matrix 
was transferred to a gravity flow column and washed with 2  10 column volumes (CV) of 
buffer B (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM imidazole, 0.1 mM TCEP) 
supplemented sequentially with (i) 1 M NaCl and then (ii) 10 mM MgCl2 + 5 mM ATP, 
followed by 5 CV of buffer B. The matrix was then resuspended in 5 CV of TNT-Iz10 (25 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1 mM TCEP, 10 mM imidazole) containing 2 µg/ml Ulp1 
protease C-terminally fused to a StrepII-tag [Ulp1-StrepII (UK1983)] and incubated with 
rotation for 16 h at 4 C. The 16 h incubated material was eluted from the Ni-NTA matrix 
which was washed with a further 5 CV of TNT-Iz10. On-bead Ulp1-cleaved protein containing 




eluate was collected and pooled and diluted 1:2 with 25 mM Tris-HCl pH 8.0 (AEX-A). The 
diluted protein was applied to an anion exchange column equilibrated in 95% AEX-A and 5% 
AEX-B (25 mM Tris-HCl, 1 M NaCl) and eluted using a linear gradient up to 50% AEX-A 
and 50% AEX-B (unless specified below). 1 mM TCEP was added to the pooled protein 
fractions (unless they had already been deliberately oxidised as detailed below) and the protein 
was concentrated using centrifugal filters (Amicon Ultra; Merck Millipore). The concentrated 
proteins were further purified by gel filtration using SEC columns equilibrated in 25 mM Tris-
HCl pH 8.0, 150 mM NaCl. All purification was conducted at 4 ºC. Unless otherwise specified 
(Table 5) anion exchanges were conducted using a RESOURCE Q 6 ml column (GE 
Healthcare). Gel filtration was conducted, depending on protein size and amount, on either a 
HiLoad 16/60 Superdex 75 or 200 prep grade column, an S200 or S75 Increase 10/300 GL 
column, or an S200 10/300 GL column (see Table 5). All proteins were purified to 
homogeneity and > 95% purity, as assessed by Coomassie-stained SDS-PAGE. Unless the 
protein was deliberately oxidised, proteins were supplemented after gel filtration with 1 mM 
TCEP. Proteins were concentrated to > 150 µM using centrifugal filters, aliquoted and snap-
frozen and stored at –80 ºC. All protein concentrations were measured with a NanoDrop 
Spectrophotometer (Thermo Fisher Scientific), using the A280 and the protein’s predicted 
extinction coefficient at 280 nm (280).  
GST-TEV fused proteins 
Proteins fused N-terminally to Glutathione S-transferase followed by a TEV cleavage sequence 
were purified as above, with minor alterations. Purification was performed without imidazole 
in the purification buffers. Cleared lysates were supplemented with 1 mM DTT and incubated 
with GSH-Sepharose 4B matrix (GE Healthcare) for 1 h at 4 ºC. 5 CV of TNT(0.1) (25 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 0.1 mM TCEP) was used as a final wash step before elution. 
Proteins were eluted with 10 mM HEPES-KOH pH 7.4, 20 mM Tris-HCl pH 8.0, 30 mM KCl, 
120 mM NaCl, 2 mM MgCl2 and 40 mM reduced glutathione. Additionally, GST-TEV-BiP 
proteins were cleaved with TEV protease (1/100 w/w; UK759), whilst dialysing into TND (25 
mM Tris-HCl pH 8.0, 150 mM NaCl plus 1 mM DTT) for 16 h at 4 ºC. Uncleaved BiP was 
depleted by incubation with GSH-Sepharose 4B matrix (1 ml matrix per 5 mg of protein) for 1 
h at 4 ºC. The flow through was collected. Retained, cleaved material was washed from the 
matrix with 5 CV of TNT(0.1) and all cleaved protein fractions were pooled. BiP was 
AMPylated as detailed below. Proteins were concentrated to > 200 µM. Aliquots were snap-
frozen in liquid nitrogen and stored at –80 °C. 













Mammalian expression of C-terminally 3xFLAG. 




















Bacterial expression of fastidious E. coli BirA biotin 





Bacterial expression of inactive human H363A mutant of 
His6-Smt3-HYPE(104–445) 




Bacterial expression of yeast Ulp1 protease with a C-





Bacterial expression of human FICD/HYPE TPR 
domain, residues 104–186  




Bacterial expression of wild type His6-Smt3-HYPE(104–
445) 












Bacterial expression of ATPase and substrate binding 







Bacterial expression of monomeric His6-Smt3-
HYPE_104–445. Enzymatically active. 




Bacterial expression of constitutively AMPylating and 
monomeric mutant of His6-Smt3-HYPE_104-445 




Bacterial expression of inactive and monomeric human 
H363A mutant of His6-Smt3-HYPE(104–445) 




Mammalian expression of full-length human FICD with 


















Catalytically dead and constitutively dimeric (disulphide 








Bacterial expression of partially monomerising G299S 
mutation into FICD(104–445) 









Dimeric FICD(H363A) made cysteine free apart from 















Bacterial expression of N-terminal AviTag labelled Full-







FL hamster BiP ATPase dead, substrate binding deficient 







Bacterial expression of human FICD/HYPE 104-445 










Table 5: List of plasmids used in this study. ID denotes the unique lab identification (UK) number of each 
plasmid. Purification contains information pertaining to any FPLC columns used in the purification of the protein 
(following strep-tactin, GSH-Sepharose, Ni-NTA affinity chromatography, and on bead cleavage and elution, as 





Bacterial expression of cysteine free FICD H363A dimer, 
potential dimer FRET probe S288C 




Bacterial expression of FL ATPase and substrate binding 
deficient His6-Smt3-BiP(27–635) 




Bacterial expression of inactive human H363A mutant of 







Bacterial expression of inactive human H363A mutant of 







Bacterial expression of inactive human H363A mutant of 








Bacterial expression of inactive human L258D H363A 









Bacterial expression of inactive human L258D H363A 









Bacterial expression of inactive human L258D H363A 












Bacterial expression of inactive human L258D H363A 









Bacterial expression of inactive human L258D H363A 









Bacterial expression of inactive human H363A mutant of 








Mammalian expression of FL CDS of L258D E234G 








Mammalian expression of FL CDS of L258D E234G 








Mammalian expression of FL CDS of L258D E234G 









Mammalian expression of FL CDS of L258D E234G 









Monomeric His6-Smt3-HYPE_104–445 TPR double 







Monomeric His6-Smt3-HYPE_104–445 TPR mutant, 
bacterial expression. Enzymatically active. 




Monomeric His6-Smt3-HYPE_104–445 TPR mutant, 
bacterial expression. Enzymatically active. 




Monomeric ∆TPR1 His6-Smt3-HYPE(138-445), 
bacterial expression. Enzymatically active. 





























Superdex 75 prep grade; S200pg, HiLoad 16/60 Superdex 200 prep grade; S75Incr, S75 Increase 10/300 GL; 
S200Incr, S200 Increase 10/300 GL. 
Preparative BiP AMPylation 
Large-scale AMPylation of BiP was achieved post-on column Ulp1 cleavage or post-TEV 
protease treatment and GSH-Sepharose depletion of uncleaved material, by addition of 10 mM 
MgCl2, 5 mM ATP and 1/50 (w/w) GST-TEV-FICD
E234G (UK1479). The AMPylation reaction 
was incubated for 16 h at 25 ºC. GST-TEV-FICD was then depleted by a 1 h incubation with 
GSH-Sepharose 4B matrix. AMPylation was confirmed as being stoichiometric by intact-
protein mass spectrometry (LC-ESI-MS) as previously detailed (Preissler et al, 2017b).  
Disulphide-linked FICD dimers  
Disulphide-linked FICD dimers (s-sFICD
A252C-H363A-C421S; UK2269), used as a ‘trap’ for BiP-
AMP during in vitro AMPylation assays, were oxidised and purified as described above with 
modification. In brief, after the affinity chromatography step, on-column Upl1-StrepII cleavage 
the retained cleavage products were washed off the beads with TN-Iz10 (25 mM Tris-HCl pH 
8.0, 150 mM NaCl, 10 mM imidazole) in the absence of reducing agent. The pooled eluate was 
concentrated and diluted 1:4 with TN-Iz10 (in order to further reduce the TCEP concentration). 
To allow for efficient disulphide bond formation the samples were supplemented with 20 mM 
oxidised glutathione and incubated overnight at 4 C. Afterwards, the protein solutions were 
diluted 1:2 with 25 mM Tris-HCl pH 8.0 and further purified by anion exchange and size 
exclusion chromatography. The final preparations were analysed by non-reducing SDS-PAGE 
to confirm quantitative formation of covalently linked dimers (> 95%).  
In vitro BiP biotinylation 
In vitro biotinylation of N-terminally avi-tagged BiPs was conducted on the tag-cleaved forms 
of unmodified or AMPylated GST-TEV-AviTag-haBiPT229A-V461F (UK2331) or His6-Smt3-
AviTag-haBiPT229A-V461F (UK2359). Biotinylation was conducted in vitro with 100 µM target 
protein, 200 µM biotin (Sigma) and 2 µM GST-BirA (UK1801) in a buffer of 2 mM ATP, 5 
mM MgCl2, 25 mM Tris-HCl pH 8.0, 150 mM NaCl and 1 mM TCEP. The reaction mixture 
was incubated for 16 h at 4 ºC. The protein was made nucleotide-free by the addition of 2 U 
calf intestinal alkaline phosphatase (NEB) per mg of BiP, plus extensive dialysis into TN buffer 
supplemented with 1 mM DTT and 2 mM EDTA. The protein was then incubated with 0.5 ml 
GSH-Sepharose 4B matrix for 1 h at 4 ºC in order to deplete the GST-BirA. The biotinylated 
BiP-containing supernatant was diluted 1:1 with AEX-A and loaded onto a MonoQ 5/50 GL 




column (GE Healthcare), equilibrated in 92.5% AEX-A and 7.5% AEX-B. BiP protein was 
eluted using a linear gradient of 7.5–50% AEX-B, over 20 CV at a flow rate of 1 ml/min. In 
the case of UK2359-derived BiP proteins the Mono Q eluted proteins were diluted with 
glycerol and stored at –20 ºC in a final buffer of TNTG (12.5 mM Tris-HCl pH 8.0, ~ 150 mM 
NaCl, 0.5 mM TCEP and 50% (v/v) glycerol) at a concentration > 1 µM. UK2331-derived BiPs 
were additionally gel filtered into HKM (25 mM HEPES-KOH pH 7.4, 150 mM NaCl and 10 
mM MgCl2) using S200 10/300 GL column with a distal 1 ml GSTrap 4B (GE Healthcare), 
connected in series. Proteinaceous fractions were pooled, supplemented with 1 mM TCEP, 
concentrated to > 20 µM, flash-frozen in small aliquots and stored at –80 C. Protein samples 
were validated as being nucleotide-free (apo) by their A260/280 ratio and reference to IP-RP-
HPLC analysis as conducted previously (Preissler et al, 2017a). Proteins were confirmed as 
being > 95% biotinylated via a streptavidin gel-shift assay. 
Biotinylated FICDH363A (UK2422) was purified like other FICD proteins, in vitro biotinylated 
as specified above and then excess biotin and residual BirA was removed by gel filtration as 
detailed for the polishing of UK2331-derived BiPs, but with the column equilibrated in TNT 
(25 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM TCEP) rather than HKM. Pooled protein 
fractions were concentrated to > 20 µM, flash-frozen in small aliquots and stored at –80 C.  
Oxidation of FICD’s TPR domain 
Purification of TPR domain oxidised (TPRox) FICDD160C-T183C-C421S proteins was achieved as 
above (for other FICDs), with the addition of an oxidation and clean-up AEX step. Note, the 
cysteine free FICDC421S mutation was previously observed to have no effect on FICD-mediated 
deAMPylation or BiP-AMP binding and a slight stimulatory effect on FICD-mediated 
AMPylation (Perera et al, 2019).  
In order to form the disulphide-bond, the FICD protein (post-Ulp1 cleavage and Ni-NTA 
column elution) was diluted down to a concentration of 5 µM in a final buffer of 25 mM Tris-
HCl pH 8.0 and 100 mM NaCl, supplemented with 0.5 mM CuSO4 and 1.75 mM 1,10-
phenanthroline (Sigma), and incubated for 16 h at 4 ºC. The oxidation reaction was then 
quenched by the addition of 2 mM EDTA. The protein, diluted down to 50 mM NaCl with 
AEX-A, was then purified on a HiTrap 5 ml Capto Q column (equilibrated in 95% AEX-A and 
5% AEX-B buffer) using a linear gradient of 5-50% AEX-B over 10 CV. Proteinaceous 
fractions were further purified as detailed above (beginning with RESOURCE Q column 




purification), culminating in the purification of dimeric or monomeric FICD (as appropriate) 
by gel filtration.  
Stoichiometric disulphide bond formation was confirmed by the use of an electrophoretic 
mobility assay (see Figure 2.3.3c), in which the putatively oxidised protein was heated for 10 
min at 70 ºC in SDS-Laemmli buffer ± DTT; all available thiols were then reacted with a large 
excess of PEG 2000 maleimide (incubated for 30 min at 25 ºC). All unreacted maleimides were 
then quenched by the addition of a molar excess of DTT (incubated for 5 min at 25 ºC) before 
the samples were analysed by SDS-PAGE. Significant PEG modification of FICD(TPRox) 
proteins was only observed in samples that were initially denatured in reducing conditions (+ 
DTT), suggesting that the two TPR domain-cysteines were not accessible for alkylation in the 
absence of DTT (on account of being oxidised to form an intramolecular disulphide bond).  
 
Chapter 6.3: Protein crystallisation and structure determination 
FICD proteins (residues 104–445) and monomeric lid-truncated BiPT229A-V461F-AMP (residues 
27–549) [UK2090] were purified as above and gel filtered into a final buffer of T(10)NT (10 
mM Tris-HCl pH 8.0, 150 mM NaCl and 1 mM TCEP). Heterodimer copurification was 
achieved by mixing FICDL258D-H363A (UK2093) and BiPT229A-V461F-AMP in a 1.5:1 molar ratio, 
supplemented with an additional 250 µM ATP, 50 mM KCl and 2 mM MgCl2. The mixture 
was incubated for 10 min at 4 ºC and purified by gel filtration on an S200 Increase 10/300 GL 
column equilibrated in TNKMT (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 50 mM KCl, 2 mM 
MgCl2 and 1 mM TCEP) with ≤ 5 mg of protein injected per SEC run. Heterodimeric protein 
fractions were pooled (as indicated in Figure 2.1.1) and concentrated to 10.3 mg/ml using a 50 
kDa MWCO centrifugal filter.  
Crystallisation solutions, consisting of 100 nl protein solution and 100 nl crystallisation 
reservoir solution, were dispensed using a mosquito crystal (SPT Labtech) and the complex 
was crystallised via sitting drop vapour diffusion at 25 ºC. State 1 crystals were obtained from 
reservoir conditions of 0.1 M MES pH 6.5, 10% PEG 4000 and 0.2 M NaCl; state 2 crystals 
were obtained from conditions of 0.1 M Tris pH 8.0 and 25% PEG 400 (see Table 1). Crystals 
were cryoprotected in a solution consisting of 25% glycerol and 75% of the respective reservoir 
solution (v/v) before being cryocooled in liquid nitrogen.  




FICD:Apo and FICD:nucleotide crystals (Table 3) were grown by dilution of FICD proteins 
to 9 mg/ml in T(10)NT. For structures containing ATP/AMPPNP, diluted protein solutions 
were supplemented with MgATP/AMPPNP (from a pH 7.4, 100 mM stock solution) to a final 
concentration of 10 mM. A drop ratio of protein solution to crystallisation well solution of 
200:100 nl was used. Where applicable crystals were obtained by microseeding (D’Arcy et al, 
2007), from conditions provided in Table 4. In these instances, a drop ratio of protein solution 
to water-diluted seeds to crystallisation well solution of 150:50:100 nl was used. The best 
diffracting crystals were obtained from the crystallisation conditions detailed in Table 4, 
cryoprotected by briefly soaking in cryoprotectant solution (also noted in Table 4) and then 
cryocooled in liquid nitrogen. 
Diffraction data were collected from the Diamond Light Source at 100 K and the data processed 
using DIALS (Beilsten-Edmands et al, 2020) [state 1 deAMPylation complex crystal], xia2 
(Winter, 2010) [state 2 deAMPylation complex crystal]  or XDS  (Kabsch, 2010) [isolated 
FICD ± nucleotide crystals] and the CCP4 module Aimless (Winn et al, 2011; Evans & 
Murshudov, 2013). Structures were solved by molecular replacement using the CCP4 module 
Phaser (McCoy et al, 2007; Winn et al, 2011). For the FICDL258D:Apo and FICD:ATP 
structures the human FICD protein (FICD:MgADP) structure (PDB 4U0U) from the Protein 
Data Bank (PDB) was used as a search model. For subsequent FICD ± nucleotides structures 
the solved FICDL258D:Apo structure was used as a search model. AMPylated BiP (PDB 5O4P) 
and monomeric FICDL258D:MgAMPPNP (PDB 6I7L) structures from the Protein Data Bank 
were used as initial search models for the deAMPylation complexes. Manual model building 
was carried out in COOT (Emsley et al, 2010) and refined using refmac5 (Winn et al, 2003) 
(in the case of the deAMPylation complexes with TLS added). Metal binding sites were 
validated using the CheckMyMetal server (Zheng et al, 2017). Polder OMIT maps were 
generated using the Polder Map module of Phenix (Liebschner et al, 2017; Adams et al, 2010). 
Structural figures were prepared using UCSF Chimera (Pettersen et al, 2004) and PyMol 
(Schrödinger, LLC, 2015), estimates of interaction surface areas were derived from PISA 
analysis (Krissinel & Henrick, 2007), interaction maps were based on an initial output from 
LigPlot+ (Laskowski & Swindells, 2011) and the chemical reaction pathway was created in 
ChemDraw (PerkinElmer Informatics). 
 




Chapter 6.4: Contrast variation small angle neutron scattering (SANS) 
Non-deuterated BiPT229A-V461F-AMP (residues 27–635; UK2521) and FICDH363A (residues 
104–445; UK1954) [hBiP-AMP and hFICD] were purified as detailed above but were gel 
filtered into a final buffer of TNKMT(0.2) [TNKMT buffer with TCEP reduced to 0.2 mM]. 
The matchout deuterium labelled protein equivalents were produced in the ILL’s deuteration 
laboratory (Grenoble, France). Deuterated proteins were expressed from E. coli BL21 Star 
(DE3) cells (Invitrogen) that were adapted to 85% deuterated Enfors minimal media containing 
unlabelled glycerol as carbon source, as described previously (Haertlein et al, 2016; Dunne et 
al, 2017), in the presence of kanamycin at a final concentration of 35 µg/ml. The temperatures 
at which the cells produced the highest amount of soluble matchout-deuterated BiP or FICD 
were chosen for cell growth using a high cell density fermentation process in a bioreactor 
(Labfors, Infors HT). For BiP expression, cells were grown using a fed-batch fermentation 
strategy at 30 °C to an OD600 of 20. The temperature was then decreased to 18 °C and protein 
expression was induced by addition of 1 mM IPTG. After a further 22 h of protein expression 
at 18 °C, bacteria were harvested by centrifugation. FICD expression was conducted likewise, 
but with induction at OD600 19 and at a temperature of 22 ºC. FICD expressing cells were 
incubated for a further 21.5 h at 22 ºC before harvesting. Matchout-deuterated proteins 
(dBiPT229A-V461F-AMP and dFICDH363A) were isolated and purified from deuterated cell pastes 
using H2O-based buffer systems, as mentioned above, and gel filtered into TNKMT(0.2).  
Heterotetrameric complexes were copurified by gel filtration of a mixture of either dBiP-AMP 
and hFICD or hBiP-AMP and dFICD (in a 1.25:1 molar ratio of BiP-AMP:FICD), with ≤ 5 mg 
of protein injected per SEC run, supplemented with 250 µM ATP. The gel filtration was 
conducted on an S200 Increase 10/300 GL column equilibrated with TNKMT(0.2). 
Heterotetrameric complex fractions were collected and concentrated to > 7 mg/ml. Some of 
this purified complex was further exchanged by the same SEC process into TNKMT(0.2) in 
which the solvent used was D2O. That is to say, the complex was exchanged into 100% D2O 
buffer. Protein fractions in 100% D2O buffer were subsequently concentrated to > 6 mg/ml. 
The elution profile appeared largely identical in both deuterated and non-deuterated buffers. 
Complexes at different %D2O were obtained by either dilution with the appropriate matched 
buffer (± D2O) or by the mixing of one complex purified in 0% D2O buffer with the same 
complex in 100% D2O buffer.  




SANS data were collected from a total of 17 samples with various D2O buffer compositions at 
12 ºC, at the ILL beamline D11. Protein complexes (ranging from 4.3 to 5.5 mg/ml) were 
analysed in a 2 mm path-length quartz cell with a 5.5 Å wavelength neutron beam at distances 
of 1.4, 8 and 20.5 m. Data from relevant buffer-only controls were also collected with similar 
data collection times and subtracted from the radially averaged sample scattering intensities to 
produce the I(q) against q scattering curves. Scattering data were initially processed with the 
GRASP (Graphical Reduction and Analysis SANS Program for Matlab; developed by Charles 
Dewhurst, ILL) and with the Igor Pro software (WaveMetrics) using SANS macros (Kline, 
2006). Data analysis was conducted using Prism 8.4 (GraphPad) and PEPSI-SANS (for fitting 
of theoretical scattering curves and flex-fit model generation; software based on PEPSI-SAXS 
(Grudinin et al, 2017)). 
Comparison of the ln(Transmission) of the 0% and 100% D2O buffer only controls with the 
ln(Transmission) of each sample (not shown) confirmed that the %D2O of each sample was 
within the margin of error of the theoretical D2O content (Zaccai, 2012). Theoretical Rg values, 
derived from structural models, were calculated using CRYSON (Svergun et al, 1998). The 
symmetry of structural models was assessed through the use of AnAnaS software (Pagès & 
Grudinin, 2020). 
 
Chapter 6.5: Differential scanning fluorimetry (DSF) 
DSF experiments presented in Chapter 3 were performed on a CFX96 Touch Real-Time PCR 
Detection System (Bio-Rad) in 96-well plates (Hard-Shell, Bio-Rad) sealed with optically clear 
Microseal ‘B’ Adhesive Sealer (Bio-Rad). Each sample was measured in technical duplicate 
and in a final volume of 20 µl. Protein was used at a final concentration of 2 µM, ATP or ADP 
(if applicable) at 5 and 2 mM, respectively, and SYPRO Orange dye (Thermo Fisher) at a 10 
× concentration in a buffer of HKM. Solutions were briefly mixed, and the plate spun at 200 × 
g for 10 s before DSF measurement. Fluorescence of the SYPRO Orange dye was monitored 
on the FRET channel over a temperature range of 25–90 ºC with 0.5 ºC intervals. Background 
fluorescence changes were subtracted from the protein sample fluorescence data using no-
protein control (NPC) wells. NPC fluorescence was unchanged by the addition of ATP or ADP. 
Data was then analysed in Prism 8.4 (GraphPad), with melting temperatures calculated as the 
global minimums of the negative first derivatives of the relative fluorescent unit (RFU) melt 
curves (with respect to temperature).  




The DSF experiments shown in Chapter 4 were conducted as above with modifications. These 
DSF experiments were performed on an ABi 7500 qPCR machine (Applied Biosciences). 
Experiments were carried out in 96-well qPCR plates (Thermofisher), with each sample in 
technical triplicate and in a final volume of 20 µl in a buffer of HKM plus 1 mM TCEP. Ligands 
were used at the indicated concentrations (2.5–20 mM). In the ATP titration experiment, the 
DSF buffer was supplemented with an additional 15 mM MgCl2 (25 mM final MgCl2 
concentration). Fluorescence of the SYPRO Orange dye was monitored over a temperature 
range of 20–95 ºC using the VIC filter set. Data was then analysed in Prism 7.0 (GraphPad) as 
above. 
 
Chapter 6.6: Bio-layer interferometry (BLI) 
All BLI experiments were conducted on the FortéBio Octet RED96 System (Pall FortéBio) in 
a buffer basis of HKM supplemented with 0.05% (v/v) Triton X-100 (HKMTx). Streptavidin 
(SA)-coated biosensors (Pall FortéBio) were hydrated in HKMTx for at least 30 min at 25 C 
prior to use. Experiments were conducted at 30 ºC. BLI reactions were prepared in 200 µl 
volumes in 96-well microplates (greiner bio-one). Ligand loading was conducted at low 
nanomolar biotinylated BiP concentrations such that the rate of all ligand loading reactions was 
roughly equivalent and all tips reached a loading threshold of 1 nm binding signal 
(displacement) within 300–600 s. All ligands loaded with a range of 1.0–1.2 nm. After loading 
of the immobilised ligand, BiP was activated in 2 mM ATP for 200 s, followed by a 50 s 
baseline in HKMTx alone, before association with apo FICD variants (all bearing a 
catalytically inactivating His363Ala mutation and at 50 nM unless otherwise specified) in 
HKMTx. The first dissociation step was initiated by the dipping of all tips into wells lacking 
FICD analyte (only HKMTx). The second dissociation step was induced by the dipping of the 
biosensor tips into HKMTx supplemented with 2 mM ATP. Experiments were conducted at a 
1000 rpm shake speed and with a 5 Hz acquisition rate. Data were processed in Prism 8.4 
(GraphPad).  
For the kinetic experiments presented in Figure 3.1.1 and Chapter 4 GST-TEV cleaved 
biotinylated BiPs (UK2331-derived) were used as ligands. BLI experiments were performed 
as above with some modifications. Biotinylated-AviTag-haBiPT229A-V461F:Apo (UK2331) was 
loaded onto the tip. The immobilised ligand sensor was then baselined in assay solution for at 
least 200 s. A 10 Hz acquisition rate was used and the baseline, association and dissociation 




steps were conducted at a 400 rpm shake speed. Preceding the baseline step biotinylated 
BiPT229A-V461F:Apo was also activated with or without 2 mM ATP (unless otherwise stated), for 
300 s at a 1000 rpm shake speed. In these experiments 250 nM FICD analyte association or 
dissociation steps were conducted in the presence or absence of nucleotide, as indicated, with 
ATP at 8 mM and ADP at 2 mM.  
In the dimer dissociation BLI experiments biotinylated AviTag-FICDH363A (UK2422) was 
diluted to 3 nM and incubated for 10 min at 25 ºC with either dimeric FICDH363A or monomeric 
FICDL258D-H363A (at 300 nM) in HKMTx. After this incubation period the streptavidin 
biosensors were loaded until the hetero-labelled dimers (biotinylated AviTag-FICDH363A with 
FICDH363A) were loaded to a 1 nm displacement. Dissociation was initiated by dipping in HKTx 
buffer (50 mM HEPES-KOH pH 7.4, 150 mM KCl and 0.05% Triton X-100) ± nucleotide at 
5 mM, as indicated. Data was processed by subtracting the respective monomer incubated 
biotinylated FICD tip from the dimeric hetero-labelled dimer dissociation, followed by fitting 
of the corrected dissociation to a mono-exponential decay function using Prism 7.0 
(GraphPad). 
 
Chapter 6.7: Fluorescence polarisation deAMPylation assay 
Measurement of deAMPylation kinetics was performed as described previously (Preissler et 
al, 2017a) with modifications. The probe BiPT229A-V461F (UK2521) modified with FAM-
labelled AMP, BiPT229A-V461F-AMP(FAM), was generated by pre-incubating 100 µM apo 
BiPT229A-V461F with 5 µM GST-FICDE234G (UK1479) and 110 µM ATP in HKM for 5 min at 
20 ºC, followed by addition of 100 µM ATP-FAM [N6-(6-Amino)hexyl-ATP-6-FAM; Jena 
Bioscience] and further incubation for 19 h at 25 ºC. To ensure complete BiP AMPylation 2 
mM ATP was then added to the reaction which was incubated for an additional 1.25 h at 25 
ºC. The reaction mixture was then incubated with GSH-Sepharose 4B matrix for 45 min at 4 
ºC in order to deplete the GST-FICDE234G. The BiP containing supernatant was buffer 
exchanged into HKM using a Zeba Spin desalting column (7K MWCO, 0.5 ml; Thermo Fisher) 
in order to remove the majority of free (FAM labelled) nucleotide. 2 mM ATP was added to 
the eluted protein and incubated for 15 min at 4 ºC (to facilitate displacement of any residual 
FAM-labelled nucleotide derivates bound by the NBD of BiP). Pure BiP-AMP(FAM) with 
BiP-AMP was then obtained by gel filtration using an S75 Increase 10/300 GL column 
equilibrated in HKM at 4 ºC. 1 mM TCEP was added to the protein fractions, which were 




concentrated using a 50K MWCO centrifugal filter and snap frozen. A labelling efficiency of 
1.8% was estimated based on the extinction coefficient for BiP-AMP:ATP (280 33.5 mM
–1  
cm–1), FAM (492 83.0 mM
–1 cm–1) and a 280/492 nm correction factor of 0.3 (Jenna 
Biosciences). 
DeAMPylation reactions were performed in HKMTx(0.1) [HKM supplemented with 0.1% 
(v/v) Triton X-100] in 384-well polystyrene microplates (black, flat bottom, µCLEAR; greiner 
bio-one) at 30 C in a final volume of 30 µl containing trace amounts of fluorescent BiPT229A-
V461F-AMP(FAM) probe (10 nM), supplemented with BiPT229A-V461F-AMP (5 µM) and FICD 
proteins (0.5 µM). A well lacking FICD protein was used for baseline FP background 
subtraction. 10 nM ATP-FAM alone was also included as a low FP control (not shown).  
Fluorescence polarisation of FAM (ex = 485 nm, em = 535 nm) was measured with an Infinite 
F500 plate reader (Tecan). The mFP y0 difference between the FICD
L258D time course and the 
same reaction composition pre-incubated for 5 h at 25 ºC before the beginning of data 
collection, was interpreted as the ∆mFP equivalent to complete (5 µM) BiP-AMP 
deAMPylation. Data analysis was achieved using Prism 8.4 (GraphPad).  
For direct calculation of kcat values deAMPylation assays were conducted as above but with 10 
µM FICD or FICDL258D and 100 or 150 µM BiP-AMP substrate. Following subtraction of a no 
enzyme background from all datasets, the mFP difference for each sample (between t = 0 and 
the mFP plateau) was interpreted as the ∆mFP equivalent to complete BiP-AMP deAMPylation 
([S]0). 
 
Chapter 6.8: In vitro AMPylation 
In vitro AMPylation reactions were performed in HKM buffer in a 7 µl volume. Reactions 
contained 10 µM ATP-FAM, 5 µM ATP-hydrolysis and substrate-binding deficient BiPT229A-
V461F (UK2521), 7.5 µM oxidised S-SFICD
A252C-H363A-C421S (UK2269, trap) to sequester any 
modified BiP [BiP-AMP(FAM)] and, unless otherwise stated, 0.5 µM FICD. Reactions were 
started by addition of nucleotide. Apart from in the presented time courses, after a 60 min 
incubation at 25 C the reactions were stopped by addition of 3 µl 3.3  LDS sample buffer 
(Sigma) containing NEM (40 mM final concentration) for non-reducing SDS-PAGE or DTT 
(50 mM final concentration) for reducing SDS-PAGE and heated for 10 min at 70 C. Samples 
were applied to a 10% SDS-PAGE gel (unless otherwise stated), the FAM-label was imaged 




with a Chemidoc MP (Bio-Rad) using the Alexa Flour 488 dye setting. Gels were subsequently 
stained with Quick Coomassie (Neo Biotech).  
 
Chapter 6.9: Mammalian cell culture and lysis 
All cells were grown on tissue culture dishes or multi-well plates (Corning) at 37 °C and 5% 
CO2. All CHO-K1 derived cells (ATCC CCL-61) were phenotypically validated as proline 
auxotrophs and their Cricetulus griseus origin was confirmed by genomic sequencing. The 
CHO-K1 FICD–/– cell line used in this study was described previously (Preissler et al, 2015b). 
The CHO-K1 S21 FICD–/– cell line (genetically engineered by Cláudia Rato da Silva) was 
generated by CRISPR-Cas9 knockout of both FICD alleles (as previously (Preissler et al, 
2015b)) into the earlier described CHO-K1 S21 cell line bearing UPR reporters CHOP::GFP 
and XBP1s::Turquoise (Sekine et al, 2016). Cells were cultured in Nutrient mixture F-12 Ham 
(Sigma) supplemented with 10% (v/v) serum (FetalClone II; HyClone), 1 × Penicillin-
Streptomycin (Sigma), and 2 mM L-glutamine (Sigma). Experiments were performed at cell 
densities of 60–90% confluence. Where indicated, cells were treated for 3 h with 
cycloheximide (Sigma) by exchanging the culture medium with pre-warmed (37 C) medium 
supplemented with cycloheximide at 100 µg/ml. Cell lines were subjected to random testing 
for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza). 
Cell lysates were obtained and analysed as in (Preissler et al, 2015a) but with some 
modifications. Mammalian cells were cultured on 10 cm dishes and treated as indicated and 
transfected using Lipofectamine LTX with 5 µg plasmid DNA, and allowed to grow for a 
further 40 h. Before lysis, the dishes were placed on ice, washed with ice-cold PBS, and cells 
were detached in PBS containing 1 mM ethylenediaminetetraacetic acid (EDTA) using a cell 
scraper. The cells were sedimented for 5 min at 370  g at 4 °C and lysed for 10 min on ice in 
HG lysis buffer consisting of 20 mM HEPES-KOH pH 7.4, 150 mM NaCl, 2 mM MgCl2, 33 
mM D-glucose, 10% (v/v) glycerol, 1% (v/v) Triton X-100 and protease inhibitors (2 mM 
phenylmethylsulphonyl fluoride (PMSF), 4 µg/ml pepstatin, 4 µg/ml leupeptin, 8 µg/ml 
aprotinin) with 100 U/ml hexokinase (from Saccharomyces cerevisiae Type F-300; Sigma). 
The lysates were cleared for 10 min at 21,000  g at 4 °C. Bio-Rad protein assay reagent 
(BioRad) was used to determine the protein concentrations of lysates and all samples were 
normalised to 6 mg/ml using HG lysis buffer. For analysis by SDS-PAGE, LDS sample buffer 
was added to the lysates and proteins were denatured by heating for 10 min at 70 °C before 




separation on 12.5% SDS polyacrylamide gels. For immunoblot detection 30 µg of lysate was 
loaded per lane, except in the case of FICD immunoblot detection where 60 µg of lysate was 
loaded.  
 
Chapter 6.10: Native polyacrylamide gel electrophoresis (native-PAGE) 
Non-denaturing native-PAGE was performed as described previously (Preissler et al, 2015a). 
Briefly, Tris-glycine polyacrylamide gels (4.5% stacking gel and a 7.5% separation gel) were 
used to separate proteins from mammalian cell lysates to detect BiP monomers and oligomers. 
The separation was performed in running buffer (25 mM Tris, 192 mM glycine, pH ~8.8) at 
120 V for 2 h. Afterwards, the proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane in blotting buffer (48 mM Tris, 39 mM glycine; pH ~9.2) supplemented with 0.04% 
(w/v) SDS for 16 h at 30 V for immunodetection. The membrane was washed for 20 minutes 
in blotting buffer (without SDS) supplemented with 20% (v/v) methanol before blocking. Equal 
volumes of lysates, corresponding to 30 µg of total protein, were loaded per lane to detect 
endogenous BiP from cell lysates by immunoblotting. 
 
Chapter 6.11: Immunoblot (IB) analysis 
After separation by SDS-PAGE or native-PAGE proteins were transferred onto PVDF 
membranes. The membranes were blocked with 5% (w/v) dried skimmed milk in TBS (25 mM 
Tris-HCl pH 7.5, 150 mM NaCl) and incubated with primary antibodies followed by IRDye 
fluorescently labelled secondary antibodies (LI-COR). The membranes were scanned with an 
Odyssey near-infrared imager (LI-COR). Primary antibodies and antisera against hamster BiP 
[chicken anti-BiP (Avezov et al, 2013)], eIF2α [mouse anti-eIF2α (Scorsone et al, 1987)] and 
FICD [chicken anti-FICD (Preissler et al, 2015b)] were used. 
 
Chapter 6.12: Flow cytometry 
FICD over-expression-dependent induction of unfolded protein response signalling was 
analysed by transient transfection of CHO-K1 S21 FICD–/– UPR reporter cell lines with 
plasmid DNA encoding the complete FICD coding sequence (with mutations as indicated) and 
mCherry as a transfection marker, using Lipofectamine LTX (Thermo Fisher) as described 




previously (Preissler et al, 2015b). 0.5 µg DNA was used to transfect cells growing in 12-well 
plates. 40 h after transfection the cells were washed with PBS and collected in PBS containing 
4 mM EDTA, and single live-cell fluorescent signals (20,000 collected per sample) were 
analysed by dual-channel flow cytometry with an LSRFortessa cell analyser (BD Biosciences). 
Turquoise and mCherry fluorescence was detected using a 405 nm excitation laser with a 
450/50 nm emission filter and a 561 nm excitation laser with a 610/20 nm emission filter, 
respectively. Data were processed using FlowJo and the extracted population parameters were 
plotted in Prism 8.4 (GraphPad). 
 
Chapter 6.13: Fluorescence monomer-dimer assay 
To generate an oligomeric state-sensitive fluorescent FICD probe Ser288Cys was introduced 
into the dimerisation-competent, cysteine-free, catalytically inactive FICDH363A-C421S. The 
resulting construct (UK2473; FICDS288C-H363A-C421S) was expressed and Ulp1-cleaved, as 
detailed above, in reducing conditions. The protein was then subject to site-specific labelling 
of the cysteine, using tetramethylrhodamine-maleimide [TMR-maleimide, a fluorophore 
chosen based on its narrow Stokes shift and therefore well-suited for homoFRET 
(Pietraszewska-Bogiel & Gadella, 2011; Yang et al, 2017)]. In brief, 100 µM protein was 
mixed with 1 mM TMR-5-maleimide (Sigma) in a final buffer composed of 50 mM HEPES 
pH 7.2, 150 mM KCl, 0.5 mM TCEP, 1 mM EDTA and 4% DMF. The 250 µl reaction mixture 
was incubated for 16 h at 4 C in the dark. The resulting labelled protein was first buffer 
exchanged into HKT(0.2) (50 mM HEPES-KOH pH 7.4, 150 mM KCl, 0.2 mM TCEP) using 
a Centri Pure P2 desalting column (emp Biotech). Any unlabelled cysteines in the eluted 
protein were then alkylated by incubation with 1 mM NEM for 1 h at 4 C, followed by 
incubation with 5 mM DTT for a further 1 h at 4 C to quench the excess NEM. The resulting 
protein was diluted 1:2 with 25 mM Tris pH 8.0 and loaded onto a Mono Q 5/50 GL column. 
The labelled protein was eluted with a linear gradient of AEX-A (plus 0.2 mM TCEP) to AEX-
B (plus 0.2 mM TCEP) of 5–35% over 30 CV. Labelled protein fractions were pooled and 
concentrated using a 30 kDa MWCO centrifugal filters (Amicon Ultra; Merck Millipore). The 
concentrated labelled protein was then buffer exchanged into HNKM (25 mM HEPES-KOH 
pH 7.4, 100 mM NaCl, 50 mM KCl and 2 mM MgCl2), and confirmed as being dimerisation 
competent, using an S200 Increase 10/300 GL column. Protein fractions were pooled and 
concentrated. The resulting protein concentration and TMR labelling efficiency were estimated 




by measurement of the A280nm and A555nm using a NanoDrop Spectrophotometer (Thermo 
Fisher Scientific). The protein concentration was calculated using the following equation: 
Protein concentration (M) = [A280nm – (A555nm  0.30)]/ 
Where 0.30 is the correction factor for the fluorophore’s absorbance at 280 nm, and  is the 
calculated molar extinction coefficient of FICD (29,340 cm–1M–1). The labelling efficiency of 
the preparation was 41% as calculated based on the A555nm value and assuming an extinction 
coefficient for TMR of 65,000 cm–1M–1.  
For the fluorescence assay, FICDS288C-H363A-C421S-TMR (FICD-TMR) was diluted to 2.5 nM 
and mixed with the titrant, as indicated, in a buffer of HKTx dispensed into 384-well non-
binding, low volume, HiBase, black microplates (greiner bio-one). Note, all FICD variants 
were dispensed directly into the microplate well solutions using a D300e digital dispenser 
(Tecan). The plate was then sealed and the final 20 µl (Figure 4.5.2a) or 15 µl reactions 
(Figure 4.5.2b) were incubated for 45 minutes at 10 C, whilst shaking at 300 rpm on a 
ThermoMixer C (Eppendorf). The plate seal was then removed, and fluorescent measurements 
were conducted using a CLARIOstar Plus plate reader (BMG Labtech), exciting at 535/20 nm 
and top reading emission at 585/30 nm. For each condition, a reference well lacking FICD-
TMR was included. This background fluorescence was subtracted from the respective 
condition with FICDS288C-H363A-C421S-TMR. In order to correct for any non-specific effects of 
the nucleotide titrants on TMR fluorescence, each fluorescence value in Figure 4.5.2b is 
presented as a fraction of the de-quenched monomeric signal from a parallel sample containing 
an additional 250 nM FICDH363A (UK1954). Independent repeat data were collected in 
technical duplicate. The displayed best fit lines were derived by non-linear regression fitting of 
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